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Influenza is a seasonal viral respiratory infection that causes considerable morbidity 
and mortality, particularly in individuals with chronic medical conditions such as 
asthma. Vaccination is one of the most effective available preventive measures against 
influenza and is recommended for children and adults with asthma. Despite the 
longstanding recommendation in developed countries that people with asthma be 
vaccinated against influenza, less than half of the asthma population eligible for the 
vaccine are immunised every year. Some of the reasons for this suboptimal coverage 
include doubts about the benefits of the vaccines and safety concerns amongst both 
healthcare providers and asthma patients. In 2012, a Cochrane systematic review 
concluded that evidence from randomised controlled trials (RCTs) on the effect of 
influenza vaccines on asthma-related clinical outcomes from influenza infection is 
unclear. However, the review confirmed that influenza vaccination was safe.  
Therefore, this doctoral research program had the following main aims: 
1. To conduct rigorous secondary research in the form of a systematic review to 
identify, appraise and integrate evidence, not limited by study design, for 
vaccine protection in asthma against influenza infection and influenza-related 
clinical outcomes. This review also included and appraised evidence on 
vaccination safety in people with asthma.  
2. To conduct  primary research work to fill evidence gaps identified in the 
systematic review by providing more accurate estimates of the protective 
effects of influenza vaccines against influenza infection in people with asthma 
over multiple influenza seasons using routinely collected data from Scotland.  
3. To estimate the effectiveness of influenza vaccination in preventing laboratory-
confirmed influenza in people with asthma, and variation in vaccine 
effectiveness (VE) between influenza seasons, influenza types/subtypes, 
influenza vaccine types and other asthma individuals’ characteristics. To 
measure the vaccine uptake and explore the main characteristics of people with 
asthma related to influenza vaccination uptake using routinely collected data 





A programme of work was undertaken which included three complementary phases. 
In the Phase One, I conducted a systematic review of the literature and searched for 
published and unpublished studies assessing the efficacy, effectiveness and safety of 
influenza vaccines over a 46-year period (1970 to 2016). Study selection, data 
extraction and quality appraisal of studies was carried out independently by two 
reviewers who followed the Preferred Reporting Items for Systematic Reviews and 
Meta-Analyses (PRISMA) reporting checklist. Meta-analysis of clinical and 
epidemiological similar studies was also performed.  
 
In Phase Two, I conducted a test-negative design (TND) case-control study to assess 
the VE against real-time polymerase chain reaction (RT-PCR) laboratory confirmed 
influenza in people with asthma. For this study, I used Scottish health administrative 
data from the Seasonal Influenza Vaccine Effectiveness II (SIVE II) project over 14 
influenza seasons (2000/01 to 2015/16). The SIVE II project used healthcare data 
collected from routinely available datasets and created a large national primary care 
and laboratory-linked dataset. The main aim of the SIVE II project was to assess the 
effectiveness of the live attenuated and trivalent inactivated influenza vaccines of all 
at-risk groups for influenza (e.g. asthma) in Scotland. Some of the SIVE project’s 
objectives were the evaluation of VE against RT-PCR laboratory-confirmed influenza 
and influenza-related clinical outcomes (e.g. influenza and asthma-related general 
practice consultations, hospitalisations and death). Therefore, my work in this phase 
was part of the SIVE II project as it focused on people with asthma. Additional 
stratified VE estimates related to various viral strains, vaccines types and asthma 
individuals’ characteristics were also provided, but from seasons 2010/11 onwards. A 
generalised additive logistic regression model was used for the calculation of all the 
VE estimates.  
 
Finally, in the Phase Three, I undertook a vaccine uptake analysis exploring factors 
related to vaccine uptake in the asthma population using data from primary care centres 
and hospitalisation over 16 influenza seasons (2000/01 to 2016/17) in Scotland. A 
multivariate logistic regression model was performed to identity any relation between 





The Systematic review identified 20,396 papers, and 35 studies met the inclusion 
criteria. It was possible to carry out meta-analyses of data from four of these studies. 
The review found that the influenza vaccination protects children and adults with 
asthma against influenza infection and influenza-related complications such as asthma 
exacerbations. However, the overall quality of evidence was rated as very low for all 
outcomes. The meta-analysis of two TND studies found a moderate VE of 45.0% (95% 
confidence interval (CI): 31.0 to 56.0) against influenza infection over two seasons in 
the United States (US) population. The protective effects of the vaccine against asthma 
exacerbations was also identified based on another US based study over a 3-year 
period in children with asthma. Specifically, the incidence rate ratio of the vaccine 
against asthma hospitalizations and emergency department visits ranged from 0.6 
(95% CI: 0.4 to 0.8) to 0.8 (95% CI: 0.6 to 1.1). The safety of the inactivated vaccines 
was also shown. Specifically, a large RCT study in US found an absolute difference 
of 1.1 percent (95% CI: -1.4 to 3.6) for asthma exacerbations between 2,032 
inactivated vaccine and placebo recipients. However, more evidence is needed to 
assess the safety of the live attenuated vaccines against asthma-related adverse events 
in preschool children.  
 
The TND case-control study included 6,921 swab samples tested for influenza and 
identified an overall VE of 49.4% (95% CI: 39.7 to 57.5) in 5,824 asthma patients over 
a 14-year period in Scotland. Higher and significant VE estimates were observed in 
seasons with good antigenic match between the viral and vaccine strains. The highest 
VE (76.1%; 95% CI: 55.6 to 87.1) was found in 2010/11 season where the A(H1N1) 
strain dominated and a good antigenic match with the vaccine was found. Significant 
protection was observed against the A(H1N1) and B strains, with non-significant 
protection for the A(H3N2) strain. Significant VE estimates were found in younger 
adults aged 18-54 years old (VE: 54.0%; 95% CI: 39.2 to 65.2) where protection was 
found against all circulating influenza strains. The live vaccines offered protection 
against the influenza B type in children < 17 years old (VE: 96.4%; 95% CI: 46.0 to 




The vaccine uptake analysis revealed characteristics in the asthma population that 
are related to higher uptake of the vaccine. The overall uptake was 33.6% among 
194,319 individuals with asthma identified from 223 general practices and 65.9% 
among 6,232 patients with asthma with an emergency hospital admission due to 
influenza or pneumonia over a 16-year period. In the community and at hospital 
settings higher uptake levels were observed for females (38.7% and 37.0%), younger 
children aged 5-11 years old (24.5% and 0.8%), older adults aged >75 years old (82.8% 
and 31.0%) and influenza vaccination history (80.5% and 56.8%). History of primary 
and secondary care visits (70.4% and 52.8%) and the presence of multiple medical 
conditions (83.2%) were also related with higher uptake in the community. Higher 
vaccination rates (65.2%) were observed in individuals using medications, particularly 
inhaled and oral corticosteroids. Females, adults aged >65 years old, individuals living 
in remote rural areas, with comorbidities, with history of influenza or pneumococcal 
vaccination, ex-smokers and with history of five primary care visits and two 




This program of work has identified evidence supporting the protective effects of 
influenza vaccination asthma from previous studies and has contributed new evidence 
supporting the use of influenza vaccination in the asthma population. In addition, 
factors related to vaccine uptake in people with asthma were explored. Thus, the 
current suboptimal uptake levels seen in the UK and globally might be improved by 
more effective targeting interventions to subgroups of people with asthma defined by 
specific demographic, clinical and other characteristics that are associated with a lower 
propensity for vaccination. The systematic review and the TND case-control study 
confirm that a moderate protection against laboratory diagnosed influenza infection 
can be achieved with current vaccines in people with asthma. Evidence from the 
systematic review also showed beneficial effects of the vaccination against clinical 
outcomes such as influenza-related asthma exacerbations and healthcare visits or 
hospital admissions. In addition, the primary research work provided stratified VE 
estimates across multiple influenza seasons and confirmed that vaccination prevents 
influenza incidence and complication in children and adults with asthma. This thesis 
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has therefore contributed to filling important gaps in the evidence base regarding the 
benefits of the influenza vaccination in people with asthma. It has also identified the 
need for additional evidence: specifically, studies should now focus on providing VE 
estimates for older adults (e.g. 55 years old), for children with LAIV administration 
and for asthma-related clinical outcomes. Vaccination policymakers can now use my 
research findings (for example, providing better estimates of safety and effectiveness 
to inform shared decision making and how to better target interventions to promote 
uptake) to enhance evidence-based recommendations for clinical practice that could 
result in improved health of people with asthma by preventing or reducing the burden 





















Lay summary  
Influenza, more commonly known as ‘flu’, is a viral infection that can affect breathing 
and trigger asthma attacks. Most people infected with the flu virus recover completely 
within a week, but sometimes flu causes severe, longer-lasting symptoms and even 
death. People who have asthma are more likely to get more severe forms of flu. In the 
UK and worldwide flu vaccination is recommended each winter for people aged six 
months who are at greater risk of severe flu, such as those who have asthma.  
However, the benefits and possible harms from vaccination in people with asthma 
against flu have not been fully described.  In this research, I aimed to assess how well 
flu vaccines protect people with asthma from flu and flu-related illness such as asthma 
attacks triggered by flu.  
To do this, I first searched for research studies already done that assessed the benefits 
and possible side-effects of the flu vaccines. Then, I studied those vaccinated against 
flu and compared the number who sought medical help and who turned out to a positive 
test for flu with those who had a negative test for flu. I used the electronic medical 
records of children and adults with asthma from 2000 to 2015 for this. I also explored 
characteristics of people with asthma in relation to vaccine uptake from 2000 to 2016. 
Electronic medical records were also used to measure the vaccine uptake in relation to 
asthma individuals’ characteristics such as gender, age, socioeconomic status, type of 
residence, smoking history, other at-risk chronic diseases, previous vaccination or 
healthcare use history and prescriptions.  
The review of the literature found that the flu vaccines can protect people with asthma 
from flu illness, asthma attacks and other important consequences (e.g. having to go 
to your GP or hospital, respiratory illness). However, the quality of these studies that 
showed the benefits of flu vaccination was poor. The review showed some evidence 
that supported the benefits of the vaccines, but the evidence was not good enough to 
draw any clear conclusions. This review also found that the flu vaccines were safe and 
generally well tolerated in children and adults with asthma.  
My research study found that the flu vaccine could prevent around half the people with 
asthma from getting flu each year. Higher protection was seen during seasons when 
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there was a good match between the vaccine and the particular kind of flu that 
circulated. The flu vaccine gave better protection to younger adults and against the flu 
types A(H1N1) and B. Finally, a live flu vaccine (nasal spray) gave very high 
protection against the flu B type to children with asthma compared to the inactivated 
vaccine (flu jab). My research work also found higher vaccination rates in people with 
asthma with characteristics including females, older adults, with multiple chronic 
diseases, non-smokers, with previous vaccination or healthcare use history and on 
prescribed medications.  
Findings from this research add support for vaccinating people with asthma against flu 
each year. In addition, this research could help the flu vaccination programme improve 
the health of people with asthma by providing evidence to help drive uptake of the 
vaccine. This would help prevent or reduce the burden of the flu and flu-related 
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Chapter 1. Introduction 
This chapter includes introductory information on the disease burden of respiratory 
viral infections, in particular that caused by the influenza virus, in people with asthma. 
Influenza vaccines are currently the only available preventive immunisation measure 
against influenza in people with asthma. This chapter describes the available influenza 
vaccines, vaccination guidelines, and considerations on how best to estimate influenza 
vaccines effectiveness (VE). The main aims of this chapter are to summarise evidence 
regarding the impact of influenza infection on morbidity and mortality in people living 
with asthma and the evidence supporting the use of the influenza vaccines to prevent 
influenza in at-risk groups nationally and globally.  
1.1 Respiratory viral infections in asthma  
Overall, upper respiratory tract viral infections (URTI) or “common colds” account 
for the majority of respiratory viral infections. In adults, the most frequently isolated 
URT viruses are rhinoviruses (40-50%) and coronaviruses (20-30%) followed by 
influenza viruses (10-15%). In infants and young children (<5 years old) respiratory 
syncytial viruses (RSV) are the most frequent circulating viruses.(1)(2)(3)    
Acute upper respiratory viral infections can induce asthma exacerbations.(4)(5) In the 
community, it is estimated that a respiratory viral infection is responsible for 80-85% 
of asthma exacerbations in children and 44% in adults.(6)(7)(8) Rhinoviruses are the 
most common viral triggers of asthma exacerbations accounting for 66% in children 
and 60% in adults.(6) In early childhood, RSV and parainfluenza viruses are the most 
common triggers of asthma attacks, while in older children rhinoviruses and influenza 





Figure 1.1: Viruses and bacteria associated with asthma exacerbations 
The prevalence of viruses and bacteria in young children (<2 years old), older children (6–17 years old) and adults, 
presented as median percentages from several studies. Enterovirus estimations in adults and bocavirus estimations 
in 6–17 year olds and in adults may be under-represented since data is not available in published studies. 
Reproduced with permissions from: Edwards MR, Bartlett NW, Hussell T, Openshaw P, Johnston SL. The 
microbiology of asthma. Nat Rev Microbiol 2012; 10(7): 459-71. 
 
Johnston and Papadopoulos (9) hypothesised that both children and adults with asthma 
are possibly susceptible to respiratory viral infections because:  
1. “People with asthma are more susceptible to virus infection than people 
without asthma” 
2. “People with asthma manifest symptoms of respiratory infection more readily 
(because they wheeze) than people without asthma and thus have fewer 
episodes of subclinical infection” 
The above hypotheses, derived from Johnston and Papadopoulos (9), observes that 
children with asthma have usually more respiratory infections than their asthma-free 
siblings and vice versa some children with frequent respiratory infection episodes are 
diagnosed with asthma.  
Relevant epidemiological evidence confirms the association between respiratory viral 
infections and asthma exacerbations. Specifically, Johnston and Papadopoulos(9) 
support their hypotheses based on the following biological criteria:  
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1. There is a seasonal variation of respiratory viruses which closely precedes that 
of asthma exacerbations in both children and adults with asthma.  
2. A dose-response relationship has been observed between the viral infections 
and asthma exacerbations. Severe asthma exacerbations are more common in 
individuals with a severe respiratory tract viral infection. 
3. The prevalence of predominant viruses for various age groups is the same for 
the viruses that trigger asthma exacerbations. 
4. The temporal variation of asthma exacerbations follows the seasonality of most 
respiratory viruses and not to other environmental triggers.  
5. Individuals with asthma are more likely to have had respiratory symptoms due 
to a viral infection which preceded asthma symptoms.  
Thus, the biological causality provided by previous epidemiological and clinical 
studies leaves no room for doubt that respiratory viruses are linked with asthma 
exacerbations and are the most common environmental triggers.(9)  
The role of bacterial respiratory tract infections in the pathogenesis of asthma 
exacerbations has also been shown in the literature.(10)(11) Most common bacterial 
pathogens associated with asthma exacerbations are Haemophilus influenzae, 
Streptococcus pneumoniae, and Moraxella catarrhalis.(12)(13)(14) A study in Japan 
reported that Haemophilus influenzae was observed in stable patients with asthma and 
other bacteria particularly Streptococcus pneumoniae was associated with asthma 
exacerbations in adult inpatients. Overall viral or bacterial infections were detected in 
70% of inpatients with an asthma attack.(15)  
Atypical bacteria such as Mycoplasma pneumoniae and Chlamydophila pneumoniae 
are also common respiratory pathogens linked with asthma exacerbations in children 
and adults with asthma.(10)(11)(15) The incidence of the atypical bacterial infections 
related to asthma exacerbations is higher (38.7%) in children older than five year olds 
compared to younger children (10.0%).(16) While, in adults studies have shown the 
presence of atypical bacterial infections caused by the Chlamydia pneumoniae 
pathogen in around 8% of asthma exacerbations.(17) The co-infection of asthma 
patients with bacterial and viral respiratory pathogens can lead to considerable higher 
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detection rates (40-60%) of these atypical bacterial pathogens during asthma 
exacerbations.(11) 
Healthcare professionals usually test for respiratory viruses in people with acute onset 
of respiratory illness or in people at-risk of severe respiratory illness due to age or 
underlying medical conditions who develop respiratory illness. For example, clinicians 
should test outpatients for influenza in high-risk patients, in patients with acute onset 
of respiratory symptoms and in patients who present with influenza-like illness, 
pneumonia or nonspecific respiratory illness. Clinicians also should test inpatients 
such as patients hospitalised with acute respiratory illness, patients with acute 
deterioration of chronic underlying conditions (e.g. cardiopulmonary disease), patients 
admitted who are at-risk of complications and present acute respiratory symptoms and 
patients that while hospitalised develop acute respiratory symptoms or respiratory 
distress without a clear alternative diagnosis.(18)  
There are various tests available to clinicians to support the diagnoses of respiratory 
viruses such as influenza. Specifically, rapid molecular tests (e.g. nucleic acid 
amplification tests) should be used in outpatients to detect influenza infection. Other 
molecular tests (e.g. multiplex reverse-transcription polymerase chain reaction assays) 
should be used in inpatients to detect influenza infection and other respiratory 
pathogens. Nowadays, viral culture is mainly used only to confirm any negative results 
from less sensitive diagnostic tests (e.g. immunofluorescence assays) and to provide 
isolates for further characterisation.(18) Viral culture has been for decades the gold-
standard test for the detection of respiratory viruses. However, diagnosis of viral 
pathogens is predominantly now carried out with molecular tests such as polymerase 
chain reaction (PCR) assays and rapid nucleic acid assays) for faster and highly 
accurate detection of viral pathogens in outpatients and inpatient clinical settings.(19) 
Molecular tests can detect fragments of a viral pathogen without requiring the whole 
infectious pathogen as it is the case in viral culture. As a result, molecular tests have 
enabled large epidemiological studies for known and newly discovered respiratory 
viral pathogens, and the diagnosis of pathogens (e.g. coronaviruses and group C 
rhinoviruses) which cannot be detected via viral culture.(19)  
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In clinical practice the use of molecular tests such as PCR tests has enabled physicians 
to provide a more accurate and timely diagnosis and treatment of viral respiratory 
infections.(19) Specifically, the early diagnosis of the type of respiratory infection (e.g. 
viral or bacterial) ensures the correct treatment regime which reduces the replication 
and the transmission of the viral pathogen. For example, children will receive prompt 
antiviral treatment which can improve clinical outcome, reduce the inappropriate use 
of antibiotics and the reduce the transmission of the infection to the community.(20)  
 
The use of PCR and other molecular tests has also improved the diagnosis of bacterial 
respiratory infections which are commonly associated with lower respiratory tract 
infections (e.g. community-acquired pneumonia).(21) Culture of specimens (e.g. 
sputum) for suspected bacterial infection is also used in hospitalised patients. 
However, detection of bacterial pathogens is less common (and is rarely carried out in 
primary care).(21) The use of these new diagnostic technologies provides better 
clinical management and has supported advancements in public health surveillance.  
1.2 Overview of influenza and asthma 
1.2.1 Basic concepts of influenza virus 
Definition  
Influenza is an acute respiratory tract infection caused by influenza viruses. Influenza 
viruses are single-stranded ribonucleic acid (RNA) viruses and derive from the 
Orthomyxoviridae family, and are classified into three categories (A, B and C) based 
on their core nucleoproteins which enclose the viral genome for functions such as RNA 
transcription, replication and packaging.(22) Influenza A virus is classified into 
subtypes according to two glycoproteins (hemagglutinin (HA) and neuraminidase 
(NA)) on its surface. There are 18 different hemagglutinin (HA) and 11 different 
neuraminidase (NA) subtypes for influenza A viruses. Influenza B virus is not divided 
into subtypes but contains one of the two lineages B/Victoria and B/Yamagata. The 
most common influenza A virus’s subtypes circulating in humans are A(H1N1) and 
A(H3N2). The main reservoir of influenza A viruses is located in wild aquatic shore 
birds. Influenza A viruses are also found in swine, domestic poultry, horses, dogs, cats, 
bats, marine mammals and humans.(23) Influenza B and C viruses are found mainly 
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in humans. Influenza A and B have a substantial effect in humans whilst influenza C 
viruses only causes mild disease and does not lead to epidemics.(24)(25)      
 
Epidemiology 
Influenza viral infection is most common in young individuals including older children 
and young adults. However, higher morbidity and mortality rates are seen in 
individuals older than 65 and among those with chronic underlying conditions such as 
chronic respiratory diseases.(26) Initial influenza infection usually occurs in school-
aged children (35-50%) before its spread to pre-school children and the elderly.(26) 
According to the World Health Organization (WHO), annual influenza epidemics 
cause about 3-5 million cases of severe illness, and about 250,000 to 500,000 deaths 
globally/year.(27) While influenza-related illness is most often mild, it can be much  
more severe and may lead to death. Hospital admissions and deaths are most likely in 
individuals who are most at risk from compilations of influenza due to underlying 
medical conditions.(27) Individuals with certain medical conditions, specific age 
groups, pregnant women and health care providers are perceived to be at high risk of 
severe disease or complications due to influenza.(28-30) However, it should be 
acknowledged that although underlying mechanisms have been proposed to explain 
why people with these conditions should have severe disease when infected with 
respiratory viruses like asthma, there are few (epidemiological) studies which have 
explored whether these underlying conditions in the presence of influenza and in the 
absence of an early intervention, would indeed lead to more severe disease or 
death.(28-30) Further work is therefore needed to explore this proposed hypothesis. 
Mutation  
Influenza viruses are constantly mutating because of a characteristic of RNA genome 
viruses which results in variability of the HA and NA antigens. Two reasons for the 
high mutation rate of influenza viruses leading to rapid rates of viral evolution include: 
a) the viral genome of influenza is RNA-based which is considered an unstable 
molecule compared to DNA viral genome. In addition, RNA viruses do not have a 
proofreading mechanism when they replicate as DNA viruses have during their 
reproductive process. Thus, errors in the RNA genome happen more frequently leading 
to high mutations rates of the influenza viruses and b) the single-stranded segmented 
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RNA genome of influenza viruses means that coding sequences are located on separate 
strands of RNA. Thus, viral genetic material is frequently combined and re-arranged 
when host cells are simultaneously infected with multiple types of influenza 
viruses.(31)(32) 
 
Two common types of mutations are the “antigenic drift” and the “antigenic shift”.  
Antigenic drift happens when minor mutations lead to small changes in the genes of 
influenza viruses. Small changes in HA antigens happen very often. Antigenic shift 
occurs when major mutations lead to substantial changes in the HA or NA antigens. 
Thus, new influenza A subtypes can emerge as well as new HA antigen or HA and NA 
antigen combinations derived from animals, resulting in different subtypes to those 
found in humans. The significance of antigenic shift compared to antigenic drift, is 
that in antigenic shift, humans will have low or no antibody memory to prevent the 
replication of these new influenza viruses which can lead to an influenza 
pandemic.(33) Antigenic shift has not been reported in influenza B viruses. The B 
virus does not affect species other than humans. Thus, the chance of substantial 
changes on its surface antigens is minimised, which further explains the absence of 
influenza B subtypes. However, small changes (antigenic drift) have been reported, 
which has resulted in co-circulation of both Victoria and Yamagata strains or so-called 
lineages of the influenza B virus.(24)(34) 
 
Transmission and infection  
Influenza viruses can be transmitted from animals to humans (rare), or between 
humans (very common). The transmission from animals to humans can occur through 
direct contact with infected animals or their by-products. Additionally, people can be 
infected from animals through interaction with environmental sources contaminated 
with influenza viruses (e.g. water sources, faeces, feathers and surfaces).(35) 
Transmission between humans occurs via droplets aerosol when someone with 
influenza infection coughs, sneezes or talks. The transmission in humans occurs via 
three main routes including droplets, droplet nuclei (or aerosols) and contact.(36-
39)Droplets are large particles (>10μm) that are produced when someone coughs or 
sneezes and travel only a short distance (<1m). Droplets usually reach the upper 
respiratory tract such as mouth or nose but not the lungs due to their large size. Droplet 
35 
 
nuclei or aerosols are small particles (<5 μm) that can be inhaled due to their small 
size. Thus, they can reach the lower respiratory tract and also deposit on the upper 
respiratory tract.(38)(39) Contact transmission occurs directly when respiratory 
particles are transferred to another person’s mucous membrane of the upper respiratory 
tract or indirectly when someone touches a contaminated object or person.(37)(39) 
 
The incubation period which refers to the time between the exposure to the influenza 
virus and the onset of the first influenza symptoms usually starts one day before the 
onset of symptoms and last five to seven days after the onset of symptoms. Symptom 
onset is usually sudden. In children, symptoms can last more than seven days, while 




The symptomatology onset of influenza is more rapid compared to other respiratory 
viral infections. Common respiratory and systemic signs and symptoms of influenza 
include: 1) fever or feverishness; 2) non-productive cough; 3) headache; 4) sore throat; 
5) runny or stuffy nose; 6) muscle or body aches; and 7) fatigue, weakness. Children 
are also more likely to have gastrointestinal symptoms such as vomiting and diarrhoea 
compared to adults.(40-42)However, people infected with influenza can also be 
asymptomatic. Serological studies have shown that around 30% to 50% of influenza 
infections in healthcare providers were asymptomatic.(36)  Most of these common 
influenza signs and symptoms are resolved in a few days to less than two weeks. Some 
people will also develop complications due to influenza or secondary infection 
(usually bacterial pneumonia).(41) Respiratory and non-respiratory complications 
include abnormalities of middle ear pressure and acute otitis media (most common in 
children), primary viral and secondary bacterial pneumonia, myocarditis, viral 
encephalitis, post-infective immune-mediated encephalomyelitis, meningitis, 
meningoencephalitis and Guillain-Barre syndrome. People with certain medical 
conditions (such as lung disease, cardiovascular disease, metabolic disease, hepatic 
disease, kidney disease, neurologic disease, immunocompromised individuals, 
haematologic conditions, morbid obesity and genetic conditions) and pregnant women 
will also experience influenza complications related to their medical 
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condition.(24)(36)(41-43) In addition, children and adults can experience severe signs 
and symptoms. Specifically, children may develop fast breathing or trouble breathing, 
bluish lips or face, ribs pulling in with each breath, chest pain, severe muscle pain, 
dehydration, not alert or interacting when awake, seizures, high fever 40°C, no fever 
in children <12 weeks old, fever or cough that improves but then return or worsen and 
worsening of chronic medical conditions. In adults, severe signs include difficulty in 
breathing or shortness of breath, persistent pain or pressure in the chest or abdomen, 
persistent dizziness, confusion or inability to arouse, seizures, not urinating, severe 
muscle pain, severe weakness or unsteadiness, fever or cough that improve but then 
return or worsen and worsening of chronic medical conditions.(42)  
 
Invasion and replication in host cells  
Tracheobronchial epithelial cells are the initial host cells: the influenza virus then 
spreads to the upper and/or lower respiratory tract.(44) The virus uses glycoproteins 
HA on its surface to enter into the host cell in an endosome. Viral RNA is then released 
in the cytoplasm of the host cell and enters the cell nucleus where transcription and 
replication of the viral genome takes place. The viral nucleic acid leaves the nucleus 
and uses the host cell’s plasma membrane in order to create all the necessary viral 






Figure 1.2: Invasion and replication of influenza virus in a host cell 
Step 1: A virion attaches to the host cell membrane via HA and enters the cytoplasm by receptor-mediated 
endocytosis and forms an endosome. A cellular trypsin-like enzyme cleaves HA into products HA1 and HA2 (not 
shown). HA2 promotes fusion of the virus envelope and the endosome membranes. A minor virus envelope protein 
M2 acts as an ion channel thereby making the inside of the virion more acidic.  
Step 2: As a result, the major envelope protein M1 dissociates from the nucleocapsid and vRNPs are translocated 
into the nucleus via interaction between NP and cellular transport machinery.  
Step 3: In the nucleus, the viral polymerase complexes transcribe (STEP 3a) and replicate (STEP 3b) the vRNAs.  
Step 4: Newly synthesized mRNAs migrate to cytoplasm where they are translated.  
Step 5: Posttranslational processing of HA, NA, and M2 includes transportation via Golgi apparatus to the cell 
membrane (STEP 5b). NP, M1, NS1 (non-structural regulatory protein - not shown) and NEP (nuclear export 
protein, a minor virion component - not shown) move to the nucleus (STEP 5a) where they bind freshly synthesized 
copies of vRNAs.  
Step 6: The newly formed nucleocapsids migrate into the cytoplasm in a NEP-dependent process and eventually 
interact via M1 with a region of the cell membrane where HA, NA and M2 have been inserted. 
Step 7: Then the newly synthesized virions bud from infected cell. NA destroys the sialic acid moiety of cellular 
receptors, thereby releasing the progeny virions.)  
Reproduced with permissions from: By User:YK Times - Redrawn from w:Image: Virusreplication.png using 





Influenza infection can be diagnosed based on either clinical signs and symptoms alone 
or in combination or laboratory tests. Health professionals can diagnose influenza like 
illness (ILI) based on clinical criteria such as fever or feverishness, malaise, headache, 
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myalgia, cough, sore throat and shortness of breath. An individual meeting criteria for 
ILI may or may not have true influenza infection, as the ILI syndrome can be caused 
by various respiratory viruses.  Thus, a diagnosis based only on clinical symptoms 
cannot confirm an influenza infection and further testing is required to distinguish ILI 
from true influenza infection.(46-48) According to the newly revised ILI clinical case 
definition by the WHO an ILI is “an acute respiratory illness with a measured 
temperature of ≥ 38 °C and cough, with onset within the past 10 days”.(49) However, 
there is heterogeneity of clinical cases of the ILI definition across countries. While no 
established definition exists in other countries (e.g. England and Scotland).(50) 
Although there should be little to no effect on VE estimates on the variability of these 
ILI definitions. For example a lower threshold for ILI (less severe) will lead to a higher 
number of possible test positive cases and negative for influenza controls - as long as 
both symptomatic vaccinated and unvaccinated individuals are tested, VE should be 
unaffected by ILI definition. The following diagnostic tests are used to confirm 
influenza infection: (51)(52) 
1) Reverse Transcription-Polymerase Chain Reaction (RT-PCR) (conventional gel-
based PCR, real-time RT-PCR and multiplex PCR) is a nucleic acid amplification 
test, which can detect viral RNA in respiratory samples with high sensitivity and 
specificity. The PCR tests are used for virological surveillance (e.g. annual 
surveillance of influenza activity) and for diagnostic purposes in patients with 
suspected influenza infection.(53) Healthcare professionals collect specimens from 
the upper and lower respiratory tract (e.g. nasopharyngeal swabs, throat swabs, 
nasopharyngeal or bronchial wash, nasal or endotracheal aspirate and sputum) of 
outpatients or inpatients with suspected influenza. The PCR tests can detect 
influenza types, subtypes and lineages. Results are available between 1 to 8 hours 
after the submission of the specimen.(54) 
2) Immunofluorescence (direct or indirect antibody staining) is an antigen-detection 
test used for the detection of virus-infected cells in original clinical specimens and 
field isolates. It is a rapid test for the detection of respiratory viruses within 2 to 4 
hours. It has moderate sensitivity and specificity, which is dependent on laboratory 
expertise and the quality of the specimen collected. Clinical specimens can be 
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derived from nasal or throat swabs, nasopharyngeal aspirates, nasal or throat wash, 
transtracheal aspirates and bronchoalveolar lavage fluids.(51) 
3) Rapid Point of Care Tests (POCTs) are rapid diagnostic tests which are using 
nucleic acid amplification technologies (NAAT). The aim of these tests is to help 
the physician to determine the best respiratory care options in an accurate and 
timely manner. Healthcare professionals perform rapid POCTs in emergency 
departments, medical admission units and outpatient settings. Healthcare 
professionals take upper respiratory tract specimens such as nose or throat swabs, 
nasopharyngeal aspirates, nasal washes and sputum. The POCTs use RT-PCR or 
similar technology to detect influenza A and B types including specific influenza 
A subtypes. The results of the POCTs are available within 15-90 minutes. The 
sensitivity and specificity of these tests is high ranging from 90-95%.(55) 
4) Viral culture (shell vial culture, isolation in cell culture) is not a screening test. 
However, it can be used during periods with low influenza activity (e.g., pre-
influenza, post-influenza and non-influenza seasons). Additionally, it can be 
performed to confirm negative test results from rapid influenza diagnostic tests or 
immunofluorescence and for public health surveillance purposes. Viral culture has 
moderately high sensitivity and the highest specificity. The results are available in 
2-10 days.  
5) Serologic tests (hemagglutinin inhibition, enzyme-linked immunosorbent assay 
(ELISA), complement-fixation, and neutralisation) are only available in reference 
laboratories. The detection of acute influenza infection is difficult because a high 
increase of antibody titres is required (e.g., four-fold increase or higher). However, 
they are useful for epidemiological and immunological studies and for the 
assessment of the antibody response following influenza vaccination. They can 
also be used for retrospective diagnosis when the influenza virus cannot be 
detected – for example, when the virus stops shedding. 
 
The clinical or laboratory diagnosis of influenza can also be challenging in the case of 
asymptomatic ILI. A high number of individuals with influenza infection have 
subclinical or asymptomatic influenza. Thus, surveillance data are unlikely to capture 
these individuals when they measure the annual burden and severity of influenza based 
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on people that develop ILI symptoms and seek care.(56) In addition, the use of 
molecular tests such as PCR tests may fail to detect influenza in asymptomatic 
individuals. A British study used PCR tests to detect influenza and other respiratory 
viruses in nasal swab samples and serology test to estimate antibody levels against 
influenza in serum. The study found that only 25% of individuals with a serologic 
confirmed influenza infection had also a PCR confirmed infection. Thus, 75% of 
individuals were asymptomatic and PCR tests failed to detect them.(56) Older 
serologic studies have also found that between 30 to 50% of healthcare providers were 
asymptomatic for influenza.(36) The absence of symptoms in infected individuals 
could indicate protection from past exposures to influenza infection or vaccination or 
older age. Studies have also found individuals with confirmed influenza infection but 
no serologic confirmed infection. Therefore, the use of molecular and serology tests 
could increase the detection of infected individuals with or without ILI symptoms.(57) 
1.2.2 Basic concepts of asthma  
Definition 
According to the updated 2018 Global Initiative for Asthma (GINA) report, asthma is: 
“Asthma is a heterogeneous disease, usually characterized by chronic airway 
inflammation. It is defined by the history of respiratory symptoms such as wheeze, 
shortness of breath, chest tightness and cough that vary over time and in intensity, 
together with variable expiratory airflow limitation.”(58) 
The definition of asthma has evolved over time. In 2014 there was a major revision of 
the GINA report which included a new definition of asthma. Specifically, GINA 
recognised that asthma is a heterogeneous disease with chronic airway 
inflammation.(59) Asthma is no longer a single disease but it is now considered a 
heterogeneous disease or an umbrella term with different asthma subtypes (e.g. allergic 
asthma, non-allergic asthma, late-onset asthma, asthma with fixed airflow limitation, 
asthma with obesity).(58-60)  
 
Epidemiology 
Asthma is globally one of the most common chronic respiratory diseases. In 2004 
Masoli et al estimated that 300 million people have asthma worldwide.(61) Estimates 
suggest that another 100 million people will develop asthma by 2025.(61) The global 
increase in asthma prevalence was also confirmed in a recent systematic review where 
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358 million cases of asthma were estimated in 2015.(62) However, according to 
Masoli et al, the true prevalence of clinical asthma cannot be estimated for several 
reasons such as lack of a unique asthma diagnostic test, lack of a single classification 
system for asthma, varying interpretation of asthma symptoms by country and the 
influence of increasing public and professional awareness of asthma.(61) In 2004, 
Masoli M et al published a report about the global burden of asthma.  According to the 
report prevalence rates were higher in Europe (with the highest prevalence of 18.4% 





Figure 1.3: Global prevalence of clinical asthma 
Reproduced with permissions from: Masoli M, et al. The global burden of asthma: executive summary of the GINA 
Dissemination Committee report. Allergy 2004; 59(5): 469-78. 
Masoli et al used a self-reported written questionnaire about wheezing symptoms in 
the previous 12 months.(61) However, wheezing is not a symptom exclusively present 
in asthma. In addition, the diagnosis of asthma is based on a combination of asthma 
symptoms, physical and physiological examinations and response to asthma 
medication over a follow-up period. Therefore, the presence of wheezing symptoms is 
not equivalent to asthma diagnosis. In addition, the questionnaire was predominantly 
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completed by urban populations where according to the study authors the prevalence 
of asthma symptoms is higher in the urban then in rural populations.(61) These study 
limitations could have led to ascertainment bias (due to false positive cases) and 
overestimation of the true global asthma prevalence.(61)  
 
Aetiology 
The aetiology of asthma is not yet fully understood; however, a combination of host 
and environmental risk factors has been found to contribute to asthma 
development.(63) Common host risk factors include: genetic (e.g. genes predisposing 
to atopy, airway hyper-responsiveness, airway inflammation), obesity and gender. 
Common environmental risk factors include: allergens (indoor and outdoor), 
occupational sensitisers and allergens, infections (mostly viral), microbiome, tobacco 
smoke (passive and active smoking), air pollution (outdoor or indoor), diet.(63)(64) 
Certain drugs such as the anti-inflammatory medications (e.g. acetaminophen) and 
stress have also been reported as risk factors for asthma development. Studies have 
found association between acetaminophen use and children and development of 
asthma. Factors other than acetaminophen may have also confounded this 
relationship.(65) The relationship between biological, individual, family, and 
community-level psychosocial stress factors has also been mentioned in the literature. 
Nevertheless, the impact of stress on asthma development is still not fully 
explored.(66)(67) Therefore, more studies are needed for establish any causal link 
between medication and stress as risk factors of asthma. 
 
Pathophysiology 
In terms of the pathophysiology of asthma the key feature is persistent chronic 
inflammation and remodelling of the airways. The inflammation affects all airways, 
but its major physiological effects are found in medium-sized airways.(64)(68) The 
airway inflammation involves multiple inflammatory cells (e.g. mucosal mast cells, 
eosinophils, T lymphocytes, dendritic cells, macrophages and neutrophils), structural 
cells (airway epithelial cells, airway smooth muscle cells, endothelial cells, fibroblasts 
and myofibroblasts and airway nerves) and over 100 different cellular mediators, 




Structural changes in the asthmatic airway epithelium are also observed, often 
described as “airway remodelling”. The main features of airway remodelling in asthma 
include subepithelial fibrosis (collagen fibres and proteoglycans depose under the 
basement membrane of the airway wall), increased airway smooth muscle (thickness 
of the airway wall due to increased size and number of smooth muscle cells), increased 
blood vessels in airway walls (abnormal formation of blood vessels, which increase 
the influence of growth factors and lead to increased airway wall thickness) and mucus 
hypersecretion (increase of the number and size of mucous glands in the airway 
epithelium).(64)(68)  
 
The persistent airway inflammation and ongoing structural remodelling leads to a 
common functional disorder of asthma reported as “airway hyper-responsiveness”. 
Airway narrowing is usually the result of this bronchial hyper-reactivity which leads 
to variable airflow limitation and asthma symptoms.(64) All changes increase the 
resistance on airways and result to decreased lung function as it has been seen in 
patients with chronic asthma.(68)   
 
Clinical features 
Asthma signs and symptoms vary from patient to patient; the most common features 
include: Nocturnal and exercised induced breathlessness, chest tightness or pain, 
wheezing (a whistling sound when exhaling) and coughing.(69)  
 
The sudden or gradual over a few days deterioration of asthma symptoms can lead to 
the common termed as asthma attack including signs such as sever and constant 
wheezing, coughing and chest tightness, severe breathlessness decreasing the ability 
to eat, speak or even sleep, fast breathing, rapid heartbeat, drowsiness, exhaustion, 
dizziness, blue lips or fingers and fainting.(70)  
 
1.2.3 Pathology of influenza virus in the asthmatic lung epithelium  
The risk of severe lower tract viral respiratory infection and subsequent exacerbation 
is higher in patients with asthma because of impaired airway epithelium and antiviral 
immune responses.(71)(72) Defective mucosal antibody and antiviral responses have 
also been observed during an influenza infection.(73)(74) In asthma patients, 
44 
 
respiratory viruses such as influenza can influence all the key elements that 
characterise acute asthma including airway inflammation, bronchoconstriction and 
remodelling through a combination of multiple cellular and molecular mechanisms 
leading to severe asthma exacerbations.(75)(76) 
 
Inflammation of the airway epithelium is one of the main characteristics of asthma, 
which involves a chain of events that can be triggered by an external stimuli such 
respiratory viruses and lead to an acute asthma exacerbation. Direct contact of the virus 
with airway epithelium cell lining triggers the production of cytokines and chemokines 
(proteins which are secreted by certain cells of the immune system and have an effect 
on other cells), which are key mediators of the inflammation response. Influenza 
viruses in particular stimulate the production of the cytokines interleukin-6 (IL-6), 
interleukin-8 (IL-8), regulated on activation, normal T expressed and secreted 
(RANTES) and eotaxin in the airway epithelial cells.(77)(78) Resident inflammatory 
cells including macrophages and lymphocytes are also activated and produce 
inflammatory mediators (similar to those produced by the epithelium) as a response to 
virus invasion and replication in them or by the local cytokine environment. The 
airway inflammation is further mediated by the recruitment and activation of other 
inflammation cells such as macrophages, eosinophils, neutrophils, mast cells and 
lymphocytes, which in turn produce of a wide range of inflammatory 
mediators.(75)(79) 
 
The virus-induced death of the airway epithelium cells can also irritate the underlying 
neural tissue and modify the neural control of the airways. The presence of 
inflammatory products, allergens or other stimuli in the area may induce the 
production of broncho-constricting neuropeptides from the stimulated neural cells. 
Viral infection also modifies the neural mechanisms related to bronchoconstriction. 
Specifically, cholinergic fibres from vagal parasympathetic nerves control the neural 
responses in the airways. The release of acetylcholine (a Broncho-constricting 
neuropeptide) from vagal parasympathetic nerves is regulated by the M2 muscarinic 
receptors of the neural system located in the airways through a negative feedback 
mechanism. However, the function of the M2 muscarinic receptors is impaired after a 
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viral infection. As a result, acetylcholine is released from vagal parasympathetic 
nerves and binds to the M3 muscarinic receptors on the airway smooth muscle cells 
resulting to smooth muscle contraction and airway bronchoconstriction (see Figure 
1.4).(75)(76)(79)  
 
Figure 1.4: Main cellular and molecular interactions related to viral infection of the 
airway epithelium 
Reproduced with permissions from: Johnston SL, et al. Respiratory Infections in Allergy and Asthma. New York: 




1.3 Epidemiology of influenza virus infection in asthma  
This section describes the epidemiological evidence regarding the impact of influenza 
virus infections in triggering asthma exacerbations and other related complications and 
summarises the results from key relevant studies in a critical manner.  
The studies summarised in Table 1.1 provide evidence regarding the burden of 
influenza infections in asthma patients due to attacks and other severe complications. 
However, these studies vary in quality, and estimates of the disease burden are 
uncertain because of potentially studying non-representative populations.  
The ‘Manual for Estimating Disease Burden Associated with Seasonal Influenza’ 
created by the WHO has been used to critically appraise the studies in Table 1.1.(80) 
According to the WHO’s  manual, the quality of the studies can be assessed by 
examining the following: 
• Number of patients with asthma recruited 
• Number of episodes studied 
• Role of chance 
• Role of bias such as selection and misclassification bias 
• Effect of healthcare seeking behaviour (especially for low-income countries) 
• Pattern of each influenza season and period over which the study was carried 
out 
• Effect of sensitivity of case definition. 
  
The studies summarised in Table 1.1 have been divided into those assessing the burden 
of influenza infection during non-pandemic years and pandemic years. According to 
the WHO Global Influenza Surveillance Network an influenza pandemic is defined as 
“worldwide outbreaks of influenza caused by influenza A viruses that have undergone 
antigenic shift. However, as recently demonstrated, an antigenically novel virus of an 
existing subtype is capable of pandemic spread”.(51) 
Therefore, a pandemic year occurs when new influenza viruses emerge and spread 
very quickly across countries because most people do not have immunity or there is 
no a widely available influenza vaccine.(81) Most studies came from temperate 
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countries (geographical zones that span between the polar and tropic regions of earth 
and present a wide range of temperatures during a calendar year) where influenza 
follows a seasonal epidemic pattern. However, in pandemic years the influenza virus 
does not follow a seasonal circulation pattern as evidenced by the latest influenza 
A(H1N1) pandemic in 2009.(81) Characteristics’ of the studies that will aid the critical 
interpretation of the findings are summarised in Table 1.1 
1.3.1 Seasonal influenza virus infection  
Studies in children  
Studies involving children have been most frequently reported over the past four 
decades, due to the increase of asthma prevalence over this period (82) and the more 
recent use of highly sensitive molecular diagnostic methods such as the PCR test since 
late 1990’s.(82)  
 
A community based longitudinal study in the United Kingdom (UK) (1989-90) 
involving 108 children (aged 9-11 years old) detected only 21 (7.2%) influenza virus 
infections out of 292 reported respiratory episodes by either the children or their 
parents.(83) However, the detection of influenza was based on direct 
immunofluorescence (a diagnostic method with low sensitivity), while PCR was used 
for the detection of rhinoviruses and enteroviruses and samples from asymptomatic 
children. An underestimation of influenza burden is therefore possible due to 
misclassification bias resulting by the false negative influenza cases.(83) In contrast, 
a study conducted in United States (US) (1971-72) in children aged 3-11 years old, 
despite its small size (n=16) is still useful, because it used surveillance methods and 
thus the data and samples for microbiological analyses were prospectively 
collected.(84) Influenza-related severe symptomatic respiratory infections followed by 
an asthma attack were found in 10% of the children. However, the influenza-related 
episodes were not clearly outlined and the involvement of other pathogens when the 
episode was well delineated could have hampered the true detection of the influenza 
virus.(84) The authors of the previous study (84) conducted again the same study but 
this time compared the number of viral respiratory infections between children with 
asthma and their healthy siblings.(85) Children with asthma experienced 54 episodes 
of viral respiratory infections compared to the 35 viral infection episodes seen in their 
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siblings. In addition, influenza viruses were observed in 23% (3/13) of severe 
symptomatic respiratory infections in children with asthma.(85) However, the 
frequency of influenza infection was similar between the children with asthma and 
their siblings (6 vs 4). In children with asthma, the low influenza infection rate (6/54) 
of all viral respiratory infections and similar to that of their healthy siblings could be 
attributed to the small sample sizeand the inclusion of a single influenza season.  
 
A two-year study in US assessed prospectively the association of respiratory infections 
and episodes of wheezing exacerbation in 32 (aged 1-5 years old) hospitalised children 
with asthma.(86) Only one influenza infection (4%) was related with wheezing episode 
in the second year. However, more than half of the children were less than three years 
old and RSV was the predominant circulating virus in young children, which was also 
confirmed in this study. In addition, the use of a serological test for the detection of 
influenza viruses and the high influenza vaccine coverage against the influenza A in 
the second year of the study children could have influenced the detection of the 
virus.(86)  
 
A large (194,725 person-years) longitudinal study in US estimated the influenza 
burden in children (aged less than 15 years old) in relation to hospitalisations, 
outpatient visits and antibiotic prescriptions from 1973 to 1993.(87) The number of 
influenza-related complications in children with asthma was higher (incidence of 
influenza-related outpatient visits and antibiotic courses were 190 and 148, 
respectively) during all seasons compared to children with other respiratory condition 
(incidence of influenza-related outpatient visits and antibiotic courses were 172 and 
121, respectively). However, the inclusion of children with medically treated asthma 
only (at least two asthma prescriptions in the previous year) yielded a low asthma 
prevalence (3%) and the use of conventional virology (viral culture) for the influenza 
detection could have underestimated the association between influenza and related 
complications in children with asthma. Nonetheless, the long follow-up period (20 




A population-based study assessed prospectively the number of hospitalisations and 
outpatients visits due to influenza during four influenza seasons in 81 children (aged 
6 to 59 months old) in 3 US counties.(88) The number of influenza-attributable 
healthcare use was higher in children with asthma compared to their healthy controls 
(see Figures 1.5 and 1.6). The use RT-PCR in combination of viral culture could have 
aid the detection of influenza viruses compared to previous studies restricted to 
conventional and less sensitive diagnostic tests. However, the diagnosis of asthma was 
based on parental reports and was not validated through a medical chart review. In 
addition, the diagnosis of asthma for children younger than five years is difficult and 
it could have also been misdiagnosed in this study leading to an overestimation of 
influenza-burden in the asthma group.(88)  
 
Figure 1.5: Annual influenza-attributable hospitalisation rates, with 95% CIs, for 
children with asthma and healthy children 6 to 59 months of age 






Figure 1.6: Average influenza-attributable hospitalisation rates, for 2000-2004, with 
95% CIs, for children with asthma and healthy children according to age group 
Reproduced with permissions from: Miller EK, et al. Influenza burden for children with 
asthma. Pediatrics 2008; 121(1): 1-8. 
 
Two surveillance studies covered 12 influenza seasons, and found  between 12% and 
16% of children with influenza-related complications such as hospitalisations, 
outpatient visits and deaths had an asthma diagnosis.(89)(90) However, these studies 
compared the burden of influenza in at-risk children rather than explicitly focusing on 
asthma. Thus, the interpretation of these results is not clear for the asthma risk 
group.(89)(90) 
 
A prospective study in France highlighted the underestimation of influenza infection 
in childhood asthma attacks during four influenza seasons.(91) The burden of 
influenza was evaluated in 232 hospitalised and 107 ambulatory-treated (out-patient) 
children with an asthma attack. Influenza A was isolated in 2.6% of asthma attacks in 
hospitalised children, but in 14.1% of asthma attacks in ambulatory-treated children. 
However, the performance of viral detection for influenza and other viruses only in 
hospitalised cases could have underestimated the burden of influenza by not including 
cases with an asthma exacerbation not requiring hospital attendance.(91) In contrast, 
a cross-sectional study in Korea found a high prevalence of influenza (25%) in 309 
children hospitalised with an asthma attack during one year.(92) Nonetheless, only 
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children with severe lower respiratory tract illness requiring a hospital admission were 
included in this study. Critically ill young children are more likely to have a positive 
test for influenza, especially when highly sensitive tests such as the multiplex RT-PCR 
used in this study are performed.(92)  
 
A review by Papadopoulos et al in 2011 assessed the association of respiratory viral 
and bacterial infections including influenza with acute asthma exacerbations.(93) 
According to the review, the prevalence of influenza-related acute asthma 
exacerbations was low in children at between 0-7%, however, an influenza-related 
asthma attack in children is more likely to lead to a hospital admission and healthcare 
utilisation.(93) The aim of the review was however to summarise up-to-date 
knowledge and developments in infection epidemiology in relation to acute asthma 
exacerbations rather than to identify all available evidence.(93) Therefore (given the 
aim of this review), eligible studies in influenza could have been omitted.  
 
Studies in adolescents and adults  
There were fewer studies assessing the burden of influenza infection and its 
complications among late childhood and young adults. The review by Papadopoulos 
et al also reported that the number of patients with asthma exacerbations requiring 
emergency or hospital admission due to an influenza infection was  highest in adults, 
and ranged from 20 to 25%.(93)  
 
A longitudinal study in New Zealand included asthma patients (aged 15-56 years old) 
and found only two influenza infections (11%) in outpatients with an asthma 
exacerbation during one influenza season.(94) However, the small sample size of the 
study (n=31) and the low circulation of the influenza virus during the study period 
increased the uncertainty of this finding. However, influenza virus was detected in 
20% of patients with a severe asthma exacerbation.(94) Another prospective study in 
Australia detected influenza in 19% of hospitalised patients for an asthma attack during 
a 12 month period.(95) The use of viral culture and especially the serology test could 
have led to underestimation of influenza infections because a number of patients did 
not return their convalescent serum sample increasing the likelihood of undetected 
viral infections.(95) On the contrary, a larger study (n=138) with patients from 
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multiple sites in the UK during a two-year period detected only one influenza infection 
(1.6%) in patients with an asthma attack.(96) The use of complement fixation tests 
instead of immunofluorescence or enzyme immunoassay could have decreased the 
ability of the detection of pathogens such as influenza viruses. This is probably due to 
decreased viral shedding seen in adults resulting in lower virus isolation rates. 
Nonetheless, influenza was still associated with the most severe asthma attacks.(96)  
1.3.2 Pandemic influenza virus infection  
The focus of this thesis was on seasonal influenza and not on pandemic influenza. 
However, years with seasonal influenza activity may not reveal the true burden of the 
influenza in the asthma population. Some of the reasons for this could be the variability 
in influenza activity year by year. For example, in seasons with low viral activity 
healthcare providers may be more likely to report an influenza-related complication 
(e.g. pneumonia) as the reason for a medical attendance rather than influenza. Thus, 
the true burden of influenza could be underestimated. On the other hand, in seasonal 
with high viral activity laboratory tests may be more likely to be taken (for either 
surveillance or diagnostic purposes) from individuals with known high risk for 
influenza disease compared to the general population. In this case the disease burden 
of influenza will be overestimated in these at-risk groups such as asthma. Therefore, 
the presence of evidence on influenza burden from seasonal years only may fail to 
reveal the actual susceptibility of individuals with asthma to severe influenza disease. 
On the contrary, in pandemic years there is a plateau of high viral activity for a 
prolonged time which affects at-risk groups but also healthy population. Therefore, 
comparisons in terms of influenza burden between subgroups of the population such 
as asthma versus healthy individuals are feasible. Subsequently, these comparisons 
should reflect the actual vulnerability of individuals with asthma.  
Influenza pandemics occur due to antigenic mutations in sub-types of the virus 
generating a novel influenza virus strain. Pandemics usually extend beyond the winter 
months and can spread from a focus population within weeks or months globally 




The following four influenza pandemics have occurred during the 20th century: 
Spanish influenza in 1918, Asian influenza in 1957, Hong-Kong influenza in 1968 and 
the Russian influenza in 1977. The Spanish influenza or “flu” was the most virulent, 
accounting for more than 20 million deaths globally.(26)  
In 2009, the swine-origin influenza A(H1N1) virus marked the first influenza 
pandemic of the 21st century. The combination of gene segments between avian, swine 
and human viruses lead to the generation of a new A(H1N1) strain that had not 
circulated before in human or swine  (Figure 1.7). Asthma was the most common co-
morbidity amongst those hospitalised due to A(H1N1)pdm09 influenza worldwide. 
Influenza-related asthma attacks were high in both children and adults with 
asthma.(97) 
 
Figure 1.7: A(H1N1) pdm09 virus and asthma exacerbations  
Reproduced with permissions from: Obuchi M, et al. Influenza A(H1N1)pdm09 virus and asthma. Front Microbiol 
2013; 4: 307. 
 
Four observational studies in US and in the UK assessed the number of A(H1N1)pdm 
infection in ambulatory and hospitalised patients. Asthma was the most frequent 
medical condition ranging from 25-54%.(98-101)  
 
A US retrospective study including 5.3 million children found asthma as the most 
common medical condition in hospitalised children during the 2009 influenza 
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pandemic.(102) In addition, influenza-associated intensive care and secondary 
pneumonia rates were 6% higher during the 2009 pandemic compared to previous 
seasons. However, clinicians were testing more intensively for influenza in 
hospitalised patients during the pandemic and increase the use of RT-PCR than in 
previous seasons increasing the likelihood of an influenza diagnosis. Data on asthma 
severity were also not available which could have explained the reasons of hospital or 
intensive care unit admissions other than influenza-related asthma attacks.(102)  
Another retrospective study also assessed the association between 2009 pandemic 
influenza and severe outcomes in asthma inpatients, but in comparison to non-asthma 
controls (n=1,520) across 75 UK hospitals.(103) Patients with asthma were more likely 
to require oxygen support during their hospital admission than non-asthma patients 
(36.4% vs 26.0%, unadjusted Odds Ratio (OR): 1.63,  95% confidence interval (CI): 
1.27 to 2.08). However, pneumonia rates were similar between asthma and non-asthma 
patients (17.1% vs 16.6%, unadjusted OR: 1.04, 95% CI: 0.77 to 1.42). In addition, 
asthma patients were less likely to have severe outcomes (which were defined as death 
or the need for a high dependency unit or intensive care unit care while hospitalised) 
than non-asthma patients. Factors associated with asthma management such as pre-
admission inhaled corticosteroid use and earlier admission were possible explanations 
of decreased number of severe outcomes in asthma patients.(103) 
The above epidemiological studies have shown a link between influenza infection and 
asthma exacerbations and other clinical outcomes. Nonetheless, various reasons 
compromise the interpretation of these studies’ findings. First, different diagnostic 
methods for influenza influence the study outcomes. Second, the use of different 
definitions and diagnoses for influenza and asthma exacerbations does not allow 
comparison of findings or provision of pooled robust estimates. Third, inadequate 
sample sizes and short follow-up periods may mean that given the seasonality of 
influenza activity a proportion of influenza-induced asthma exacerbations are 
undetected. Thus, large cohort studies with standardised definitions and diagnoses for 
influenza and asthma exacerbations including multiple influenza seasons are required 














Respiratory viral, including influenza, induced complications in individuals with asthma 
Non-pandemic influenza seasons 
McIntosh86 1967-69 1-5 Hospital Culture; 
Serum 
Respiratory viral infection associated with an exacerbation of wheezing: 58/139 (42%) 
 
Influenza associated with wheezing episodes: 1/27 (4%) 
Minor84 1971-72 3-11 Allergy clinic Culture  Symptomatic respiratory infection associated with an asthma attack: 42/61 (70%) 
  
Influenza associated with an asthma attack: 6/61 (10%) 
Minor85 1971-72 3-11 O/P private 
practice 
Serum Influenza associated with a viral respiratory infection: 6/54 (11%) 
 
Influenza associated with a severe symptomatic respiratory infection: 3/13 (23%) 
Neuzil87 1973-93 <15 Database: 
Medicaid  
 
Culture   Incidence of influenza-associated hospitalisation for acute cardiopulmonary per 1000 
children (1 to <3 years): 5.6 
Incidence of influenza-associated hospitalisation for acute cardiopulmonary per 1000 
children (3 to <15 years): -0.7 
Incidence of influenza-associated outpatient visits per 1000 children (1 to <3 years): 190 
Incidence of influenza-associated outpatient visits per 1000 children (3 to <15 years): 93 
Incidence of influenza-associated antibiotic courses per 1000 children (1 to <3 years): 148 
Incidence of influenza-associated antibiotic courses per 1000 children (3 to <15 years): 132 
Beasley94 1984 15-56 O/P clinic Culture; Influenza associated with respiratory illness: 2/23 (9%) 
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 Serum Influenza associated with asthma exacerbation: 2/18 (11%)  
Influenza associated with severe asthma exacerbation: 2/10 (20%) 





 Respiratory illness associated with a respiratory tract viral infection: 155/184 (84%)  
Influenza associated respiratory illness: 21/292 (7.2%) 
Nicholson96 1990-92 19-46 Multiple Culture; 
Serum 
 Non-bacterial upper respiratory tract infections associated with an asthma exacerbation: 
27/61 (44%) 
Influenza associated with an asthma exacerbation: 1/61 (1.6%) 
Teichtahl95 1993-94 16-60 Hospital Culture; 
 Serum 
 Influenza A and B detected in hospitalised patients due to an asthma attack: 15/79 (19%) 
Miller88 2000-04 6-
59m 
Multiple   Culture; 
RT-PCR  
 Average annual influenza-attributable hospitalization rates (6-23 months): 2.8 cases per 
1000 children 
Average annual influenza-attributable hospitalization rates (24-59 months): 0.6 cases per 
1000 children 
Outpatient influenza-attributable visits (6-23 months): 316 cases per 1000 children 
Outpatient influenza-attributable visits (24-59 months): 188 cases per 1000 children 
Poehling89 2000-04 <59m Multiple  Culture; 
RT-PCR 
Out of 160 children with an influenza-related hospitalisation 20 (12%) had asthma 
Out of 267 children with an outpatient influenza infection 44 (16%) had asthma 
Wong90 2004-12 <18 Database Lab. 
confirmed 











Influenza A detected in hospitalised children for acute asthma exacerbation: 6/232 (2.6%) 
Influenza A detected in outpatient children for acute asthma exacerbation: 15/107 (14.1%) 
Kwon92 2010-11 5.3-
61m 
Ped. hospital RT-PCR Prevalence of influenza infection in hospitalised patients with an asthma exacerbation: 7/28 
(25%) 
2009 pandemic influenza season  
Dawood102 2003-09 2-17 Database Lab. 
confirmed 
 During the 2003-09 influenza seasons, 701 (32%) of 2165 children with an influenza-
related hospitalisation had asthma 
During the  2009 H1N1 pandemic, 733 (44%) of 1660 children with an influenza-related 
hospitalisation had asthma 
Intensive care due to seasonal influenza: 16% 
Intensive care due to 2009 pandemic H1N1 influenza: 22% 
Pneumonia related to seasonal influenza: 40% 
Pneumonia related to 2009 pandemic H1N1 influenza: 46%  
Asthma exacerbations due to influenza A: 51% 
Asthma exacerbations due to influenza B: 29% 
Mistry98 2008-09 0-19 ED Multiplex-
PCR 















2009 <1 to 
>75 
Hospital RT-PCR Out of 631 hospitalised patients with a confirmed A(H1N1)pdm influenza 159 (25%) had 
asthma 
Myles103 2009-10 <1 to 
>86 
Hospital RT-PCR Oxygen support for patients with a confirmed A(H1N1) influenza hospital admission: 
140/385 (36.4%)  
Pneumonia diagnosis in hospitalised patients with a confirmed influenza A(H1N1): 66/385 
(17.1%) 
O/P = outpatient; Pulm = pulmonary; RT-PCR = reverse transcriptase chain reaction; ED = emergency department; Ped = paediatric  
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1.4 Prevention of influenza infection  
Influenza vaccination is the main preventive measure against infection and related 
complications. However, new vaccines are needed for most years due to antigenic drift 
the viruses. Thus, WHO makes recommendations on influenza strains that should be 
included in the vaccine for the forthcoming year. Specifically, WHO has developed 
the Global Influenza Surveillance and Response System (GISRS) which provides 
influenza surveillance data which aid the monitoring of influenza activity in different 
parts of the world.(105) Sentinel practices have been established that receive influenza 
specimens from people with ILI and submit them to laboratories within national 
influenza centres. There are 110 such laboratories in 79 countries. When new influenza 
virus strains emerge, the samples are sent to one of the four WHO reference centres 
(Atlanta, London, Melbourne and Tokyo) for antigenic analysis. The results from the 
analysis are then sent to WHO which recommends the strains for inclusion in the new 
vaccines for the northern and southern hemisphere.(106) WHO in order to increase the 
efficacy of the influenza vaccines against the most dominant viral strains circulating 
in the northern and southern hemispheres revises its recommendations on the vaccines’ 
composition twice every year. Therefore, if new dominant influenza strains are 
circulating in the southern hemisphere, the WHO adjusts accordingly its vaccine 
composition recommendation for the northern hemisphere and vice versa.(24)(105) 
1.4.1 Influenza vaccines                                                                                                                 
Influenza vaccines can be classified into three broad categories: 
• Inactivated vaccines 
• Live attenuated vaccines 
• Recombinant vaccine  
Inactivated vaccines are the oldest (more than 70 years in use) and most commonly 
used vaccines worldwide. Inactivated vaccines (also called the flu shot) are 
administrated intramuscular or intradermally. They use an egg-based manufacture 
technology, where the candidate vaccine strains are grown in hen’s eggs for several 
days until sufficiently replicated and inactivated later before the vaccine is 
administered.(107) The influenza vaccine with adjuvant is another type of inactivated 
vaccine (also use egg-based technology), which was approved for the first time in 1997 
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in Italy. An adjuvant is an ingredient such as the MF-59 which has been added to the 
influenza vaccine in order to enhance immunogenicity and is usually used in older 
people (65 years or above) to trigger a stronger immune response.(108)   
Cell-based manufacture technology is also used to produce inactivated vaccines, with 
the first such vaccine (commercially named as “Flucelvax”), approved in November 
2012 in USA for adults only (18 years or above). The candidate vaccine strains are 
produced in a similar way to that of egg-based vaccines, but they are grown in 
mammalian eggs instead of hen’s eggs.(107)  
Live attenuated vaccines contain attenuated and cold-adapted influenza viruses 
generated in temperatures between 25o to 33o (thus unable to replicate at body core 
temperature) and which have been grown in hen’s eggs. It is administered as a nasal 
spray and it is recommended mostly for young and healthy populations.(107) The 
immunological benefits of live vaccines compared to the inactivated vaccines include 
the direct delivery of the viral antigen into the bronchial epithelium through its local 
administration to nasal passages than parenteral and the wider immunological 
response.(109) 
Recombinant vaccine (commercial name is “Flublok”) was approved in January 2013 
in the USA. It differs from the previous vaccines as it uses protein-based technology 
and does not need hen’s eggs to grow. The vaccine is produced using only the HA 
surface protein of the virus, which is known to trigger immune response in humans. It 
is only recommended for young adults, aged 18 to 49 years.(107)   
The current recommended influenza vaccines can further be categorised as trivalent or 
quadrivalent based on the number of virus strains included in the vaccine. Trivalent 
vaccines include two subtypes of influenza A virus (e.g., H1N1 and H3N2) and one 
lineage of the influenza B virus (e.g., Victoria or Yamagata), while quadrivalent 
vaccines include two subtypes of influenza A virus and both influenza B lineages.(36) 
Most seasons both lineages of influenza B circulate. Thus, quadrivalent vaccine aims 
to improve the antigenic match between circulating and vaccine strains and thus offer 
broader protection against influenza B.(36) Quadrivalent vaccines  are also more cost-
effective compared to trivalent vaccines. This is because influenza B viruses are more 
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common in children. Thus, the quadrivalent vaccine provides better direct protection 
in children and indirect protection in adults by reducing the transmission of the virus 
from children.(36)  
The development of “universal influenza vaccines” with high potency, duration and 
broad protection is a major priority. This is especially so for low and middle-income 
countries with limited or no immunisation resources prohibiting the annual seasonal 
vaccination of whole populations.(110)(111) The universal vaccines can be divided 
into those aiming to prevent influenza or those aiming to reduce disease severity (e.g. 
asthma exacerbation).  
1.4.2 Milestones of influenza vaccines development  
 
Figure 1.8: Landmarks on the road to influenza vaccines development 
 
In 429 before Christ (BC) the Greek historian Thucydides observed that individuals 
who survived the smallpox plague in Athens were not re-infected with smallpox.(112) 
A primitive type of vaccination called “variolation” was first used by the Chinese in 
900 anno domino (AD).(112) In 1976, vaccination similar to current forms was 
discovered by the British physician Dr. Edward Jenner.(112) Jenner used matter from 
cowpox lesions on the hands and arms of a dairymaid in order to inoculate an 8-year 
old boy. The boy developed immediately mild symptoms related to infection (e.g. mild 
fever) who fully recovered after a week. Jenner inoculated again the boy but with 
matter from smallpox lesions this time. The boy did not present any signs or symptoms 
related to smallpox which confirmed Jenner’s hypothesis that the boy was completely 
protected. The Latin word for cow and cowpox is vacca and vaccinia respectively. 
Thus, Jenner decided to name this new process vaccination. Jenner repeated his 
experiment in a few more cases where the results confirmed his hypothesis. He was 
therefore the first to prove the protective effects of the vaccination to the global 




In 1931, the American physician Ernest William Goodpasture discovered that several 
viruses including influenza can be cultivated in the chorioallantoic membrane of chick 
embryos.(114) Thus, a few years later,  in 1935, the first egg-based vaccine was 
manufactured.(115) Between 1935 and 1941, the first  influenza vaccines were tested 
in humans.(116) During the Second World War (1942-43) influenza vaccines were 
used for the first time in US army troops in Europe.(117)  
In 1946-47 scientists from the US Army Epidemiological Board and from the Office 
of the Surgeon General observed that strains of the influenza virus can mutate 
annually.(118) In 1997 the first adjuvant influenza vaccine was licensed in Italy.(81) 
In 2003, the first live attenuated influenza vaccine was licensed in US.(119)  In 2007 
the first cell-based technology influenza vaccine commercially named as “Optaflu” 
was licensed in Europe.(120) In 2013 the first recombinant-based technology influenza 
vaccine commercially named as “Flublok” was approved by the Food and Drug 
Administration (FDA) of the US (see Figure 1.8).(107) 
1.4.3 Priority groups for influenza vaccination                                                                                                    
According to WHO (121) and national committees, some groups should be vaccinated 
every year due to their high risk of influenza and influenza-related complications. The 
recommended targets groups include: children 6 months to 5 years old, older people 
aged 65 and above, pregnant women, persons with certain chronic diseases, health and 
social care providers, residents in nursing care homes or chronic care facilities and 
international travellers.(36)(121)  
• Children 6 months to 5 years old should be vaccinated due to the high risk of 
influenza and related complications in this age group. Young infants less than 6 
months old are not eligible to receive an influenza vaccine and they should be 
protected through the vaccination that their mother received during pregnancy or 
through herd immunity provided by its close contacts.(36)(121)  
• Older people (65 years and above) are recommended for vaccination due to their 
weak immune system and their high mortality risk.(36)(121)  
• Pregnant women should be vaccinated with quadrivalent inactivated vaccine 
(QIV) during pregnancy.(122) The risk of morbidity and mortality due to influenza 
is substantial in this group. In addition, the morbidity or mortality risk is even 
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higher in pregnant women with chronic diseases.(36)(121) For example, the risk 
of hospitalisation in pregnant women with asthma has shown to be 10-fold higher 
compared to healthy pregnant women.(121) Vaccination during pregnancy also 
protects young infants (<6 months old). Evidence from randomised trials 
conducted in low to middle income countries have shown that maternal vaccination 
reduces the incidence of influenza illness in mothers and their infants.(123-
125)Thus, WHO’s recommendation on vaccination in pregnancy of any stage 
protects mothers and their infants under six months.(121)  
• Persons with chronic diseases such as asthma, chronic heart disease, chronic 
neurologic disease, chronic kidney disease, chronic liver disease, diabetes, 
immunosuppression due to disease or treatment, asplenia or dysfunction of the 
spleen are more likely to infected with influenza.(36) Thus, individuals in this 
clinically at-risk group should be vaccinated according to immunisation 
programmes.(121)  
• Residents in nursing homes and patients in chronic care facilities are highly 
vulnerable to influenza due the rapid spread of the virus within residencies. Thus, 
vaccination is crucial in preventing the transmission of the virus and the subsequent 
influenza outbreak.(121) 




1.5 Rationale for a PhD in influenza vaccines in asthma 
I have always been interested in infectious diseases, especially for vaccine-preventable 
infections which their disease burden can be reduced or even eliminated at a national 
and global level. As a registered nurse, I have already provided care to patients with 
infections and I was always recommending and encouraging patients and colleagues 
to receive all their scheduled vaccines.    
During my undergraduate and postgraduate studies, I developed a particular interest in 
the influenza virus as it is such a genetically unstable virus due to almost annual 
mutations of its genetic code. Most people think of influenza as a common cold illness 
that will pass after a few days at home. However, as a healthcare professional I 
experienced first-hand the severe complications of the virus especially in patients with 
impaired lung epithelium and antiviral responses such as asthma patients. Thus, I was 
wondering why people that are at-risk of having serious influenza complications still 
refuse or undervalue the influenza vaccines, which can be life saving for some of these 
patients. In addition, why some patients that are immunised against the virus annually 
still experience complications, given that the vaccines have been in the market for 
almost 70 years now and many vaccine types have been developed since then.  
In 2014, after reading carefully the research proposal for this PhD and the relevant 
work conducted already by the Seasonal Influenza Vaccine Effectiveness (SIVE) 
study (126) in Scotland, I realised that the use of a large healthcare administrative 
dataset is the best method to answer my questions. In addition, this PhD programme 
was supported by the extensive infrastructure of the Asthma UK Centre for Applied 
Research (AUKCAR).(127) Specifically, the AUKCAR included a UK-wide 
postgraduate training platform which provides training on various topics on asthma 
and on research related skills. Other infrastructure includes programmes related to 
research methodology and data resources such as the Methodology platform, Asthma 
Observatory platform and REACH – Database for Research Volunteers. The Patient 
and Public Involvement platform also supports researchers with their studies by 
helping them to involve people with asthma during the whole research process.(96) 
This PhD was also part of the SIVE II project which aimed to assess the effectiveness 
of the influenza vaccination (as in the SIVE study) but aimed to use a larger scale of 
65 
 
data and subsequently answer more research questions relation to influenza 
vaccination effectiveness and safety. Working with the SIVE II team also meant that I 
would be able to get the statistical and epidemiological support needed for this PhD. 
Any research output would have also been examined by experienced researchers on 
influenza vaccines which decreases any doubts of the validity of any study 
findings.(128)  
I was unable to find any previous studies investigating the protection providing by the 
influenza vaccines in the asthma population. I therefore decided that outcomes form 
this PhD project will be particularly valuable to National Health Services (NHS) in 
Scotland and other international policymakers to decide whether the seasonal 
influenza vaccination programme is effective in the asthma population.  The findings 
will also help to maximize the seasonal influenza vaccination programme's impact on 
the health of the Scottish population with asthma by reducing asthma exacerbations, 
hospitalisations and deaths that may be viral-triggered. 
1.6 Summary to Chapter 1  
Respiratory viruses are a common trigger of asthma exacerbations, particularly in 
children. Influenza virus accounts for only 10-15% of all upper respiratory tract 
viruses. However, it can cause considerable morbidity and mortality among people 
living with asthma, as it has been observed during seasons with high influenza 
infectivity such as in the recent 2009 H1N1 pandemic. The protection against influenza 
is provided by the seasonal and pandemic vaccines which have been on the market for 
over 70 years.  
Having described the basic concepts of influenza and asthma, the impact of influenza 
in asthma, the available influenza vaccines and the rationale for this PhD project I will 
now outline, in the following chapter, the general aim and the individual components 
of the related empirical studies I undertook for the completion of this programme.
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Chapter 2. Aims, objectives and conceptual overview of methods 
2.1 Introduction  
Preventing influenza among people living with asthma is important because associated 
illness episodes are generally more severe and more common and vaccination is the 
main preventive strategy against influenza infection. Thus far, we do not know how 
many people with asthma take up influenza vaccination, how well influenza 
vaccination prevents influenza, and how the vaccination prevents the many other 
associated consequences of influenza among people living with asthma.  
2.2 Overall aim 
At the beginning of this PhD project, there was only one systematic review, performed 
by a Cochrane group in 2012 published by Cates et al which assessed the protective 
effects of the influenza vaccines in asthma. This review used evidence solely from 
randomised controlled trials (RCTs) up to 2012.(129) By only including RCTs, little 
evidence was found on the protective effects of the vaccines in people with asthma. In 
addition, according to the SIVE and AUKCAR researchers there was no up-to-date 
large observational studies trying to answer this question in the Scottish or UK-wide 
asthma population despite the UK being among countries with the highest asthma 
prevalence.(61) The overall aim of this thesis was to estimate  the protective effects of 
the influenza vaccines in asthma. In order to fulfil this aim I carried out three main 
phases of work including the systematic review of the literature and primary studies 
which are further described in section 2.4.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
2.3 Objectives  
The objectives of this PhD research work for people living with asthma were to:   
• Explore previous literature on the protective effects and safety of influenza 
vaccines. 
• Measure vaccine uptake and explore the factors influencing the propensity of 
a person with asthma to receive the vaccine.   
• Estimate the vaccine effectiveness (VE) in reducing RT-PCR confirmed 
influenza using a test-negative design (TND) case-control study. 
• Estimate VE in reducing clinical outcomes including asthma exacerbations, 
influenza-related primary care consultations, influenza, pneumonia, 
67 
 
respiratory, cardio- and cerebro-vascular hospital admissions and death using 
a retrospective cohort study design. 
2.4 Conceptual overview of the thesis  
In this PhD research programme the evaluation of the effectiveness of the influenza 
vaccine in people with asthma was achieved through successive phases  
The first phase (Chapter 3) included the identification and assessment of evidence 
related to the protective effects and the safety of seasonal influenza vaccination in 
children and adults with asthma through a systematic review. The findings from this 
phase guided the work undertaken in phases two and four.  
The second phase (Chapter 5) of the PhD included a TND case-control study in which 
I assessed the VE against influenza infection using healthcare data over multiple 
influenza seasons. This enabled the further assessment of the VE and the provision of 
stratified VE estimates (e.g. influenza season, influenza types and subtypes, vaccine 
type and age groups).  
For the third phase (Chapter 6) of my PhD I explored key demographic and clinical 
characteristics of vaccinated and unvaccinated for influenza people with asthma. I 
measured the vaccine uptake and conducted a vaccine uptake analysis to explore key 
characteristics related to vaccination of people with an asthma diagnosis in the 
community (general practices). The same people with asthma were then followed up 
in secondary care settings (hospitals) for an additional exploration of the same key 
characteristics related to vaccine uptake.  
The fourth phase (it is not yet completed and thus not included in this thesis) involves 
the assessment of the VE against clinical outcomes (e.g. influenza or pneumonia 
related primary or secondary medical attendance, influenza-related deaths) in patients 
with asthma. This phase is currently underway and its completion is estimated after 
the submission of this thesis.   
The synthesis of the thesis was guided from findings from complementary and 
successive phases of work.  Results from phase one which included the review of the 
literature on vaccination protection and safety were used to inform phase two which 
included the VE assessment through a case-control study. Phase one will also inform 
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the ongoing phase four which aims to assess the VE through a retrospective cohort 
study. Finally, findings from phase three regarding the factors influencing the vaccine 
uptake will aid the study in phase four to determine which factors need to be included 






    Figure 2.1: Conceptual overview of the PhD 
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2.5 Evolution of this thesis  
The evolution of this research programme was achieved through two main steps (see 
Figure 2.2):  
Systematic review: Before conducting the modelling work to estimate the protection 
of the vaccines, it was first necessary to interrogate the literature to identify any 
previous relevant work and gaps. I decided to do this using a systematic review where 
I investigated the evidence regarding the protective effects and the safety of vaccines 
in asthma. Searches for published and unpublished literature were carried out 
independently by two authors (Karim El Ferkh and I) in 2016. All studies found 
eligible for inclusion by both authors were then appraised regarding quality and any 
relevant data were extracted. The review showed that the vaccines can protect people 
with asthma from influenza and accompanying complications, however, the studies 
supporting this conclusion had several methodological and statistical limitations. Thus, 
the lack of robust evidence means we still question the protective effects of vaccination 
in the asthma population. In addition, the safety assessment of the vaccines as a 
secondary objective of this review could still not answer the evidence gap in live 
vaccines for young children with asthma (< 6 years old). An evidence gap was also 
reported in a previous systematic review by Cates et al in 2013.(129) The studies 
identified in my review guided my primary research work for the provision of robust 
evidence regarding the protection of vaccines in asthma.  
Epidemiological observational studies: The aim was to assess the influenza 
vaccination programme in Scotland being delivered by primary care to people with 
asthma using a national longitudinal retrospective observational study. The 
effectiveness and uptake of the vaccine in asthma was estimated using healthcare 
administrative data from national laboratory and secondary care databases linked to 
primary care database provided by the SIVE II project (a 20% sample of the Scottish 
population).(128) Data covered approximately 20 million patient-influenza seasons 
from 2000/01 to 2015/16. The effectiveness of the vaccine in preventing laboratory 
confirmed influenza was assessed using a TND case-control study (see Chapters 4 and 
5 for details on this study design). The effectiveness of the vaccine against non-specific 
clinical outcomes (e.g. asthma exacerbations) was another objective of this PhD 
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project. However, the results from this work were not available in time for inclusion 
in the thesis. Unexpected delays related to the access of the healthcare data for this 
study meant that the data preparation and analyses phases were completed at a later 
stage. Only preliminary results have been produced by the SIVE II team for the VE 
against influenza or pneumonia emergency hospital admissions. However, the absence 
of high-quality evidence (given the presence of bias and confounding related to cohort 
studies measuring non-specific clinical outcomes – see Chapter 4) for the VE against 
clinical outcomes means that it was not possible to make any definitive assessments 
of the VE; hence, additional analyses are required for these outcomes. I also explored 
characteristics of the asthma population specific to influenza vaccine uptake. 
Vaccination occurs primarily in the community (general practices). I first explored 
characteristics of the general asthma population in the community and then followed 
them up in secondary care to explore characteristics of those that were hospitalised 
due to influenza or pneumonia (see Chapter 6).   
Future work: The evidence gap in safety of the live vaccine in young children with 
asthma identified during the literature phase of this thesis could not be addressed in 
this project due to time limitations. However, this research question needs to be 
answered given that the live vaccine is one of the predominant vaccines administered 









2.6 Summary to Chapter 2  
In this chapter, I have outlined the aim, objectives, the conceptual overview and the 
evolution of this thesis. I will now move on to assessing the literature about the 
effectiveness and safety of influenza vaccines in children and adults with asthma based 
on clinical and epidemiological studies against laboratory and clinical outcomes. 
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Chapter 3. Effectiveness and safety of influenza vaccines in asthma: 
a systematic review and meta-analysis 
In this chapter, I will examine the existing published and unpublished literature to 
identify evidence regarding the protective or adverse effects of influenza vaccines in 
asthma. The review of the literature including the identification, data extraction and 
quality appraisal of the eligible studies will be conducted in a systematic and objective 
approach by two independent reviewers. Relevant qualitative and quantitative 
synthesis of the literature will also be conducted, if relevant.  
3.1 Introduction 
Influenza is an acute respiratory illness caused by infection with the influenza virus, 
which can be severe and, particularly in high-risk groups, result in considerable 
morbidity and, in some cases, death.(130)(131) Worldwide, influenza causes an 
estimated five million cases of severe illness and half a million deaths each year. The 
overall cost to health services in the US has been estimated at US$87 billion per 
annum.(132)(133) 
 
The burden of influenza is particularly high in individuals with chronic medical 
conditions.(36) In people with asthma, it is thought that chronic airway inflammation 
and type-2 immune responses impair antiviral immunity in the respiratory tract,(134) 
resulting in susceptibility to severe influenza illness and associated bacterial infection. 
Mechanisms of increased susceptibility to influenza in asthma include weaker innate 
immune and T-helper 1 cell responses and a deficient interferon alpha response of 
plasmacytoid dendritic cells to influenza.(74)(134) Furthermore, influenza infections 
can lead to severe asthma attacks often requiring hospitalisation. In adults, it is 
estimated that about 20-25% of acute asthma exacerbations leading to emergency 
department visits or hospital admissions are associated with influenza.(93)  
 
Annual immunisation with influenza vaccine is currently recommended by the WHO 
and national immunisation technical advisory groups in the US and a number of 
European and other high-income countries.(36)(50)(121)(135)(136) The uptake in 
people with at-risk conditions – including asthma – is however well below the target 
of 75%; it was, for example, only 40% in the US during the 2015-16 influenza 
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season.(137-139) The reasons for this lack of coverage are complex and multifactorial, 
but include a lack of confidence in healthcare providers and patients in the 
effectiveness and safety of influenza vaccine.(140)(141) Decreased perceived risk and 
severity of influenza may also influence the vaccine uptake.(142) Nonetheless, 
evidence has shown that about 75% of people with influenza are asymptomatic and 
25% of influenza infections are detected by PCR test. Only 17% of people with 
influenza infection confirmed by PCR test were medically attended.(56) Failure to 
detect asymptomatic and non-medically attended influenza cases may underestimate 
the true influenza burden leading to lack of public awareness on the impact of  
influenza and public misbelief that vaccination is unnecessary.(104) Important in this 
respect is the hypothesis that the defective mucosal and systemic immunity in asthma 
(72)(143) may reduce protection provided by influenza vaccines. There may be some 
grounds to this concern in the context of asthma as a recent Cochrane systematic 
review (129) investigating the effectiveness of influenza vaccination in those with 
asthma was inconclusive regarding the efficacy of influenza vaccines. Also of concern 
is that the safety of live influenza vaccines in infants with wheezing disorders/asthma 
has not yet been conclusively established.(129) Given that placebo RCTs of influenza 
vaccination are no longer being undertaken in people with asthma (the last placebo 
RCT was carried out in 2001 and there is none planned),(144) there is the need to in 
addition to RCTs also consider evidence from other study designs.(145) We therefore 
carried out a systematic review and meta-analysis of RCTs and robust quasi-
experimental and epidemiological studies to evaluate the efficacy, effectiveness and 
safety of influenza vaccination in people with asthma. 
 
3.2 Methods 
3.2.1 Selection criteria and search strategy 
Our methods have been described in detail in our published protocol (146) and our 
registration of this systematic review in the international prospective register of 
systematic reviews (PROSPERO) database (CRD42016037219). We included papers 
which adopted definitions reflecting the heterogeneous definition of asthma.(64) These 
included people with a history of asthma symptoms and evidence of reversible 
obstruction of respiratory airways (e.g. bronchodilator reversibility tests or other tests) 
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in the preceding 12 months, confirmed by a clinician. Patients with asthma were 
included in the review regardless of their current asthma treatment. Additionally, study 
participants who had asthma or other chronic medical conditions were included in the 
review provided that separate data on asthma were available from the study or by 
personal communication with the authors.  
 
We included studies of influenza vaccines of any type except for pandemic influenza 
vaccine, any dose and any schedule when compared with placebo, no vaccine or other 
vaccine. We excluded previous systematic reviews and meta-analyses, which were 
used only for identifying additional studies.  
 
Our primary outcomes were: 1) a laboratory-confirmed diagnosis of influenza; that is, 
the incidence or prevalence of laboratory-confirmed influenza infection using any of 
the available diagnostic tests (RT-PCR or other laboratory tests);(36)(52) and 2) 
asthma exacerbations.  
 
Our secondary outcomes were: 1) hospitalisations (asthma related and all-cause); 2) 
deaths (all-cause and respiratory illness); 3) primary care consultations (asthma-related 
and acute respiratory illness, including ILI); 4) respiratory illnesses (clinically 
diagnosed or by self-report) and 5) safety, as assessed by asthma exacerbations and 
other local or systemic reactions.(36)(147)(148) 
 
We included published and unpublished research reports of RCTs or controlled clinical 
trials and the following observational study designs: TND studies, prospective and 
retrospective cohort, case-control studies and nested case-control studies.  
 
We searched the published literature from January 1970 to January 2016 for studies 
investigating the effectiveness of influenza vaccination in people with asthma. This 
start date was chosen because the evidence on this subject began to accrue following 




We searched MEDLINE (Ovid), EMBASE (Ovid), Cumulative Index to Nursing and 
Allied Health Literature (CINAHL), Cochrane Central Register of Controlled Trials 
(CENTRAL), Scopus, Cochrane Database of Systematic Reviews (CDSR), Web of 
Science Core Collection, Science direct, WHO Library Information System 
(WHOLIS), Global Health Library and Chinese databases (CNKI, Wanfang and 
ChongQing VIP) for published experimental and observational studies. Electronic 
searches were complemented by manually searching reference lists of included papers 
for additional studies. In addition, forward citation search was performed on all 
identified studies using Web of Science. Furthermore, unpublished or ongoing clinical 
trials were searched in clinical trials registry databases using http://www.controlled-
trials.com/, http://www.clinicalTrials.gov/ and the WHO International Clinical Trials 
Registry Platform (ICTRP) using http://www.who.int/ictrp/en.  We contacted 
pharmaceutical companies that manufacture influenza vaccines used in the trials to 
identify additional published or unpublished studies. Authors of the studies included 
in the review were contacted when we required additional information. There was no 
language restriction. Specific search strategies were developed for each database (see 
appendix A1; p 239).  
3.2.2 Risk of bias assessment and data extraction  
Two reviewers (EV and KF) independently assessed the risk of bias, and 
disagreements were resolved through discussion or by the involvement of a third 
reviewer (CS). The risk of bias of experimental studies was assessed using the criteria 
outlined in the Cochrane Collaboration’s tool (152) according to the following six 
domains: 1) sequence generation; 2) allocation concealment; 3) blinding of 
participants and personnel and outcome assessors; 4) outcome ascertainment; 5) 
selective outcome reporting; and 6) other bias. Risk of bias in included studies was 
divided into three categories: high, low, or unclear. The overall risk of bias rating was 
based on the suggested algorithm in the Cochrane Collaboration’s tool.(152) 
Specifically, overall low risk of bias was assigned to a study with low risk of bias 
ratings across all six domains, overall unclear risk of bias to a study with unclear risk 
of bias ratings in one or more domains and overall high risk of bias to a study with 
high risk of bias ratings in one or more domains.  
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The Quality Assessment Tool for Quantitative Studies Dictionary developed by the 
Effective Public Health Practice Project (EPHPP) was used for the evaluation of 
observational studies and non-randomised controlled studies.(153) The EPHPP tool 
contains the following eight components: selection bias (external validity), study 
design (allocation bias), confounders, blinding (detection bias), data collection 
methods, withdrawals and dropouts (attrition bias), intervention integrity and analyses. 
The first six components are rated as strong, moderate, or weak. There was no rating 
for the last two components. The overall study rating was judged as strong, moderate, 
or weak based on the component ratings. Specifically, the overall quality of a study 
was assigned as strong in the absence of weak ratings across all six components, 
moderate in the presence of one weak rating and weak in the presence of one or more 
weak ratings. Relevant data from studies eligible for inclusion were extracted by two 
reviewers (EV and KF), independently, using a data abstraction form designed for this 
review (see appendix A2; p 251). Any disagreement upon the extraction of data of the 
included studies was resolved through discussion or by the involvement of a third 
reviewer (CS). 
3.2.3 Grading the quality of evidence 
The strength of evidence for each outcome was assessed using the Grading of 
Recommendations Assessment, Development and Evaluation (GRADE) Working 
Group methodology.(154) This evaluation was based on the following five domains: 
risk of bias, consistency, directness, precision and publication bias. There were four 
possible levels of quality: high, moderate, low, and very low. The GRADEpro software 
was used to determine the overall quality rating for each outcome. However, the 
GRADE tables were adjusted based on components that are more suitable for the 
current review. 
3.2.4 Data analysis 
Separate meta-analyses were performed for clinically and methodologically 
comparable experimental and observational studies in order to estimate the incidence 
or frequency of influenza infection (laboratory confirmed) and febrile illness. 
Random-effects models were used to summarise the findings depending on the degree 
of clinical heterogeneity of the studies. For dichotomous outcomes, the treatment 
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effect was estimated using a risk ratio (RR) with 95% CI or OR with 95% CIs. Vaccine 
efficacy and VE is usually reported as a percentage e.g. (1-OR)*100. Safety data from 
cross-over trials could not be pooled together due to lack of adequate data regarding 
the two cross-over periods. Statistical heterogeneity was assessed using the standard 
χ2 test and the I2 statistic, which describes the proportion of dispersion across studies 
due to true heterogeneity rather than to a sampling error (0-100% heterogeneity). We 
contacted authors of included studies that had missing data. All statistical analyses 
were undertaken using RStudio version 0.99.893.(155)   
 
We were unable to perform any sensitivity, subgroup analyses due to small number of 
studies included in our meta-analyses. Similarly, publication bias assessment could not 





3.3.1 Selection of studies and study characteristics  
Our initial research identified 20,396 unduplicated records. After screening of titles 
and abstracts, 318 potentially eligible studies were selected for full review. Thirty-two 
studies eligible for inclusion were identified through database searches and a further 
three studies through reference screening. We therefore included 35 studies enrolling 
142,519 patients with asthma in qualitative synthesis and four studies in the meta-
analyses (see Figure 3.1).(144)(149)(156-188) 
 
 
Figure 3.1: PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-
Analyses) diagram 
Fifteen studies were conducted in Europe,(144)(157)(159)(161-163)(166)(167)(170-
172)(174)(177)(186)(187) 10 in the US,(149)(156)(158)(164)(169)(180)(182-185) 
eight in Asia,(160)(165)(173)(176)(178)(179)(181)(188) one in Mexico,(168) and one 
in Australia.(175) Data for people with asthma were provided by two (184)(185) out 
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of 35 studies. A third study identified from references (161) did not report data 
separately for people with asthma. However, Cates et al (129) were able to obtain these 
data and we therefore included the data reported by Cates et al in our review. No 
eligible studies were found through trial registries or influenza vaccine manufacturers. 
Twenty RCTs were included,(144)(149)(156-173) six non-RCTs,(174-179) seven 
cohort studies (180-183)(186-188)and two case-control studies were also 
identified.(184)(185)  
 
Seventeen studies recruited children as study 
participants.(144)(149)(157)(159)(160)(165)(168)(169)(173)(176)(179-
183)(186)(187) Ten studies included adult participants 
(156)(161)(163)(164)(166)(170)(171)(174)(177)(178)and seven studies included both 
children and adults.(160)(162)(172)(175)(184)(185)(188)No age range of patients was 
reported in one study.(167) Inactivated influenza vaccine was the intervention in 22 
studies,(144)(149)(157)(158)(161-164)(166-168)(170-172)(174-179)(187)and live 
attenuated vaccine (LAIV) in four studies.(156)(165)(169)(173) One study compared 
live with inactivated vaccination.(159) However, eight studies did not specify the type 
of vaccination.(160)(180)(182-186)(188)  
 
The protective effects of the vaccine were assessed in 20 studies against our primary 
and/or secondary outcomes of interest. Specifically, laboratory confirmed influenza 
was assessed in seven studies (159)(165)(170)(173)(184-186) (three RCTs, one non-
RCT, one cohort study, and two TND case-control studies), asthma exacerbation in 
seven studies (144)(160)(174)(179)(181)(182)(188)(two RCTs, two non-RCTs, three 
cohort studies), hospital admissions in six studies (149)(160)(174)(179-181)(two 
RCTs, two non-RCTs, two cohort studies), primary care consultations in two studies 
(159)(180)(one RCT and one cohort study), respiratory illness in eight studies 
(144)(164)(173)(174)(179)(181)(186)(187)(three RCTs, two non-RCTs, three cohort 
studies), emergency department visits in three studies (160)(180)(181)(one RCT and 
two cohort studies), increased use of asthma medication in two studies (160)(181) (one 
RCT and one cohort study), pulmonary function in one study (143) (one non-RCT) 
and school or work absenteeism in one study (159) (one RCT). Safety of the vaccine 
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against asthma attacks, local and systemic adverse reactions, healthcare use, influenza 
infection, respiratory illness, pulmonary function, asthma medication and work or 
school absenteeism was evaluated in 19 RCTs,(149)(156-173) four non-RCTs,(175-
178) and one cohort study.(183) 
3.3.2 Risk of bias assessment in individual studies 
We preferentially looked at data from RCTs. The overall risk of bias was high in five 
RCTs, unclear in 12 RCTs and low in three RCTs. The overall quality of 12 studies 
(six non-RCTs and six cohort studies) was rated as “weak”. In two case-control studies 
and in one cohort study, the overall quality was rated as “moderate” (see Figures 3.2 





Figure 3.2: Risk of bias summary: review authors’ judgments about each risk of bias 






Figure 3.3: Quality assessment of the non-RCTs and observational studies using the 
EPHPP quality assessment tool 
 
3.3.3 Overall quality of evidence 
The body of evidence regarding influenza VE and safety regarding primary and 
secondary outcomes was rated using the GRADE approach as being of very low 
quality due to inconsistency, indirectness, and imprecision across studies. In addition, 
the strength of evidence for the protective effects of vaccination against pulmonary 
function and school or work absenteeism was rated as very low since the evidence was 
based on single studies. Thus, the consistency, directness, and precision of the pooled 
overall estimation could not be assessed. Similarly, the evidence of safety of influenza 
vaccination against influenza infection and respiratory tract illness was assigned as 




3.3.4 Vaccine efficacy and effectiveness against influenza infection  
Nosocomial outbreaks of A (H1N1) and B subtypes were observed during two 
consecutive years (1988-89 and 1989-90) among 84 children with asthma.(165)(173) 
Protection provided by LAIV in these children against laboratory confirmed influenza 
was found in two small RCTs (pooled VE 81%; 95% CI: 33 to 94; see Figure 3.4). A 
large multicenter RCT evaluated the efficacy of the live vaccine compared to the 
inactivated vaccine against community-acquired culture-confirmed influenza illness in 
children (aged 6-17 years).(159) The efficacy of LAIV was significantly higher than 
the inactivated influenza vaccine. The live vaccine efficacy against influenza subtypes 
antigenically similar to those included in the vaccine was 35% (95% CI: 4 to 56).  
 
 
Figure 3.4: Live attenuated influenza vaccine versus no vaccine against influenza 
infection (RCTs) 
A meta-analysis was undertaken of two TND studies performed in the US during the 
seasons 2011-13.(184)(185) In 2011/12, the influenza vaccine was well matched and 
influenza A H3N2 predominated with A H1N1 and both influenza B (Victoria and 
Yamagata) also circulating.(189) In 2012/13, H3N2 again predominated in the US 
with a late season predominance of influenza B.(190) The influenza VE for people 
with asthma ranged was 38% (95% CIs -0.05 to 63·0) in 2011/12 and 46% (95% CIs 
32 to 58) in 2012/13. Once these results were pooled, we found an overall VE of 45% 
(95% CI 31 to 56; see Figure 3.5) in preventing influenza (RT-PCR laboratory 




Figure 3.5: Seasonal influenza vaccine versus no vaccine against laboratory 
confirmed (RT-PCR) influenza infection (test-negative design studies) 
One prospective cohort study assessed the effectiveness of the influenza vaccine in 
preventing influenza in 338 children during the 2005-2006 season. There were no 
laboratory confirmed influenza infection cases in the vaccinated group, while eight 
(4·4%) unvaccinated children had an infection.(186) In a non-RCT, the overall 
efficacy of inactivated vaccine was 42% (95% CIs 21 to 57) against influenza infection 
(diagnosed by virus isolation or HI antibody titre increase) in 137 children (aged 2-14 
years).(179) During the epidemic period, antigenic drift was observed in A(H3N2) flu 
strain. However, the efficacy against the A (H3N2) subtype was higher (VE 68%) than 
of the well-matched B subtype (VE 44%), particularly in children >7 years old 
(p<0.01).  
3.3.5 Vaccine efficacy and effectiveness against asthma attacks and other clinical 
outcomes  
The protective effects of vaccination against asthma exacerbation were also observed 
in four studies.(160)(181)(182)(188) One RCT (160) found protective effects of the 
influenza vaccine against the incidence, frequency and duration of asthma attacks in 
201 children (aged 1-15 years). Acute asthma attacks were lower in the vaccinated 
group (39/79) compared to the unvaccinated group (82/122) (RR 0.73; 95% CI: 0.57 
to 0.95).   
 
VE against asthma attacks was also studied in three observational cohort 
studies.(181)(182)(188)In the first study, inactivated influenza vaccine provided 
higher protection against asthma attacks (defined as wheezing episodes) (mean + S.D.: 
1·6 + 1.6) compared to the unimmunised group (mean + S.D.: 6·2 + 3.9) 
(p<0.001).(181) The second study provided evidence regarding reduction in attacks 
after controlling for asthma severity and other confounders. Protective incidence rate 
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ratios were observed for the 1994-5 season (0·59; 95% CI: 0·43 to 0·81), and the 1995-
6 season (0·65; 95% CI: 0·52 to 0·80), but not for the 1993-4 season (0·78; 95% CI: 
0·55 to 1·10).(151) In the third study, the rate of asthma attacks was significantly 
(p=0.037) lower in the vaccine group (mean + S.D.: 0·14 + 0·4) compared to control 
group (mean + S.D.: 0·35 + 0·61) during the 2002-3 season, but not in the 2001-2 
season.(188) 
 
Six studies assessed VE in preventing hospitalisations due to asthma attacks or 
respiratory infections (e.g., pneumonia, influenza-like illness and 
pharyngitis).(149)(160)(174)(179-181)A RCT assessed the duration of hospitalisation 
for ILI accompanied by asthma, ILI and asthma alone in 93 children (aged 6-16). The 
length of hospitalisation for ILI alone (p<0·01) and ILI accompanied by asthma 
(p<0·05) was significantly lower in the bivalent inactivated vaccine group compared 
to the unvaccinated group.(149) In a cohort study, the number of hospitalisations was 
0·2 + 0·6 (mean + S.D.) among the inactivated vaccine recipients and 1·3 + 1·5 (mean 
+ S.D.) among controls (p<0.001).(181) 
 
Two studies (159)(180)assessed the protective effects of vaccination against asthma 
or respiratory illness consultations. A retrospective cohort study reported higher visits 
to a paediatric clinic among vaccine recipients (2.14) than in the unvaccinated ones 
(0.71; OR: 2·9; 95% CI: 2·0 to 4·1).(180) 
 
VE against respiratory illness was found in four studies.(179)(181)(186)(187) Pooled 
estimates regarding live attenuated VE against febrile illness were estimated from two 
RCTs.(165)(173)Pooled VE of 72% (95% CI: 20 to 90; see Figure 3.6) was observed 
against febrile illness during two nosocomial outbreaks with A (H1N1) and B 
subtypes.(165)(173) In another trial, clinical efficacy of inactivated subunit vaccine 
against febrile influenza illness was 49% (95% CI: 24 to 66)  in 137 children (aged 2-
14 years) (p<0.01). A higher vaccine efficacy (74%) was observed in children at least 





Figure 3.6: Live attenuated influenza vaccine versus no vaccine against febrile illness 
(RCTs) 
The protective effects of vaccination against respiratory illness were also reported in 
three cohort studies. In the first study, the number of respiratory tract illnesses were 
significantly lower (mean + S.D.: 2·2 + 2·1) in the inactivated vaccine recipients 
compared to the unvaccinated group (mean + S.D.: 6·9 + 3·9) (p<0.001).(181) The 
second study found that 0·6% of vaccine recipients had a RSV infection compared to 
2·5% of controls. In addition, protective effects of the vaccine were also observed 
against other respiratory infections (RR: 0·61; 95% CI: 0·29 to 0·95) and bronchiolitis 
(RR: 0·47; 95% CI: 0·26 to 0·84).(186) In the last study, the effectiveness of the 
inactivated subunit vaccine was 56% (95% CI: 18 to 76) against acute respiratory 
disease (defined as ILI, bronchitis, bronchiolitis, asthma exacerbation or otitis media) 
during the 1996-7 season. In particular, higher VE of 77% (95% CI: 35 to 92) was 
found in younger children < six years old.(187)  
 
The VE in preventing asthma-related emergency department (ED) visits was evaluated 
in three studies.(160)(180)(181)A cohort study observed lower ED visits for asthma 
exacerbations among inactivated vaccine recipients (mean + S.D.: 0·4 + 0·9) than the 
unvaccinated group (mean + S.D.: 2·2 + 2·6) (p<0.001).(150) In contrast, another 
cohort study of vaccinated children had more ED visits for asthma or pneumonia (OR 
2·0; 95% CI: 1·2 to 3·1).(180) 
 
The protective effects against increased use of asthma medication were also reported 
in two studies.(160)(181) In a RCT, the frequency of bronchodilators use was lower 
in the vaccinated group (35/79) compared to unvaccinated group (77/122; OR 0.46; 
95% CI 0.26 to 0.83).(160) A cohort study reported significantly (p<0.001) higher 
number of bronchodilator administrations in the unvaccinated group (mean + S.D.: 6·2 
+ 3·9) than the inactivated vaccine group (mean + S.D.: 1·6 + 1·6). Similarly, 
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prednisolone administrations were significantly (p<0.001) higher in the unvaccinated 
group (mean + S.D.: 1·1 + 1·2) compared to vaccinated group (mean + S.D.: 0·1 + 
0·3).(181) No improvements in pulmonary function and reduction in work/school 
absenteeism were found from influenza vaccine.(159)(174)  
3.3.6 Safety of influenza vaccines  
The safety of the vaccination against asthma exacerbation was measured in eight 
studies.(158)(159)(163)(166)(169)(169)(178)(183) One cross-over RCT (166) 
reported moderate to severe exacerbation of asthma within 72 hours following 
immunisation with inactivated vaccines vs. placebo. The risk of asthma exacerbation 
was considerably higher in the first-time vaccine recipients (1 in 16) compared to 
second-time vaccine recipients (1 in 83). However, the increased risk of exacerbation 
was no longer significant after excluding patients with colds or incomplete symptom 
diaries. A cohort study found higher risk of influenza-vaccine asthma exacerbations 
among the vaccine recipients. However, the incidence rate ratios were 0·58 (95% CI: 
0·36 to 0·95), 0·74 (95% CI: 0·47 to 1·17), and 0·98 (95% CI: 0·76 to 1·27) after 
controlling for severity of asthma and other potential confounders during all three 
seasons (1993-96).(183) 
 
The risk of local and systemic adverse reactions, including asthma-related symptoms 
following vaccination was estimated in 20 trials.(157-163)(165-173)(175-
178)However, significant differences were observed in eight trials.(157-
160)(166)(167)(170)(173)Side-effects (fever, body pain, sore throat, cough, 
rhinorrhoea, headache, and malaise) were reported in nine (11·4%) out of the seventy 
nine vaccine recipients and none in the placebo group within two weeks after 
immunisation.(160) The number of systemic symptoms and all symptoms were 
significantly higher in the inactivated vaccine group than the placebo within three days 
following vaccination.(166) Erythema (23%) and painful or stiff arm (48%) were more 
frequent among inactivated vaccine recipients than placebo during the first week after 
vaccination.(157) Influenza-like illness symptoms including fever (8%), headache 
(10%), myalgia (18%), and hoarseness (5%) were also more often reported in the 
vaccine group.(144) Cough (8%) was the only asthma symptom that was found to be 
significantly higher in the vaccine group than placebo.(157) 
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Myalgia was significantly higher in the inactivated vaccine group (25·1%) than 
placebo group (20·8%) two weeks after vaccination.(158) One month after 
immunisation with inactivated vaccine eight patients developed systemic symptoms 
(sore throat, fever, and malaise) and one patient developed a local reaction at the 
injection site. No adverse reactions were found in the placebo group.(170) Redness at 
the site of injection was the only local adverse effect within six weeks following 
immunisation with inactivated subunit, split and placebo injection.(167) Diarrhoea was 
the only significant systemic adverse reaction in five patients after the first vaccination 
(mainly after the split vaccine), and in four patients after the second vaccination with 
the subunit vaccine.(167) 
 
The safety of LAIVs against local and systemic adverse reactions was also assessed in 
four RCTs.(159)(165)(169)(173)Rhinorrhoea was significantly higher in live vaccine 
recipients (80%) than placebo controls (52%) within one week following 
immunisation.(173) The incidence of adverse events was similar between the live and 
inactivated vaccine groups within 15 and 28 days after immunisation. However, LAIV 
recipients reported runny nose or nasal congestion (66·2% Vs 52·5%), rhinitis (7·4% 
Vs 3·9%) and headache (6·5% Vs 4·2%) more often than TIV recipients while wheeze 
was observed more often in the inactivated group (23·8%) than live vaccine group 
(19·5%). In addition, local reactions at the injection site were reported in 70·8% of 
TIV recipients. 59·8% of TIV recipients reported pain at the injection site.(159) 
 
Pulmonary function deterioration following vaccination was assessed in 16 clinical 
trials.(149)(156)(158)(159)(162)(166-172)(175-178)Three studies found a decrease in 
lung function after immunisation.(149)(166)(175) However, the decrease in lung 
function was not accompanied with an exacerbation of asthma (asthma symptoms, 
increased medication or health-care use). No significant differences were reported 
post-vaccination for use of asthma medication, health-care use, influenza, respiratory 
illness, and work or school absence.(156-158)(166)(178) We found four non-RCTs 
(175-178) and one observational study (183) (not included in the Cates review [129]).  
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These papers found that the influenza vaccine led to no increase in post-vaccine asthma 
attack or symptoms when compared to placebo (for non-RCT studies) or no vaccine 



















































































































   No No Yes Yes No  
Bell 1978 
    Yes   Yes  
Bueving 2004   
 Yes Yes No No    No 
Castro 2001 No No Yes No No    No 
Fleming 2006 No No Yes     No  
Gharagozlou 2006 
  Yes       
Govaert 1993 
  No       
Hahn 1980 
  No     No  
Kmiecik 2007 No  Yes       
Miller 2003 No         
Miyazaki 1993 
  No       
Nicholson 1998 Yes  Yes No No   No  
Ortwein 1987 
  Yes     No  
Pedroza 2009 
  No     No  
Redding 2002 No No No  No   No  
Reid 1998 
 No Yes  No   No  
Sener 1999 
 No No  No   No  
Stenius 1986 
 No   No   No  
Tanaka 1993  
  Yes       
Non-RCTs  
Campbell 1984 
 No   No   No  
Chiu 2003 
 No      No  
Kava 1987  
  No  No   No  
Kim 2003  No No  No No   No  
Observational study  
Kramarz 2000* No         
 
Figure 3.7: Safety outcomes in experimental and observational studies 
*Asthma exacerbations were significantly higher only in the 1993-94 influenza season (p-value: 0.03).   
 
Summary of all studies’ findings are also provided in appendix (see Appendix A8; p 
279). Additional graphical presentation of the VE against primary and secondary 




Our findings indicate that there is some evidence supporting the effectiveness of 
influenza vaccination to prevent influenza and other clinically important health 
outcomes in people with asthma. In particular, pooled estimates from observational 
TND studies suggest that influenza vaccination is beneficial against laboratory-
confirmed influenza (VEs ranging from 38-46%, with a pooled estimate of 
45%).(184)(185) The effectiveness of vaccination in reducing asthma exacerbations, 
healthcare use, respiratory illness and medications for asthma was also 
identified.(149)(160)(165)(173)(179)(181)(182)(186)(188) However, much of this 
evidence comes from observational studies and therefore bias, residual confounding 
and confounding by indication are alternative possible explanations. Also, for each 
outcome the quality of the body of evidence (across all included studies) was very low 
according to the GRADE methodology.  
There are several reasons why there is a need to consider evidence from robust quasi-
experimental and observational studies. A Cochrane review of RCTs on this subject, 
which found inconclusive evidence to support influenza vaccination in those with 
asthma,(129) whilst well conducted, was however of limited value to decision makers, 
clinicians or patients. This is because there have been no relevant placebo RCTs over 
the last 15 years and no new trials are in progress or planned as it has been considered 
unethical to withhold vaccination, particularly from those most at risk of severe 
influenza illness. There are various reasons why RCTs of influenza vaccination in 
people with asthma are not conducted. First, influenza vaccines are included in public 
health guidelines, therefore RCTs are automatically disallowed as there is no 
uncertainty regarding the benefits of the vaccines in asthma patients. Second, new 
influenza vaccines are developed with the assumption that they are more efficacious 
than current vaccines. Third, RCTs will delay providing any results in a timely manner 
given that the influenza strains change constantly from season to season or even within 
the season. For example, it would be unethical to conduct an RCT for the new vaccines 
and delay giving life-saving immunisation protection to at-risk populations. Finally, 
even a large and robust RCT will only be able to provide subject, place, time and 
influenza strain and vaccine strain specific results. This is because influenza vaccine 
strains change every season, new influenza vaccines are developed every few years, 
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circulating influenza strains change by time (e.g. season) and the subjects’ pre-existing 
immunity from previous exposure to influenza (or the influenza vaccine) varies by 
time, place and age. Therefore, ethical and logistic reasons would render RCTs 
inappropriate and improper for estimating the protective effects in current and new 
influenza vaccines in asthma patients.(191)(192)  
 
Furthermore, observational TND studies are now being used to help inform national 
advisory bodies on their influenza vaccination programmes. For instance the Advisory 
Committee on Immunization Practices (ACIP) has not recommended the use of LAIV 
in the US during the 2016/17 seasons.(193) Evidence of no effectiveness (3%) of 
LAIV vs. good effectiveness of inactivated vaccine (63%) from US based TND studies 
was the primary reason for this decision.(193) In 2018/19 season ACIP started 
recommending the LAIV for children aged 2 to 17 years old.(194) Evidence from the 
UK LAIV programme shows VE particularly for the influenza B and A(H1N1) strains. 
Specifically, in 2016/17 season the overall VE was 66% while no overall significant 
VE was observed in 2017/18 season. However, in 2017/18 season high VE of 60% and 
90% was found for the influenza B and A(H1N1) strains.(195)(196) Therefore, the 
findings from the UK on the LAIV VE justifies the continuation of the LAIVs in 
children. In addition, amongst children with a history of asthma or wheezing asthma 
superior efficacy of LAIV was found compared to trivalent inactivated influenza 
vaccine.(197) Therefore, further research to establish the effectiveness of LAIV 
amongst children with asthma using observational study data is required.(128)  
Most studies differed by recruitment methods, vaccine ascertainment methods, type of 
vaccines and outcome definitions (in some cases outcomes were not described) (see 
appendix A10; p 294). Particularly, the definition and evaluation of asthma 
exacerbations is an important point of variability across studies (see appendix A10;  
p 294). Most studies (experimental and observational) also recruited children or adults 
less than 65 years old. Thus, only a few studies have assessed the effectiveness of 
influenza vaccination in older people with asthma.  
 
Influenza infection was confirmed by viral cultures or by a > 4-fold rise of antibody 
titre, in three RCTs.(165)(173)(179) However, the low sensitivity of these tests might 
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affect the VE estimates. Residual immunity from previous vaccination may have also 
affected VE estimates in two studies.(184)(185) Similarly, residual immunity from 
previous seasons might have also underestimated the VE in another study.(187)  
In a RCT (159) about 70% of patients were on steroid therapy and 31% had a history 
of asthma hospitalization. Thus, asthma severity could have decreased the vaccine 
efficacy. Similarly, VE was found in a cohort study (182) only after adjustment for 
asthma severity. No VE against health-care use was found in another cohort 
study.(180) However, if only children with severe asthma were more likely to be 
vaccinated that could explain the lack of VE amongst the vaccinated group. 
With the small number of studies included in each meta-analysis, publication bias 
could not be adequately assessed. Our planned subgroup or sensitivity analysis for VE 
could not be carried out due to lack of data from the included studies.(146) In 
particular, evidence is needed for VE against influenza B and influenza A sub-types. 
Also, more in-depth analyses, which include the number, nature and antigenic distance 
specified by virus mutations across sequential circulating variants and vaccine 
components and the role of prior vaccination are required.(198) This will require larger 
TND studies with pooling of data across regions and countries. No new substantive 
evidence for LAIV safety, beyond the vaccine safety studies included in the Cates’ 
review,(129) was found. 
 
Public health initiatives are required to improve the current low vaccine uptake in 
people with asthma.(139) Evidence from clinical trials and observational studies 
suggests likely benefits for people with asthma of vaccination against influenza 
infection, respiratory illness, asthma attacks and other influenza-related asthma 
complications including asthma related emergency department visits and 
hospitalisations.   
3.5 Summary to chapter 3  
The literature indicates that influenza vaccines provide some protection against 
laboratory and clinical complications and they do not cause any severe adverse events 
in asthma individuals. However, the evidence regarding the VE estimates derived 
mostly from observational studies with inherited methodological and statistical 
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limitations. The methodological limitations when estimating the influenza VE in 
observational studies will be further discussed in the following chapter before the 





































Chapter 4. Estimation of influenza vaccine effectiveness in 
observational studies 
This chapter aims to define the terms vaccine efficacy and effectiveness which are 
commonly used in clinical trials and observational studies, respectively. The 
distinction between the two terms is crucial when assessing the protective effects of 
the influenza vaccines in order to understand what aspects of the vaccine are assessed 
during an epidemiological study. The factors that influence the measurement of the 
protection provided by the influenza vaccines in observational studies are also 
described in this chapter.  
4.1 Definitions  
During the development of a new influenza vaccine, many pre-licensure trials are 
conducted to assess its efficacy to prevent a potential influenza infection. Vaccine 
efficacy reflects only the potency of the vaccine itself to protect against influenza. Its 
measurement is quantified by comparing the reduction of influenza infection between 
vaccinated and unvaccinated groups. Vaccine efficacy is ideally measured through a 
RCTs, where the ideal and controlled conditions of a trial permit its unbiased 
estimation.(199) Specifically, the following three conditions exist when efficacy of the 
vaccine is measured in a RCT:  
1) Both vaccinated and unvaccinated groups should have the same exposure rate to 
influenza virus. 
2) The exposure to influenza vaccination should be randomly allocated among study 
participants 
3) Vaccine efficacy estimates the direct benefit of vaccination in vaccinated 
compared to unvaccinated - the unit of the study is the individual, and not the whole 
population.(50) 
 
During the post-licensure period the potency of the vaccine at a population level needs 
also to be assessed. A clinical trial can assess the vaccine potency at population level.  
For example, a large clinical trial can follow-up a population over multiple consecutive 
influenza seasons to estimate the VE. Alternatively, a multi-centre clinical trial can be 
designed to assess the VE during one influenza season across various geographical 
97 
 
locations at national or international level.(159) The design of the clinical trials would 
therefore overcome any sample size issues allowing the real-time VE population. 
 
However certain challenges arise when VE is estimated in clinical trials such as the 
required follow-up period and the type of measured outcome . For example, VE against 
a laboratory-confirmed influenza infection outcome should be assessed during a whole 
influenza season (e.g. September in year 1 until end of influenza circulation in year 2). 
Every influenza season is unpredictable in terms of the volume and type of circulating 
influenza strains therefore the follow-up period for this outcome should be at least one 
influenza season. This time length allows a sufficient number of influenza cases to be 
included in the trial to empower any planned analyses.(200) Nonetheless, the long 
follow-up observation period will increase the cost and the operational complexity of 
the clinical trials.   In contrast, the assessment of the immune response induced by the 
vaccines via serologic tests requires a shorter follow-up time period (e.g. 1-3 months) 
but not less than two weeks since full immune protection is achieved 14 days post 
vaccination. This study endpoint measures the rise in antibody titers as a result of 
body’s exposure to influenza virus via exposure to vaccination. However, a problem 
with serology testing is the existence of antibodies from previous influenza infection 
or vaccination. Pre-existing antibody against influenza will cross-react with antibodies 
generated from current vaccination. Therefore, the interpretation of the observed rise 
in antibody titers is challenging. Some studies overcome this uncertainty by comparing 
the rise in antibody levels between pre- and post-vaccination blood samples.(200) 
 
Thus, the assessment of VE via epidemiological observational studies is a more 
appropriate measurement to monitor how well the vaccine can protect against 
influenza in relation to vaccine programs and population-related characteristics.(201) 
VE refers to the reduction of influenza infection and other influenza-related 
complications in vaccinated individuals compared to unvaccinated  in a real-life setting 
rather than  in an ideal environment such as a controlled clinical trial. VE is usually 




Both vaccine efficacy and effectiveness refer to the percent reduction in incidence 
among vaccinated individuals due to influenza vaccination and can be estimated using 
the following formula:  
 
 
The reduction of incidence rate among unvaccinated (IRU) is subtracted by the 
incidence rate among vaccinated (IRV) individuals and then divided by the IRU. The 
VE formula is also equal to one minus the RR. In studies that the RR cannot be 
estimated the OR can be used instead. Thus, VE will also be equal to 1-OR.(50) 
4.2 Factors influencing the estimation of influenza vaccine effectiveness in 
observational studies  
The estimation of influenza vaccine effectiveness is influenced by many factors, which 
can be grouped under the following five broad categories: study design, vaccination 
exposure, population, influenza virus and its match or mismatch with vaccine strains, 
and confounding. The consideration of all these factors is crucial during the design and 
conduct of an observational study for the provision of unbiased VE estimates (see 
Figure 4.1).(50) 
 
Study design  
Type of outcomes  
Most observational studies include specific clinical outcomes (laboratory confirmed 
influenza), non-specific clinical outcomes (ILI, acute respiratory infection, 
hospitalisation, death due to any cause) or a combination of the two.  
 
Individuals at high risk for influenza are more likely to be hospitalised due to influenza 
or other related consequences. Thus, in observational studies the outcome of 
hospitalisation is usually attributed to various reasons such as influenza, pneumonia, 
cardiovascular or other causes. However, these are not specific outcomes and may 




Death due to influenza infection is rarely recorded on medical records. The 
complication of influenza infection is usually recorded as the death cause and not the 
infection-trigger. For example, pneumonia is a common complication of influenza and 
it is usually recorded as the primary cause of death. Thus, researchers use various 
causes of death, which may not specifically be related to influenza.(202)(203)  
 
Outcomes such as acute respiratory infection and ILI are usually diagnosed through 
clinical signs and symptoms. However, other non-influenza respiratory viruses can 
induce similar clinical symptomatology to influenza. Additionally, the definition of 
ILI or acute respiratory infection based on signs and symptoms differs among countries 
or does not exist. The symptomatology of ILI is also affected by age. For example, the 
signs and symptoms of ILI in older people may not reflect the severity of the illness. 
Specifically, older people may have serious infection, which may not be accompanied 
by serious signs and symptoms.(204-206)  
 
Laboratory confirmed influenza is considered the most precise outcome for the 
estimation of VE. Influenza infection is diagnosed through the real-time RT-PCR 
laboratory technique, which has become the gold standard for detection of influenza 
virus due to its high sensitivity and specificity.(204-206)  
 
Influenza vaccines provide protection only against influenza viruses and not other 
respiratory viral pathogens. In addition, influenza illness has similar signs and 
symptoms with other respiratory viral illnesses. Thus, an ILI cannot be attributed 
solely to influenza virus. The specificity of the ILI also varies by the activity of the 
influenza and other respiratory viruses. For example, in seasons with high influenza 
activity ILI may be more specific as a higher proportion of the illness will attributed 
to influenza compared to other co-circulating respiratory viral pathogens. However, 
the specificity of the ILI would still be lower compared to a laboratory confirmed 
influenza infection. As a result, the use of non-specific clinical outcomes (e.g. ILI) 
underestimates the true VE in a population. Clinical outcomes based on laboratory 




Population source for cohort studies 
Administrative databases, sentinel general practice networks and institutions are some 
of the common sources to obtain a target population for a cohort study. Specifically, 
databases such as population registries, immunisation registries, primary care records 
and insurance scheme databases can be linked using a unique identifier for each 
individual in some countries. The linkage of various databases provides information 
including general practice records, hospital records, death records and vaccine 
records.(50)(208)  
 
Some issues using administrative databases include external validity. The sample 
included in the database should be representative of the source population. For 
example, some individuals may have lower access to health care and may not be 
included in the database. Thus, the external validity of the database will be lower due 
to lack of representativeness of the general population.(50) In addition, the accuracy  
of health records is another issue to be considered. Specifically, accuracy refers to 
agreement between the information provided in databases to those in health records. 
The agreement between medical records and computer databases varies according to 
previous studies in the UK and in the USA. However, all studies reported high 
accuracy level of data recorded in databases.(209-211) Completeness of the computer 
databases should also be considered. For example, the completeness of coded 
morbidity data in 41 Scottish practices was about 75%.(211)  
 
Sentinel GP networks are another population source for cohort studies that exist in 
most European Union (EU) countries. These networks are part of the surveillance 
scheme in each country. They detect cases with ILI and for a sample of patients 
presenting with influenza like symptoms confirm the infection using swabs which are 
sent to virology laboratories (according to the surveillance regulations).(209)(212) 
 
Institutions such as long-term residencies or care facilities are another source of 
populations for a cohort study. However, issues including the generalisation of the 
target population and the difficulty of finding unexposed individuals due to the high 




Population source for case-control studies 
Cases can be obtained from general practices, hospitals, nursing homes and death 
registries. However, the selection of controls from each of the above sources should 
be carefully determined and several issues should be considered.(50) 
 
Specifically, controls for cases from general practices can derive from a random 
sample. For example, cases may be patients with laboratory confirmed influenza or 
with ILI and controls could be a random sample of patients from the GP practice in 
question (which in turn may include some of the cases).(50) Additionally, cases may 
be patients that were diagnosed with influenza - those with a negative diagnosis can 
be used as controls. Specifically, general practitioners (GPs) are taking swabs from 
patients with ILI symptoms. Patients’ samples are then tested for influenza through the 
real-time RT-PCR laboratory technique. This is a new type of case-control study, 
referred to as a TND, where patients with a positive laboratory test result are 
characterised as cases and those with a negative test result serve as controls. The 
estimation of VE through test-negative design is considered to be more precise due to 
laboratory confirmed flu using the real time RT-PCR test. Additionally, the selection 
of controls from ILI cases (with a negative test result) reduces the methodological 
problems and costs of a case-control study. Thus, TND as a new type of case-control 
studies has been proved to be of high validity.(50) Finally, cases can be patients with 
ILI from sentinel general practices, while controls may be obtained from health 
surveys that provide information on influenza vaccination of interviewees.(50) 
 
Hospitals are another source of cases. Cases are usually patients hospitalised for 
pneumonia and influenza or cardiovascular and respiratory diseases (and in some cases 
from people admitted for any cause). Controls can be a random sample from the 
hospital, general practice or community.(50) In addition, cases can be derived from a 
long-term care or resident facility and controls could be those without the outcomes of 
interest. However, VE may be overestimated when the incidence of influenza is high, 
and control participants’ vaccine coverage may be less representative of the nursing 
home as a whole.(50) Death registries can also be used to obtain cases, whereas 
102 
 
controls can be derived from the community, a database or from the influenza season 
following the season where cases were obtained.(50) 
 
Cases can be easily selected from various sources. However, the selection of controls 
should be always representative of the source population. Specifically, the vaccine 
status of controls should represent that of the source population. Thus, randomly 
selected controls are more likely to have a vaccine coverage representative of the 
source population and VE is less likely to be over- or underestimated.(50)(215) 
 
Vaccination exposure  
Vaccine status ascertainment is usually based on medical records, immunisation 
records, health insurance or through interviews. Thus, the vaccination status of the 
study individuals can be confirmed by more than one source.(215) 
 
The time between the date of vaccination and the development of antibody titres 
should be taken into account, when the vaccine status is determined. Some studies 
consider an individual vaccinated 14 days following the vaccine administration, while 
other studies consider an individual vaccinated the day of vaccination. However, the 
immune system requires approximately 14 days to develop sufficient immune memory 
following the exposure to vaccine strains.(209) Finally, some studies have shown that 
vaccination in previous seasons may influence the protection provided by the vaccine 




In older people, the vaccine may be less effective due to immune senescence and 
therefore there is a lower immune response to vaccine strains.(217) Similarly, in very 
young individuals (6 months to 3 years old) the influenza vaccine may be less effective 
due to their immature immune system or the absence of immune memory.(218) 
Furthermore, VE in individuals with immunosuppression (e.g. COPD, HIV-infected 
patients) may be lower due to their vulnerable immune system.(219)(220) VE in 
people with severe asthma (e.g. Step 5 of the British Thoracic Society Guidelines) may 
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be lower due to modifying effects caused by oral corticosteroids.(221) The impact  of 
immunosuppressants (e.g. oral or inhaled corticosteroids) on vaccine protection in 
individuals with respiratory conditions (e.g. asthma) has also been assessed. No 
significant differences were reported between individuals on medium-dose or high-
dose inhaled corticosteroids or oral corticosteroids compared to individuals on low-
dose inhaled corticosteroids or not on corticosteroids.(221) However, more studies are 
required to assess any modifying effect of steroids and other immunosuppressant 
medication in individuals with respiratory conditions due to paucity of evidence as 
identified in a systematic review.(222)  
 
In addition, individuals with co-morbidities and old age are more likely to be 
vaccinated as one of the target populations for annual vaccination.(223) The source of 
population may also affect the VE. For example, individuals in long term residencies 
or care facilities are more likely to be vaccinated.(224)  
 
Influenza virus  
VE is influenced according to the activity of the influenza virus each season. 
Specifically, VE may be underestimated in small studies during seasons with low 
influenza incidence.(225)  
 
The similarity (match) between the circulating influenza virus and the influenza strains 
included in the vaccine is also important. For example, in seasons where there is a 




Confounding by indication and healthy vaccine effect are the common confounders 
found in observational studies measuring VE. “Confounding by indication is a term 
used when a variable is a risk factor for a disease among nonexposed persons and is 
associated with the exposure of interest in the population from which the cases derive, 





Confounding by indication occurs when individuals at high risk for influenza infection 
are more likely to be vaccinated compared to those with lower risk. Thus, VE may 
appear lower because more people at high-risk for influenza are vaccinated.(215) Due 
to a lack of randomisation of the vaccination allocation in observational studies, 
confounders such as comorbidities should be taken into account when measuring VE. 
The healthy vaccine effect occurs when healthy individuals are more likely to be 
vaccinated compared to those with higher risk for influenza and it may be less likely 
that individuals with decreased functional status (i.e. those near to death) are 
vaccinated.(50) Thus, VE against non-specific clinical outcomes such as pneumonia, 
heart and respiratory disease, hospitalisation and death may be overestimated.(215)  
4.3 Summary to chapter 4  
The efficacy of vaccines refers to the ability of a vaccine to prevent an infection in an 
ideal setting and thus is usually estimated in clinical trials, while the effectiveness of 
vaccines refers to the protective ability of a vaccine in real time settings and at a 
population level. Since the VE is estimated at a population level through observational 
studies, various factors can potentially hamper the provision of true estimates that 
cannot be fully controlled due to the nature of the study design.  
In this chapter, I provided the definition of VE and explained how the most common 
factors influencing its estimation particularly in observational epidemiological studies. 
The theoretical knowledge acquired in this chapter will enhance the understanding of 
the next chapter which involves a test-negative design case-control observational 
study. Therefore, the methodology of the study in terms of how the VE was measured 
and what are its main strengths and limitations in comparison to other common 









Figure 4.1: Factors influencing VE estimation in observational studies
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Chapter 5. Seasonal influenza vaccine effectiveness for the prevention 
of laboratory-confirmed influenza in a Scottish asthma population: a 
test-negative design case-control study 
The studies reviewed in Chapter 3 have shown the protective effect of the influenza 
vaccination against influenza infection in asthma. The low study quality combined 
with the inadequate sample size in those studies made it difficult to give a robust 
answer regarding the vaccine protection. Thus, in Chapter 4 I discussed how VE is 
measured in observational studies and methodological issues that need to be 
considered in these studies. In this chapter, I therefore aim to assess the preventive 
ability of the influenza vaccines against influenza infection using a more 
methodologically and statistically robust study with an adequate sample. As a result, 
this study will enable the answer of the main and any other secondary questions leading 
to a full exploration of the benefits of the vaccine in the asthma population.  
5.1 Introduction 
The majority of national immunisation committees assess the effectiveness of the 
influenza vaccines based on evidence from observational studies rather than  placebo 
RCTs which are no longer conducted in people with asthma (the reasons are discussed 
in the section 3.1 of Chapter 3 describing the systematic review).(145) Specifically, 
the VE for each influenza season is determined based on the TND case-control study, 
which is becoming the gold standard for generating precise VE estimates.(229-231) 
The TND study evaluates the influenza VE on patients that seek care for acute 
respiratory infection. Cases are those testing positive for influenza and controls are 
those testing negative for influenza. In essence, the TND involves identifying those 
with proven influenza infection and comparing the proportions of those who were 
vaccinated with those who were unvaccinated. VE is calculated by (1 - OR)*100%, 
where OR is the ratio of the odds of being vaccinated in cases versus the odds being 
vaccinated in controls.(231) According to Jackson et al “This study avoids confounding 
by care-seeking, as the study population is restricted to those who would seek care if 
they developed an ARI”.(230) As a result, TNDs studies are less prone to selection 
bias that may happen in case of a strong positive relationship between vaccine receipt 
and health-care seeking behaviour which may increase the possibility of subject 
recruitment.(231) Thus, any differences in health care-seeking behaviour between 
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vaccinated and unvaccinated individuals are reduced in a TND study. However, 
studies with specific (influenza related) end-points that are restricted to single seasons 
may be underpowered to provide a reliable VE estimate.(145)(232) Another advantage 
of the TND study is that it can be cheap and produce rapid results since these studies 
can be nested in routine national surveillance systems.(231) The speed of the TND 
study also allows the provision of interim within-season VE estimates which can be 
used as a proxy for end of season VE estimates and guide health professionals on 
influenza prevention.(233)  
The majority of the TND studies do not set out to explicitly assess the VE in 
individuals with asthma, but in those with chronic respiratory conditions including 
asthma.(234) As a result, only two TNDs were identified in the systematic 
review.(234) Two case-control studies published after the search date of my literature 
review assessed VE in individuals with asthma based on more than one influenza 
season.(235)(236) Specifically, the study by Suearez-Varela et al compared the VE 
between asthma and non-asthma hospitalised patients for laboratory-confirmed 
influenza.(235) However, the VE in asthma was inconclusive which was expected 
given that less than 20% of cases and controls had asthma and included only patients 
aged 65 years or above during two seasons.(235) In the second study, the authors 
assessed the VE in children 6-59 months during four seasons by various characteristics 
including asthma.(236) VE in the asthma subgroup was significant and up to 43.3% 
(95% CI: 17.1 to 61.2). However, no further analyses in relation to other demographics 
or other characteristics related to influenza infection or the vaccination were performed 
for the asthma subgroup.(236) 
Based on evidence from the systematic review in this thesis and subsequently 
published, relevant studies, VE in asthma remains understudied. Specifically, various 
characteristics related to the asthma population, influenza infection, and the different 
vaccine types are still to be explored.  
The aim of this study was to assess the VE in children and adults with asthma. More 
specifically, the objectives of this study were to: (1) evaluate the seasonal influenza 
VE across and in single seasons; (2) evaluate the VE against common seasonal 
circulating viral strains; (3) provide VE estimates for by age groups; (4) assess the VE 
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between live and inactivated vaccines in children; (5) assess the VE in a combination 
of previous and current vaccination history and (6) assess the VE by location of swab 
collection (primary versus secondary care).  
 
5.2 Methods 
The SIVE II study was an observational study which aimed to evaluate the 
effectiveness and safety of the seasonal live and inactivated influenza vaccines in 
children and at-risk groups respectively.(128) Therefore, the assessment of the VE in 
people with asthma was part of the objectives of the SIVE II study. The SIVE II study 
included linked routinely administrative healthcare data sources from primary care, 
secondary care and laboratory datasets in Scotland.(128)   
I was part of the SIVE II team as evidenced by my significant intellectual contribution 
to the development and writing of both the published study protocol (128) and the final 
study report to the National Institute for Health Research – Health Technology 
Assessment. I conducted the TND case-control study against laboratory-confirmed 
influenza in people with asthma which was guided by the SIVE II study.  
I also led additional analyses within the TND case-control study which were asthma 
specific and neither pre-specified in the published protocol of the SIVE II study nor 
included in the final report of the SIVE II study. I provided VE estimates for all pre-
pandemic (before the 2009/10 pandemic) and post-pandemic seasons for asthma while 
the final report of the SIVE II study included only VE estimates on post-pandemic 
seasons.  In addition, I conducted a number of subgroup analyses which were not 
specified in the SIVE II published protocol. Specifically, these analyses included VE 
estimation by age group, vaccine type, vaccine history, predominant influenza A 
subtypes and primary or secondary care settings of swab collection.  
5.2.1 Study design and population  
I used a TND case-control study to estimate VE against laboratory-confirmed 
influenza in children and adults with asthma by pooling data from 14 influenza seasons 
(2000/01 to 2015/16). Various influenza A(H1N1) subtypes circulated predominantly 
during seven of the seasons (2000/01, 2007/08, 2010/11, 2012-14, 2015/16). However, 
the influenza A/California/07/2009 strain of the A(H1N1) subtype was observed in the 
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seasons following the 2009 A(H1N1) pandemic. The A(H3N2) influenza A subtype 
dominated in nine seasons (2001-05, 2006/07, 2008/09, 2011-13, 2014/15). Influenza 
B co-dominated during nine seasons (2000/01, 2002/03, 2004-06, 2008/09, 2010/12, 
2012/13, 2014-16) with other influenza A subtypes (see Chapter 1 for details on these 
strains). Only during the season 2012/13 all influenza A and B types/sub-types co-
dominated – this was characterised as a mixed season.  
The cohort of people with asthma was defined as ever general practice diagnosis of 
asthma using Read codes.(237)  
Patients were swabbed in either general practices (sentinel and non-sentinel) or 
hospitals and tested for influenza as they had symptoms compatible with influenza. 
The multiplex RT-PCR assay - a laboratory test with the highest rapid and predictive 
detection rates for acute respiratory tract infections - was used to determine influenza 
positivity.(238) Patients with a positive test for influenza were classified as cases, 
while those with a negative test for influenza were classified as controls (see Figure 
5.1). A person could not contribute more than one swab per season.  For negative 
swabs the first was used and for patients with a positive and negative swab the first 
positive was used. In patients with more than one positive swab only the first positive 
swab was used. It is possible that the same patient appeared in more than one seasons 
but this is very rare. VE estimates were yielded by comparing the influenza vaccine 




Figure 5.1: Test-negative design case control study for influenza VE estimation based 
on swab samples taken only from sentinel surveillance settings 
Reproduced with permissions from: Sullivan SG, et al. Potential of the test-negative design for measuring influenza 
vaccine effectiveness: a systematic review. Expert Rev Vaccines 2014; 13(12): 1571-91. 
 
5.2.2 Study databases  
Virtually the entire Scottish population has access to primary healthcare that is free at 
the point of delivery and is registered with a primary care practice. Each resident in 
Scotland has a Community Health index (CHI) number, which is a unique patient 
identifier adopted by the NHS. The linkage of the following databases was carried out 
using the CHI number.(128) The electronic Data Research and Innovation service 
(eDRIS) as part of the National Services Scotland (NSS) carried out the linkage of the 
databases, hosted the analytical dataset and provided a trusted research environment 
for the statistical analysis.(128)  
Primary care: GPs provide primary care services to almost all residents in Scotland 
and hold information about vaccine administration (including information on 
pharmacy immunisation where passed on the GP by the pharmacist) and medical 
history data.(128) Additionally, they provide services such as prescriptions and decide 
who needs referral to a hospital or other health specialist facility. They facilitate the 
transition of a patient from a hospital back to the community by supervising and 
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providing care when required.(128) Data provided by Scottish general practices are 
considered of high quality and their valuable contribution to epidemiological research 
has been previously proven.(211)(240) Specifically, the Information Services Division 
(ISD) of NHS Scotland has reported that the completeness and accuracy of coding 
included in general practice data are over 91%.(240) Annual influenza vaccinations 
are performed mostly in primary care practices and in less extent in pharmacies (except 
for the live attenuated vaccine which is administered in primary schools from 2013 in 
Scotland). 
Sentinel GP-based swabbing scheme: GPs are also part of the sentinel swabbing 
scheme which is currently set up in 100 general practices across all 14 NHS Health 
Boards in Scotland. Each participating GP has to take up to five nasal/throat swab 
samples obtained from GP consultations with patients with influenza-related 
symptoms on a weekly basis. Thus, the first five people with ILI symptoms presented 
in a sentinel GP are swabbed which could mainly refer to an opportunistic sampling 
method as some people may also refuse to be swabbed. Then, sentinel GPs send these 
swab samples to the Scottish Influenza Surveillance Reporting Scheme (SISRS) based 
at Health Protection Scotland (HPS), which monitors the activity of the influenza virus 
every season in Scotland. In this study swab samples were also collected from non-
sentinel GPs and secondary healthcare settings (for diagnostic purposes) which 
exceeded the number of swab samples derived from the sentinel GPs for surveillance 
purposes. The SISRS is also using a number of other complementary surveillance 
systems (e.g. NHS24 cold/flu calls, severe influenza monitoring or influenza vaccine 
uptake and antiviral prescribing patterns) in order to assess the activity of the virus and 
the success of the control measures (e.g. vaccination) since a single surveillance 
system cannot provide all the required information.(241)  
 
Scottish Immunisation & Recall System: The Scottish Immunisation & Recall 
System (SIRS) is a database that holds records of all vaccinations including the 
influenza vaccine administrated in children less than six years according to the UK 
childhood immunisation schedule.(242) Thus, data on  influenza vaccines 
administrated predominantly in schools were obtained through SIRS. The 
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administration of seasonal inactivated and live influenza vaccines was determined via 
the use of Read codes.(237)   
Electronic Communication of Surveillance in Scotland: The Electronic 
Communication of Surveillance in Scotland (ECOSS) division of the HPS is a database 
that holds records on various microorganisms (e.g. influenza virus) and infections 
reported from participating diagnostic laboratories.(243) However, in this study only 
data on RT-PCR tests for influenza were accessed from the ECOSS database. Patient 
identifiable information is also collected, which enabled linkage with vaccination 
records (see Figure 5.2). Data on all laboratory tests carried out in non-sentinel primary 
and secondary health care facilities were also collected by the ECOSS database.  
5.2.3 Recruitment process and characteristics of the GPs in this study  
Scottish primary care practices were invited to assist the SIVE II study through a 
formal electronic invitation. An information sheet was also designed to provide more 
detailed information about the research project. The SIVE II study recruited 223 GPs 
through the Scottish School of Primary Care (SSPC) in collaboration with Albasoft 
Ltd.(244)  The SSPC facilitated collaboration between academics with significant 
primary care research output and key stakeholders in primary care. Albasoft Ltd was 
the trusted third party that carried out the data extraction from all 223 GPs using the 
Enhanced Services Contract Reporting Options (ESCRO ) system. ESCRO is an 
email/web based system that supports GPs by providing enhanced services (e.g. 
payment system for GPs) within NHS Scotland.(245) ESCRO also provides healthcare 
informatics services to Scottish Universities such as provision of data extraction 
facilities.(245) Thus, GPs were not actively involved in the data extraction (other than 
permissions as data custodians). The data extraction was carried outside of working 
hours of the GPs to avoid any interference with their daily operations. The SIVE II 
study also reimbursed each participating general practice with a £50 administration 
fee. Out of the 223 GPs, 40 were also part of the of the sentinel surveillance system 
for influenza in Scotland.(241)  These sentinel GPs are encouraged (through financial 
incentives) to take swabs from up to ten patients with influenza illness each day. The 
recruitment of the 223 GPs was broadly representative of the Scottish primary care 
population by gender, age and socioeconomic status. However, no additional specific 
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information are known for these 223 GPs since only anonymised data where retrieved 




























5.2.4 Study period  
This study included 14 influenza seasons (2000/01 to 2015/16). Specifically, all 
relevant data were used from 1 September 2000 to 31 August 2016. The unit of 
analysis was person-time for each individual with asthma that was alive and had a 
general practice registry. Each year was separated into four periods (see Figure 5.3). 
Influenza surveillance data were used to determine the start and end of each influenza 
season.(241) However, pre-specified dates were used to define the rest periods. 
Specifically, pre-influenza season starts in 1 September, post-influenza season ends in 
31 May and non-influenza season ranges from 1 June to 31 August.(128)  
 
Figure 5.3: Division of each study year into four influenza season periods 
Reproduced with permissions from: Simpson CR, et al. Evaluating the effectiveness, impact and safety of live 
attenuated and seasonal inactivated influenza vaccination: protocol for the Seasonal Influenza Vaccination 
Effectiveness II (SIVE II) study. BMJ Open 2017; 7(2): e014200.  
5.2.5 Exposure definition 
Influenza vaccines are provided free of charge in Scotland to any individual with a 
high-risk medical condition, such as asthma.(36) The administration is predominantly 
carried out in general practices. In addition, the CHI number and other data related to 
vaccine administration are recorded from the general practice in order to be 
compensated.(246) Vaccination records were also available from primary 
schools.(247) The latent period between influenza vaccine administration and 
serologic response is two weeks.(248) Thus, an individual is considered fully protected 
14 days following vaccination. The exposure status was based on vaccination 
administrated between the start of the pre-influenza season and the end of the influenza 
season (see Figure 5.3). Individuals vaccinated from 1st of September until the end of 
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of the influenza season and the 14th day following vaccination defined the “unexposed” 
group. Individuals with no vaccination record or being vaccinated after the being tested 
for influenza were classified as the “unexposed” group. Those tested for influenza and 
with a vaccination history of less than 14 days also defined the “unexposed” group.  
5.2.6 Study outcomes  
General practices that were part of the sentinel scheme were asked to obtain diagnostic 
nasal or nasopharyngeal swabs from patients that present ILI symptoms. Each general 
practice was required to collect up to five samples per week and submit to the West of 
Scotland Specialist Virology Centre (WoSSVC).(249) Each swab sample was tested 
by the WoSSVC using the multiplex PCR test for a number of respiratory pathogens, 
including influenza. Subtype and genetic characterisation was also performed of 
positive samples for influenza.  
5.2.7 Population characteristics and confounding factors  
A number of population characteristics were determined at the baseline of each 
influenza season, which referred to the first day of each pre-influenza season (1st 
September). These characteristics can potentially confound the relationship between 
influenza vaccine and infection and where included in the analyses if they were found 
(through statistical tests or based on epidemiologic knowledge) to confound the 
relationship between vaccination and influenza infection. 
 
Sex at birth was included in a binary format (females and males). Age was split into 
eight categories based on eligibility for various vaccinations. Specifically, the 0-1 year 
group represented mainly infants where those less than six months old were not 
eligible for vaccination. The 2-4 age group included pre-school children who have 
been eligible to receive the live attenuated vaccine since 2013 at GPs. The 5-11 age 
group represented primary-school children eligible for the live attenuated vaccine at 
school. The 12-17 age group included secondary-school children where they can 
receive the live attenuated vaccine through their GPs. The age groups 18-44 and 45-
64 included working adults who currently are not included in one of the at-risk groups 
eligible for a free vaccination in the UK.(36)  The age groups 65-74 and >75 included 
older people that are at high risk of severe ILI according to the UK immunisation 
guidelines.(36) Socio-economic status (SES) was assessed using the Scottish Index of 
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Multiple Deprivation (SIMD). The SIMD classification is based on quintiles of 
deprivation: quintile 1 is the most deprived and quintile 5 is the least deprived. In 
addition, the SIMD combines 38 indicators across the following seven domains: 
income, employment, health, education, housing, geographical access to services and 
crime (see appendix A11; p 316).(250) Type of settlement was assessed using the 
urban/rural 8 fold classification (UR8). The UR8 is a standard definition of rural areas 
in Scotland; 1 is assigned to large urban areas, which corresponds to settlements of 
125,000 or more people and 8 is assigned to remote rural areas, which corresponds to 
settlements with a population of less than 3,000 people, and with a drive time of over 
60 minutes to a settlement of 10,000 or more.(251) Underlying chronic medical 
conditions other than asthma (respiratory disease such as COPD, chronic heart disease, 
chronic liver disease, chronic neurological disease, diabetes and  immunosuppression) 
which increase the risk of influenza illness were also included this study.(246) The 
number of at-risk conditions (co-morbidities) was also included and presented in six 
risk groups; 1 was assigned to individuals with an additional medical condition other 
than asthma and 6 was assigned to those with six additional medical conditions. 
Receipt of influenza vaccine in the previous season was included in a binary format 
(yes or no). The location where the swab samples were collected was also presented 
in three categories: general practice, hospital and unknown.  
5.2.8 Statistical analysis  
Baseline characteristics of study participants were described. The relation between 
vaccination status and baseline characteristics was also provided for both case and 
control groups. Proportions and ORs were used to describe differences between study 
groups depending on the nature of each variable.(128) In addition, all baseline 
population characteristics were presented as categorical variables and the x2 test was 
used to describe any association in relation to exposure or outcome. Any missing data 
between cases and controls was also reported.(128) All planned tests were two-tailed 
and the level of significance was set at P<0.05. All statistical analyses were carried out 
using RStudio (Version 1.0.143).(252) 
Primary and secondary analysis 
The primary analysis of this study was the provision of a pooled VE estimate across 
all seasons. Individual-level analysis was also performed separately for each of the 14 
118 
 
influenza seasons according to the published protocol.(128) All secondary analyses 
(subgroup and sensitivity) were focused on the post-pandemic influenza seasons 
(2010/11 to 2015/16). The number of swab samples was small in the pre-pandemic 
years (2000/10 to 2008/09), which prohibited the amount of analyses that could be 
carried out for these years.  
 
Individual-level subgroup analysis for influenza A and B types and sub-types was 
performed for each influenza season.(128) Post-hoc analyses included stratification of 
the VE by age groups in order to investigate what age the VE begins declining in adults 
due to the phenomenon of immunosenescence. VE estimates for the new childhood 
LAIV by influenza strain was also explored to assess if the vaccine provides higher 
protection due to its composition. Stratified VE analysis by previous vaccination 
history was also conducted to explore any impact of previous influenza vaccination. 
The effect of previous influenza vaccination on the current vaccination estimates was 
assessed using one previous season. This was because I was only interested in the 
recent effects of vaccination. In addition, there are methodological challenges in the 
evaluation of repeated vaccination effects in more than one prior influenza season. 
Specifically, studies which have looked more than one previous year have ended up 
coding individuals as never vaccinated, always vaccinated and sometimes vaccinated 
as the two biggest groups are never and always vaccinated.(253) Thus, the inclusion 
of one previous influenza season was sufficient and allowed to investigate the 
interaction between previous and current vaccination. VE estimates when influenza 
A(H3) and A(H1N1) strains dominated were also conducted to increase the power of 
the analysis and provide more precise VE estimates for these common circulating 
strains. Finally, I stratified the VE by swab sample location to explore if the there are 
differences between primary (sentinel or non-sentinel) and secondary care settings that 
could affect the VE. Sensitivity analysis was also conducted comparing pooled VE 








The VE was estimated comparing the vaccine status between cases and controls. 
Patients with ILI symptoms and a positive test for influenza were defined as cases, 
while those who had consulted with ILI symptoms and who had a negative test for 
influenza were defined as controls. Patients were considered as vaccinated if the data 
of vaccination was two weeks or more before the swab sample was taken. While, if 
the vaccination was performed less or within two weeks before a swab sample was 
taken this was defined as unvaccinated.  
 
VE and 95% CIs were estimated based on adjusted ORs).(128) ORs were calculated 
by the regression coefficients of the vaccine status in the model. A generalised additive 
logistic regression model was used to explain the relationship between our binary 
outcome (influenza infection) and our predictor (influenza vaccine) in presence of 
other confounding covariates. I used a logistic regression model because of the 
dichotomous format of my study outcome. In addition, the flexibility of the generalised 
additive models meant that I could fit most of my data even with the presence of 
nonlinear relationships and significant noise in the predictor variables.(254) However, 
it is not recommended to over-fit the data despite the flexibility of these models. This 
is because a complex model (with high number of degrees of freedom) would be 
difficult to be replicated in other datasets. The model can also become too tailored in 
order to fit data from all the included covariates and random noise in the sample rather 
than reflecting the true effect estimate in the overall population.  
 
The sample of my study was not large enough to support an overly complex model 
with all potential confounding covariates included. The presence of missing values in 
some of my study covariates (e.g. SIMD) could also not support a complex model. 
Finally, only a few covariates are associated with influenza positivity. Thus, a 
parsimonious (or less-complex) approach was employed to fit my study data and 
develop the model for the provision of the adjusted VE estimates. The aim of this 
approach is to fit the best model for the available data by initially including all 
covariates in the model and then exclude those covariates that are not statistically or 
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clinically significant. However, covariates that may not be statistically, but clinically 
related with the outcome can be still included in the final model.  
 
Specifically, in my study I followed the two-stage step indicated by this parsimonious 
approach in order to build my final model for the provision of the adjusted VE 
estimates. First, I included all potential confounding covariates and then I removed all 
the statistically non-significant covariates. However, I still kept the age covariate in 
my model as it is widely accepted in the literature that it can confound the relationship 
between influenza vaccination and infection. Thus, the model which provided VE 
estimates was adjusted for the effects of the covariates: time, age, underlying medical 
conditions and the source of swab sample collection which were either statistically or 
epidemiologically associated with the outcome. Adjustment for time was performed 
for the provision of the adjusted, but also of the unadjusted VE estimates.  
 
Time was included as a spline function to model the baseline rate of influenza activity 
for every season. This method helped correct for any bias related to the number of 
patients with influenza positive and influenza negative tests at different time periods 
during a season. In September the influenza positivity is usually very low and peaks 
in December at around 10-20% during seasonal and 40% in pandemic years. In 
February to March the influenza positivity decreases to around 5%. Therefore, the 
epidemic curve of the influenza virus is not a symmetric or a uniform curve and its 
pattern differs from season to season. Thus, the spline function and to an extent the 
generalised additive regression models are able to describe the epidemic curve of the 
influenza virus regardless of its pattern every season due to their high flexibility. The 
overall aim of the spline function and the respective adjustment for time in the model 
was to avoid the introduction of bias. Specifically, bias can result from the fact that at 
the end of each season more people will have a test positive for influenza and at the 
same time a higher number of vaccinated individuals will be observed compared to the 
beginning of the season. Thus, the spline function prohibits any bias related to time 





Meta-analysis for pooled VE estimates for all influenza types/subtypes  
Pooled VE estimates for all influenza A and B strains were also produced using the 
generic inverse variance method for meta-analysis. The standard χ2 test and the I2 
statistic were used to determine statistical heterogeneity for pooled VE estimates. 
Forest plots were used to display any statistically heterogeneity for pooled VE across 
multiple seasons. Pooled and individual-season ORs and their 95% CIs were provided 
using the adjusted ORs and their intervals (at a logarithm scale) already calculated in 
the subgroup analyses (see Table 5.4 and Table 5.5) for all influenza strains as input. 
In case of heterogeneity the effect estimates from the random-effects model were 
chosen due to variability of each influenza season. Thus, each vaccine effect estimate 
from each influenza season was considered as an estimate coming from a different 
‘study’ justifying the use of random-effects models over fixed-effects models.  
5.2.9 Sample size and power calculation 
A sample size of 1.25 million patients was included in the SIVE II study from 223 
general practices. In Scotland, the Pandemic Influenza Primary Care Reporting 
(PIPER) 2014/15 cohort had 263,000 individuals.(128) PIPER is surveillance system 
for influenza in Scotland which routinely extracted pre-existing primary care related 
to ILI or ARI and influenza or pneumococcal vaccination.(241) Thus, PIPER enabled 
the timely provision of trends on influenza activity and vaccine effectiveness 
(including the 2009/10 pandemic).(241) The size of the SIVE II study is five times 
larger than in PIPER 2014/15 cohort giving a multiplier ratio of about 5:1. There were 
1,745 swab samples in the PIPER 2014/15 cohort and this gives 8,725 (1,745*5) swab 
samples for the SIVE II study per year.(128) If the annual prevalence of asthma is 
around 8.0% in Scotland, then 1 in 12 individuals have asthma.(255) Thus, I expected 
727 (8,725/12) patients with asthma swabbed every year as about 8.0% (or 1 in 12) of 
the Scottish population has asthma and 1,454 (727*2) swab samples for ILI would 
have been taken from asthma patients in the final two seasons. Assuming that 582 or 
40.0% (1,454*0.40) of the asthma patients had been vaccinated for influenza and the 
number of tests positive for influenza was 218 or 15.0% (1,454*0.15), this gave an 
80.0% power to detect a VE of 33.0%.  
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5.2.10 Ethics and permissions 
Permissions were obtained from the Privacy Advisory Committee of the Information 
Services Division, NHS Scotland [68/14], the National Research Ethics Committee 
West Midlands – Edgbaston [15/WM/0035], the National Caldicott Guardian and 
General Practice Data Custodians.  
5.2.11 Reporting checklists for observational epidemiological studies  
I used the Strengthening the Reporting of Observational studies in Epidemiology 
(STROBE) and REporting of studies Conducted using Observational Routinely-
collected Data (RECORD) checklists to guide the reporting of this TND case-control 








5.3 Results  
5.3.1 Study population characteristics  
A total of 6,921 swab samples were taken from 5,824 asthma patients presenting (of a 
total registered primary care asthma population of 1,830,772 person-seasons). These 
swabs were carried out in primary or secondary care settings on people with a 
diagnosis of asthma with ILI symptoms over 14 influenza seasons and then tested for 
influenza infection with real-time RT-PCR test (see Figure 5.4). 
 
Figure 5.4: Flow diagram for the test-negative design case-control study for an asthma 
population for the influenza seasons 2000/01 to 2015/16, Scotland, UK 
Of the 6,921 swab samples included in the study population, 901 (13.0%) tested 
positive for influenza and classified as cases (see Table 5.1). Out of the 6,921 total 
collected swab samples, 6,020 (87%) were negative for influenza and were classified 




  Table 5.1: Number of influenza (sub)types out of the 901 influenza positive cases 
Influenza  (sub)types No. of influenza (sub)types / No. of cases (%) 
Influenza A  677/901 (74.0) 
A(H1N1)  276/901 (30.6) 
A(H3) 228/901 (25.3) 
A(unknown) 173/901 (19.2) 
Influenza B 229/901 (25.4) 
Influenza A & B  <10/901 (0.6) 
 
All subgroups were represented in the study. However, swab samples were more likely 
to be from adults less than 65 years old, female, and socioeconomically deprived 
patients with cardiopulmonary conditions such as COPD, chronic heart disease and 
diabetes and living in large urban areas. Swab samples were also more often collected 
during secondary care consultations (hospital) than in a primary care setting.  
Demographic characteristics and vaccination status of the study populations are 
provided in Table 5.2. During the study, 13% of swab samples were positive for RT-
PCR-confirmed influenza. Patients more likely to test positive for influenza were aged 
12-44 years, lived in remote small towns, with no previous season influenza vaccine 
and had a swab sample collected from a primary care setting. There was no difference 
between cases and controls in sex, socioeconomic deprivation and at-risk chronic 
diseases (COPD, heart disease, liver disease, neurological disease, diabetes, 
immunosuppression). The vaccination coverage was higher in women, in older adults 
(>65 years old), in those least deprived (5th quintile), in large urban areas, with at-risk 
chronic conditions such as COPD, heart disease, neurological disease and diabetes, in 
those with the most co-morbidities, in those with an influenza vaccine in the previous 








No. Vaccinated  
at test 
(% of total) 
P value* No. of positive 
swabs 
(% of total) 




Gender                                                                                                   
  Female (ref) 4139 1939(46.8) 0.003 529(12.8) 0.5 NA NA 
  Male  2782 1204(43.3) 372(13.4) 1.05 0.9 to 1.2 
Age group (years) b 
  0-1    11    3(27.3) <0.001 1(9.1) 0.4 0.7 0.04 to 3.6 
  2-4 219  72(32.9) 23(10.5) 0.8 0.5 to 1.3 
  5-11 661 233(35.2) 73(11.0) 0.9 0.6 to 1.2 
  12-17 517 134(25.9) 69(13.3) 1.1 0.8 to 1.5 
  18-44    2014 504(25.0)       275(13.7)  1.1 0.9 to 1.4 
  45-64    1827 923(50.5)       256(14.0) 1.1 0.9 to 1.4 
  65-74 806 595(73.8)  94(11.7) 0.9 0.7 to 1.2 
  >75 (ref) 865 678(78.4)       110(12.7) NA NA 
Deprivation quintilec 
  1d (ref) 1672 710(42.5) 0.03 219(13.1 ) 0.5 NA NA 
  2 1721 798(46.4) 209(12.1) 0.9 0.7 to 1.1 
  3 1201 567(47.2)  172(14.3) 1.1 0.9 to 1.4 
  4 1119 506(45.2) 143(12.8) 1.0 0.8 to 1.2 
  5 1055 507(48.1) 130(12.3) 0.9 0.7 to 1.2 
Urban/rural scoree 
  1 (ref) 3802 1732(45.6) 0.006 433(11.4) <0.001 NA NA 
  2 1720   749(43.5) 247(14.4) 1.3 1.1 to 1.5 
  3   448   198(44.2)   71(15.8) 1.5 1.1 to 2.0 
  4     91     40(44.0)   16(17.6) 1.7 0.9 to 2.8 
  5    66     25(37.9)   17(25.8) 2.7 1.5 to 4.6 
  6 502   265(52.8)   65(12.9) 1.2 0.9 to 1.5 
  7   69     27(39.1)   16(23.2) 2.3 1.3 to 4.0 
  8f 123    66(53.7)   17(13.8) 1.2 0.7 to 2.0 




COPD 834 561(67.3) <0.001 98(11.8) 0.2 0.9 0.7 to 1.1 
Chronic heart disease 774 565(73.0) <0.001 95(12.3) 0.5 0.9 0.7 to 1.2 
Chronic liver disease 113   57(50.4) <0.001 15(13.3) 0.9 1.0 0.6 to 1.7 
Chronic neurological disease 373 263(70.5) <0.001 46(12.3) 0.7 0.9 0.7 to 1.3 
Diabetes 638 447(70.1) <0.001 79(12.4) 0.6 0.9 0.7 to 1.2 
Immunosupression 182  90(49.5) 0.3 20(11.0) 0.4 0.8 0.5 to 1.3 
Number of risk groups (comorbidities)  
  1 (ref) 4512        1608(35.6) <0.001     598(13.3) 0.7 NA NA 
  2 1150          675(58.7)     149(13.0) 1.0 0.8 to 1.2 
  3   763          500(65.5)       97(12.7) 1.0 0.8 to 1.2 
  4   350          254(72.6)       39(11.1) 0.8 0.6 to 1.1 
  5   121 87(71.9)       13(10.7) 0.8 0.4 to 1.4 
  6      25 19(76.0)         5(20.0) 1.6 0.5 to 4.1 
Influenza vaccine in previous season 
Yes 3624 2604(71.9) <0.001 422(11.6) <0.001 0.8 0.7 to 0.9 
No (ref) 3297   539(16.3) 479(14.5) NA NA 
Swab samples taken in general practices or hospitals 
General practice (ref)  1884 628(33.3) <0.001 266(14.1) 0.03 NA NA 
Hospital 5010 2494(49.8) 628(12.5) 0.9 0.7 to 1.0 
Unknown      27      21(77.8)     7(25.9) 2.1 0.8 to 4.9 
Abbreviations: OR: odds ratio; CI: confidence interval; NA: not applicable  
a Adjusted for gender, age and socioeconomic deprivation 
b Age group available for 6,920 swabs  
c Deprivation score only available for 6,768 swabs 
d Most socioeconomically deprived  
e Urban/rural score only available for 6,821 swabs  
f Remote rural areas 





5.3.2 Vaccine effectiveness  
The protective effects of the vaccination are provided below into the following order: 
a) overall VE estimates for each pre- and post-pandemic season, b) influenza strain 
specific VE estimates for each post-pandemic season, c) pooled VE estimates (meta-
analyses) for influenza strains circulating in the post-pandemic seasons, d) pooled VE 
estimates across all post-pandemic seasons stratified by age group and influenza strain, 
e) pooled VE estimates from post-pandemic seasons where either the influenza 
A(H1N1) or A(H3N2) strains predominated, f) pooled VE estimates across all post-
pandemic seasons stratified by previous and current season vaccination history, g) 
pooled VE estimates  from 2013/14 to 2015/16 seasons stratified by vaccine type in 
children, and h) pooled VE estimates stratified by influenza swab sample location.  
Overall, there were 901 cases who were influenza positive, and 6,020 controls who 
were influenza negative. The pooled VE was 49.4% (95% CI: 39.7 to 57.5) in the 
asthma population across all 14 influenza seasons (2000/01 to 2015/16).  
 
Pre-pandemic influenza seasons  
The VE for the seasons 2000/01, 2001/02 and 2002/03 could not be estimated as there 
were only a total of 78, 59 and 76 swabs from people with asthma with less than 10 
positive swabs in each season and none of the cases had been vaccinated. The VE for 
the influenza seasons 2003/04 to 2007/08 were estimated, but the estimates were 
imprecise (wide 95% CIs) due to low number of cases (<20) and the low number of 
swabs from people who were vaccinated (<5). Similarly, the adjusted VE could not be 
estimated for the season 2006/07 due to low numbers. In the 2008/09 season the VE 
was -227.7% (95% CI: -667.4 to -39.9) and significant. Although there was a higher 
vaccine uptake amongst cases compared to controls which resulted in this negative VE 
estimate, the imprecise estimate was due to the low number of cases.  
 
Post-pandemic influenza seasons  
2010/11: The VE in the first post-pandemic season 2010-11 was 76.1% (95% CI: 55.6 
to 87.1). This season was characterised by a large proportion of positive swabs 
(n=123/487, 25.3%) and A(H1N1) being the predominating circulating strain.  
Vaccine uptake was over 20.0% higher in the control group compared to cases.  
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2011/12: No significant VE was observed for the 2011/12 season which was 45.1% 
(95% CI: -35.1 to 77.7). Only 4.9% of the total samples were positive for influenza 
and the vaccine uptake was higher amongst cases.  
2012/13: The VE was 45.2% (95% CI: 13.8 to 65.1) for the 2012/13 season where all 
influenza types and subtypes co-circulated and a high number of samples tested 
positive for influenza (n=143/834, 17.2%) was observed.  
2013/14: In the 2013/14 season the adjusted VE was significant and up to 52.3% (95% 
CI: 6.5 to 75.6) where the H1N1 strain predominated. The CIs were, however, wide 
due to the small number of positive samples during that season (n=54/932, 5.8%).  
2014/15: During the season 2014/15 a significant VE of 48.6% (95% CI: 27.8 to 63.4) 
was found despite the higher number of vaccinated individuals amongst cases. The 
H3N2 strain predominated and a substantial higher influenza positivity was observed 
(n=232/1413, 16.4%) than in the previous season. Additional subgroup analyses 
(which will be described below) revealed that the VE was due to influenza B which 
contributed to an overall positive and significant estimate.  
2015/16: In the last season 2015/16 a higher and significant VE of 57.8% (95% CI: 
40.1 to 70.3) estimate was observed compared to the previous season. However, the 
number of tests positive for influenza were slightly lower (n=201/1670, 12.0%) 
compared to the previous season and the H1N1 strain was the predominant circulating 











































6,921 354/901 39.3 2,789/6,020 46.3 13.0 46.4* 
(37.1 to 54.3) 
49.4*b 
(39.7 to 57.5) 
NA 
2000/1 78 0/6 0.0 22/72 30.6 7.7 100  
(-Inf to 100) 
100  





2001/2 59 0/3 0.0 11/56 19.6 5.1 100  
(-Inf to 100) 
100  
(-Inf to 100) 
A/Panama/2007/99 
(H3N2) 
2002/3 76 0/3 0.0 17/73 23.3 4.0 100  
(-Inf to 100) 
100  





2003/4 123 1/15 6.7 24/108 22.2 12.2 54.4  
(-304.6 to 94.9) 
34.9  
(-599.1 to 93.9) 
A/Fujian/411/2002 
(H3N2) 
2004/5 99 4/16 25.0 24/83 28.9 16.2 36.2  
(-145.6 to 83.4) 
27.4  





2005/6 90 2/11 18.2 28/79 35.4 12.2 74.0  
(-44.8 to 95.3) 
-46.0  
(-1286.2 to 84.6) 
B/Malaysia/2506/2
004 
2006/7 75 2/7 28.6 15/68 22.1 9.3 16.7  
(-513.5 to 88.7) 
0.00  
(-Inf to 100.) 
A/Wisconsin/67/05 
(H3N2) 




2007/8 87 1/9 11.1 19/78 24.4 10.3 77.1  
(-118.1 to 97.6) 
76.3  




2008/9 324 18/50 36.0 81/274 29.6 15.4 -57.0  
(-207.2 to 19.7) 
-227.7 
(-667.4 to -39.9) 
A/Brisbane/10/200
7 (H3N2)  
2010/11 487 29/123 23.6 176/364 48.4 25.3 70.1 
(49.5 to 82.3) 
76.1  






2011/12 574 14/28 50.0 241/546 44.1 4.9 34.4  
(-44.3 to 70.1) 
45.1  
(-35.1 to 77.7) 
A/Victoria/208/200
9 (H3N2) 
2012/13 834 50/143 35.0 323/691 46.7 17.2 48.2 
(22.2 to 65.5) 
45.2  











2013/14 932 26/54 48.2 457/878 52.1 5.8 37.7 
 (-10.7 to 64.9) 
52.3 
(6.5 to 75.6) 
A/California/07/20
09 (H1N1)pdm09 
2014/15 1413 122/232 52.6 605/1181 51.2 16.4 36.3 
(13.3 to 53.2) 
48.6 




2015/16 1670 85/201 42.3 746/1469 50.8 12.0 54.8 
(37.8 to 67.1) 
57.8  









Abbreviations: CI: confidence interval; NA: not applicable  
a Adjusted for time (i.e. days) only  
b Adjusted for time (i.e. days), age, number of risk groups, swab location (i.e. GP or hospital)  
-VE estimates for the seasons 2000/01 to 2008/09 were adjusted only for time and age while the rest seasons were adjusted for all variables mentioned in the 
b annotation.  
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5.3.3 Subgroup and sensitivity analyses  
Vaccine effectiveness by influenza type and subtype 
The VE for the most common influenza A and B circulating strains was estimated for 
each influenza season where possible. The VE for the influenza seasons 2000/01 to 
2002/03 for various influenza types and subtypes was not estimated.  The small 
number of swab samples in these seasons prohibited the estimation of the overall VE 
against any influenza infection, thus any further exploration was abandoned. VE 
estimates for the pre-pandemic seasons (2003-08) against influenza A and B 
types/subtypes were estimated for this thesis (see appendix A14; p 327). However, all 
additional analyses were focused on post-pandemic seasons (2010-15) where the 
sample size was adequate and the vaccine records were more accurately recorded for 
further exploration.  
 
In the first post-pandemic season (2010/11), the overall VE was significant mainly 
against influenza A(H1N1) subtype and B with estimates 70.7% (95% CI: 32.5 to 87.3) 
and 83.17% (95% CI: 44.3 to 94.9), respectively. In 2011/12, the VE against any 
influenza strain was not significant due to small number of cases resulting in very 
imprecise estimates for the A(H3) subtype and no estimate for the A(H1N1) subtype. 
The VE against influenza A was 51.9% (95% CI: 18.2 to 71.8) in 2012/13 season 
where all influenza A subtypes co-dominated. A particularly high VE up to 77.5% 
(95% CI: 9.8 to 94.4) was observed against A(H1N1), but no significant VE for co-
circulating subtype A(H3) and type influenza B (see Table 5.4). The overall VE for 
2013/14 was significant, but no significant VEs were observed for any influenza A or 
B type or subtype. The overall positive VE was likely from influenza A and its 
A(H1N1) subtype which had a positive non-significant VE, imprecision being due to 
low swab positivity for that season (due to low circulating influenza). In 2014/15, an 
overall significant VE was found with a high swab positivity (16.4%). This was likely 
driven by the significant VE of 77.0% (95% CI: 53.9 to 88.5) found for influenza B 
which was one of the predominant circulating strains. In 2015/16, the overall VE was 
higher than other strain specific estimates and the swab positivity was up to 12.0%. A 
lower VE of 52.3% (95% CI: 27.5 to 68.6) against influenza A was observed. No 
significant VE was found for influenza A subtypes. VE estimate of 54.7% (95% CI: 







































Influenza A & 
B 
29/123 23.6 176/364 48.4 25.3 70.1 
(49.5 to 82.3) 
76.1 
(55.6 to 87.1) 
Influenza A 24/98 24.5 181/389 46.5 20.1 63.1 
(33.5 to 79.5) 
69.4 
(37.9 to 84.9) 
A(H3) 0/0 0.0 205/487 42.1 0.0 0.0  
(-Inf to 100) 
0.0  
(-Inf to100) 
A(H1N1) 17/79 21.5 188/408 46.1 16.2 68.8  
(37.9 to 84.3) 
70.7 
(32.5 to 87.3) 
Influenza B 5/26 19.2 200/461 43.4 5.3 78.0 
(37.3 to 92.3) 
83.2  





Influenza A & 
B 
14/28 50.0 241/546 44.1 4.9 34.4 
(-44.3 to 70.1) 
45.1 
(-35.1 to 77.7) 
Influenza A 12/23 52.2 243/551 44.1 4.0 27.0 
(-74.6 to 69.5) 
40.2 
(-68.4 to 78.8) 
A(H3) 6/11 54.6 249/563 44.2 1.9 20.1 
(-173.0 to 76.6) 
3.7 
(-240.5 to 75.0) 
A(H1N1) 0/0 0.0 255/574 44.4 0.0 0.0 
(-Inf to 100) 
0.0 
(-Inf to 100) 
Influenza B 2/5 40.0 253/569 44.5 0.9 57.1  
(-186.7 to 93.6) 
71.8 
(-358.1 to 98.3) 
Season: 2012-2013  
 
Influenza A & 
B 
50/143 35.0 323/691 46.7 17.2 48.2 
(22.2 to 65.5) 
45.2 
(13.8 to 65.1) 
Influenza A 32/91 35.2 341/743 45.9 10.9 43.8 51.9  



























(9.6 to 65.1) (18.2 to 71.8) 
A(H3) 17/45 37.8 356/789 45.1 5.4 27.9  
(-36.3 to 61.9) 
38.0  
(-25.7 to 69.4) 
A(H1N1) 3/17 17.7 370/817 45.3 2.0 79.8 
(28.3 to 94.3) 
77.5 
(9.8 to 94.4) 
Influenza B 18/53 34.0 355/781 45.5 6.4 40.0  
(-9.8 to 67.3) 
11.7  
(-70.7 to 54.3) 
Abbreviations: CI: confidence interval; NA: not applicable  
a  Adjusted for time (i.e. days) only 
b Adjusted for time (i.e. days), age, number of risk groups, swab location (i.e. GP or hospital) 
-There are cases with unknown influenza A subtype which explains why the total influenza A(H3) and A(H1N1) samples do not add exactly to the total  









































Influenza A & B  26/54 48.2 457/878 52.1 5.8 37.7  
(-10.7 to 64.9) 
52.3 
(6.5 to 75.6) 
Influenza A 
 
24/50 48.0 459/882 52.0 5.4 39.0  
(-11.0 to 66.4) 
49.8  
(-0.6 to 74.9) 
A(H3) 2/6 33.3 481/926 51.9 0.6 65.9  






18/34 52.9 465/898 51.8 3.7 21.4  
(-59.2 to 61.2) 
32.0  
(-52.2 to 69.6) 
Influenza B 2/5 40.0 481/927 51.9 0.5 45.2  
(-259.1 to 91.7) 
100  







Influenza A & B 122/232 52.6 605/1181 51.2 16.4 36.3 
(13.3 to 53.2) 
48.6 
(27.8 to 63.4) 
Influenza A 103/184 56.0 624/1229 50.8 13.0 21.2 
(-12.0 to 44.5) 
30.4 
(-2.0 to 52.5) 
A(H3) 
 
79/140 56.4 648/1273 50.9 9.9 21.1 
(-16.0 to 46.4) 
26.4 
(-12.0 to 51.6) 
A(H1N1) 
 
5/6 83.3 722/1407 51.3 0.4 -290.9 




Influenza B 20/49 40.8 707/1364 51.8 3.5 62.0 
(30.3 to 79.3) 
77.0 
(53.9 to 88.5) 
Season: 2015-16  
 
Influenza A & B 85/201 42.3 746/1469 50.8 12.0 54.8 
(37.8 to 67.1) 
57.8 
(40.1 to 70.23) 
 











Influenza A 60/135 44.4 771/1535 50.2 8.1 45.1 
(20.1 to 62.2) 
52.3 





2/6 33.3 829/1664 49.8 0.4 39.0  
(-294.0 to 90.5) 
78.1 
(-102.6 to 97.6) 
A(H1N1) 51/104 49.0 780/1566 49.8 6.2 32.8  
(-2.0 to 55.7) 
36.7 
(-0.6 to 60.2) 
Influenza B 26/67 38.8 805/1603 50.2 4.0 60.9 
(33.9 to 76.8) 
54.7 
(19.5 to 74.5) 
Abbreviations: CI: confidence interval; NA: not applicable  
a  Adjusted for time (i.e. days) only 
b Adjusted for time (i.e. days), age, number of risk groups, swab location (i.e. GP or hospital) 
-There are cases with unknown influenza A subtype which explains why the total influenza A(H3) and A(H1N1) samples do not add exactly to the total  
influenza A samples   
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Pooled vaccine effectiveness for influenza types and subtypes (meta-analysis)  
The overall VE estimate was 55.0% (95% CI: 44.0 to 63.0) against influenza A and B 
types as it is shown by the OR provided in the random-effects model below. 
Heterogeneity for this pooled estimate was detected, but it was small and non-
significant (see Figure 5.5). Lower pooled VE of 47.0% (95% CI: 34.0 to 57.0) against 
influenza A type. However, no heterogeneity was observed for this type (see Figure 
5.6).  
 
A substantially lower VE estimate of 29.0% (95% CI: 1.0 to 49.0) was detected for the 
influenza A(H3) subtype. The pooled VE point estimate was also not significant, but 
no heterogeneity was shown (see Figure 5.7). A higher pooled VE of 48.0% (95% CI: 
19.0 to 67.0) was found against the influenza A(H1N1) subtype compared to the A(H3) 
subtype as it shown by the OR of the random effects model. However, low-to-
moderate non-significant heterogeneity was observed across seasons (see Figure 5.8). 
The highest pooled VE was 62.0% (95% CI: 32.0 to 79.0), detected for influenza B 
subtype according to the OR of the random-effects model. A Higher heterogeneity of 
52.0% (but non-significant) was also observed for the influenza B compared to other 
types and subtypes. In addition, the OR appears zero during the 2013/14 season. This 
happened due to low circulating levels of influenza B strains resulting in small to zero 
OR which prohibited the provision of any meaningful OR in the meta-analysis and a 


















Figure 5.5: Vaccine effectiveness against laboratory confirmed overall influenza (influenza A and B) by season 












Figure 5.6: Vaccine effectiveness against laboratory confirmed influenza A type by season 





Figure 5.7: Vaccine effectiveness against laboratory confirmed influenza A(H3) subtype by season 










 Figure 5.8: Vaccine effectiveness against laboratory confirmed influenza A(H1N1) subtype by season 
















Figure 5.9: Vaccine effectiveness against laboratory confirmed influenza B subtype by season 






Vaccine effectiveness by age group  
When an analysis was performed by age group (in order to investigate the age where 
immunosenescence begins) in relation to VE. This analysis showed that the VE was 
low in those 55 years and above against influenza A and its subtypes (except 65-74 
year old for type A), while significantly positive high VEs for influenza B were found. 
VE was high in people with asthma under 18 years of age, with a non-significant VE 





































Influenza A & B 
326/781 41.7 2548/5129 49.7 13.2 48.6 
(39.2 to 56.6) 
55.0 
(45.8 to 62.7) 
Influenza A 
255/581 43.9 2619/5329 49.2 9.8 39.7 
(26.9 to 50.3) 
48.1 
(35.8 to 58.1) 
A(H3) 
106/208 51.0 2768/5701 48.5 3.5 26.0 
(-0.8 to 45.6) 
33.8 
(6.7 to 53.1) 
A(H1N1)  
94/240 39.2 2780/5670 49.0 4.1 43.2 
(23.6 to 57.8) 
46.6 
(25.4 to 61.8) 
Influenza B  
73/205 35.6 2801/5705 49.1 3.5 59.0 
(44.2 to 69.9) 
61.5 
(45.7 to 72.7) 
<17  
Influenza A & B 
31/101 30.7 368/974 37.8 9.4 52.9 
(23.4 to 71.0) 
46.0 
(11.2 to 67.2) 
Influenza A 
19/59 32.2 380/1016 37.4 5.5 45.9 
(0.6 to 70.5) 
41.6 
(-9.1 to 68.7) 
A(H3) 
8/26 30.8 391/1049 37.3 2.4 55.7 
(-11.0 to 82.3) 
51.1 
(-25.4 to 80.9) 
A(H1N1) 
4/15 26.7 395/1060 37.3 1.4 64.9 
(-66.8 to 92.6) 
90.5 
(-45.4 to 99.4) 
Influenza B 
12/45 26.7 387/1030 37.6 4.2 69.6 
(26.1 to 87.5) 
56.3 
(3.8 to 80.2) 
18-54  
Influenza A & B 
94/376 25.0 733/2093 35.0 15.2 54.0 
(39.2 to 65.2) 
57.0 
(42.3 to 68.0) 
Influenza A 
73/288 25.4 754/2181 34.6 11.7 50.5 
(32.4 to 63.8) 
53.4 
(35.3 to 66.5) 






22/84 26.2 805/2385 33.8 3.4 58.4 
(28.4 to 75.8) 
53.3 
(17.9 to 73.5) 
A(H1N1) 
33/143 23.1 794/2326 34.1 5.8 45.7 
(14.4 to 65.5) 
53.0 
(23.8 to 71.1) 
Influenza B 
22/89 24.7 805/2380 33.8 3.6 49.9 
(15.9 to 70.1) 
54.9 
(21.1 to 73.7) 
55-64  
Influenza A & B 
51/104 49.0 384/667 57.6 13.5 51.1 
(22.0 to 69.4) 
57.6 
(29.6 to 74.5) 
Influenza A 
44/80 55.0 391/691 56.6 10.4 28.8 
(-20.7 to 58.0) 
33.9  
(-16.6 to 62.5) 
A(H3) 
18/29 62.1 417/742 56.2 3.8 2.6 
(-145.9 to 61.4) 
2.1  
(-178.5 to 65.6) 
A(H1N1) 
17/33 51.5 418/738 56.6 4.3 38.0 
(-36.3 to 71.8) 
38.7 
(-43.4 to 73.8) 
Influenza B 
7/24 29.2 428/747 57.3 3.1 78.7 
(45.0 to 91.8) 
88.2 
(61.2 to 96.4) 
65-74 
Influenza A & B 
61/91 67.0 488/656 74.4 12.2 54.8 
(22.5 to 73.6) 
56.8 
(24.0 to 74.9) 
Influenza A 
49/71 69.0 500/676 74.0 9.5 49.8 
(5.3 to 73.3) 
50.8 
(5.3 to 74.4) 
A(H3) 
18/24 75.0 531/723 73.4 3.2 -13.4  
(-249.3 to 63.2) 
1.0 
(-196.9 to 67.0) 
A(H1N1) 
22/30 73.3 527/717 73.5 4.0 57.5 
(-37.4 to 86.9) 
60.5 
(-37.9 to 88.7) 
Influenza B 
12/20 60.0 537/727 73.9 2.7 65.3 
(9.0 to 86.9) 
65.8 
(5.2 to 87.6) 
>75 
Influenza A & B 
89/109 81.7 575/739 77.8 12.9 48.9 
(4.8 to 72.5) 
51.9 
(9.2 to 74.5) 
Influenza A 
70/83 84.3 594/765 77.7 9.9 25.2 
(-53.4 to 63.5) 
28.0 
(-50.6 to 65.6) 









(-232.9 to 61.3) (-278.2 to 64.8) 
A(H1N1) 
18/19 94.7 646/829 77.9 2.2 -542.3 
(-6752.7 to 39.8) 
-501.0 
(-5639.5 to 37.1) 
Influenza B 
20/27 74.1 644/821 78.4 3.2  67.6 
(15.1 to 87.6) 
70.4 
(19.8 to 89.1)  
Abbreviations: CI: confidence interval 
a  Adjusted for time (i.e. days) only 





Vaccine effectiveness for seasons with A(H1N1) predominate strain  
Post-pandemic seasons with the same dominant influenza A subtype were also pooled 
for the provision of overall and influenza strain specific VE estimates. This analysis 
aimed to increase the power to identify more precise VE estimates for the A(H1N1) 
and A(H3) subtypes as they usually do not co-dominate every season. In addition, the 
pooling of seasons with the same influenza A dominant subtype would decrease the 
heterogeneity between seasons due to differences in circulating viral strains. Thus, the 
seasons 2010/11, 2013/14 and 2015/16 were pooled when the A(H1N1) was the 
predominant strain. The total VE was 60.4% (95% CI: 47.8 to 70.0) and 45.3% (95% 
CI: 21.8 to 61.7) against the A(H1N1) strain. No significant VE was found against the 
A(H3) strain since it circulated at low levels during those seasons. High VE of 62.9% 
(95% CI: 38.5 to 77.6) was, however, found against influenza B which co-dominated 
with the A(H1N1) strain in 2010/11 and in 2015/16 seasons (see Table 5.7).  
 
Vaccine effectiveness for seasons with A(H3N2) predominate strain  
Pooled VE of 47.8% (95% CI: 32.6 to 59.6) was also provided when the A(H3) strain 
dominated in 2011-13 and 2014/15 seasons. Significant VE was found for both 
influenza A and B. However, the adjusted VE for influenza A(H3) was significant 
despite higher vaccine uptake amongst cases. Further investigation with a larger 


































Influenza A & B 140/378 37.0 1379/2711 50.9 12.2 56.5 
(44.5 to 66.0) 
60.4 
(47.8 to 70.0) 
Influenza A 108/283 38.2 1411/2806 50.3 9.2 48.5 
(32.0 to 61.0) 
55.3 
(38.7 to 67.4) 
A(H3) 4/12 33.3 1515/3077 49.2 0.4 53.1  
(-69.4 to 87.0) 
69.3  
(-33.6 to 92.9) 
A(H1N1)  86/217 39.6 1433/2872 49.9 7.0 42.1 
(20.6 to 57.8) 
45.3 
(21.8 to 61.7) 
Influenza B 33/98 33.7 1486/2991 49.7 3.2 64.4 
(44.2 to 77.4) 
62.9 
(38.5 to 77.6) 
Abbreviations: CI: confidence interval; NA: not applicable  
a Adjusted for time (i.e. days) only 
b Adjusted for time (i.e. days), age, number of risk groups, swab location (i.e. GP or hospital) 
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Influenza A & B 186/403 46.2 1169/2418 48.4 14.3 39.9 
(24.1 to 52.4) 
47.8 
(32.6 to 59.6) 
Influenza A 147/298 49.3 1208/2523 47.9 10.6 30.0 
(8.6 to 46.3) 
40.0c 
(19.7 to 55.2) 
A(H3) 102/196 52.0 1253/2625 47.7 7.0 23.2  
(-5.6 to 44.1) 
29.8 
(0.1 to 50.7) 
A(H1N1)  8/23 34.8 1347/2798 48.1 0.8 50.7 
(-18.6 to 79.5) 
57.0 
(-19.0 to 84.5)  
Influenza B 40/107 37.4 1315/2714 48.5 3.8 53.7 
(29.3 to 69.6) 
61.4 
(38.2 to 75.9)  
Abbreviations: CI: confidence interval; NA: not applicable  
a Adjusted for time (i.e. days) only 
b Adjusted for time (i.e. days), age, number of risk groups, swab location (i.e. GP or hospital 
c The VE for influenza A may be explained by the adjusted VE for Influenza A unknown subtype, adjVE: 39.7 (95%CI: -0.4 to 63.8) and raw numbers 
(46.8% vaccinated cases vs 48.1 vaccinated controls and total positive 2.8%)  
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Effect of current and prior season vaccination  
The effect of previous season vaccination on the current season was also explored by 
combining previous and current vaccination histories compared with individuals with 
no vaccination history. The VE was lower in those vaccinated in both seasons than 
those vaccinated in the current season only. However, the point VE estimates did not 
differ significantly as evidenced from their overlapping confidence intervals. In 
addition, no significant VE was found for those vaccinated in the previous, but not in 
the current season (see Table 5.9).   
 
Table 5.9: Vaccine effectiveness of the combined influenza vaccinations in the previous and current 




Vaccine effectiveness of LAIV versus TIV   
For the sub-group analysis VE in children for the LAIV and the TIV vaccine from 
2013/14 to 2015/16, significant VE for LAIV against influenza B was found. There 




















Unvaccinated Unvaccinated 0.0 
(0.0 to 0.0) 
0.0 
(0.0 to 0.0) 
NA 
Vaccinated Unvaccinated 3.7 
(-26.7 to 26.8) 
-4.0 
(-66.8 to 35.0) 
0.9 
Unvaccinated Vaccinated 60.8 
(43.3 to 73.0) 
83.2 
(57.5 to 93.3) 
0.0002 
Vaccinated Vaccinated 46.9 
(36.2 to 55.9) 
55.1 
(34.4 to 69.2) 
<0.001 
Abbreviations: CI: confidence interval; NA: not applicable  
a  Adjusted for time (i.e. days) only 






     Table 5.10: Vaccine effectiveness for laboratory-confirmed influenza (sub)types by influenza vaccine type in children (<17 years old),  



































TIV 9/38 23.7 118/460 25.7 7.6 51.2  
(-11.0 to 78.5) 
48.7  
(-18.8 to 77.8) 
LAIV 10/39 25.6 105/447 23.5 8.0 44.9  
(-24.3 to 75.6) 
37.8 
(-44.0 to 73.1) 
Influenza A TIV 5/24 20.8 122/474 25.7 4.8 56.4  
(-25.9 to 84.9) 
53.4  
(-36.7 to 84.1) 
LAIV 9/28 32.1 106/458 23.1 5.8 -0.2  
(-144.6 to 58.9) 
  -7.9  
(-174.2 to 57.5) 
A(H3) TIV 3/11 27.3 124/487 25.5 2.2 41.7  
(-146.0 to 86.2) 
33.3  
(-186.2 to 84.4) 
LAIV 3/11 27.3 112/475 23.6 2.3 24.32  
(-224.78 to 82.37) 
20.6  
(-269.3 to 82.9) 
A(H1N1) TIV 1/6 16.7 126/492 25.6 1.2 59.6  
(-264.8 to 95.5) 
23.2  
(-772.3 to 93.2) 
LAIV 3/8 37.5 112/478 23.4 1.7 1.2  
(-353.2 to 78.4) 
-16.2  
(-656.7 to 82.2) 
Influenza B TIV 4/15 26.7 123/483 25.5 3.0 65.6  
(-80.6 to 93.5) 
85.3  
(-22.2 to 98.3) 
LAIV 1/12 8.3 114/474 24.1 2.5 96.8*  
(57.5 to 99.8) 
96.4*  
(45.9 to 99.8)  
Abbreviations: CI: confidence interval; NA: not applicable; TIV: trivalent inactivated vaccine; LAIV: live attenuated influenza vaccine  
*No vaccine is the reference group  
a  Adjusted for time (i.e. days) only  
b Adjusted for time (i.e. days), age, number of risk groups and  swab location (i.e. GP or hospital)  
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Vaccine effectiveness by location of swab sample  
The number of swab samples from general practices was 873 samples compared to 
4,710 from hospitals. There were no significant differences in VE estimates as 
evidenced by their overlapping confidence intervals (see Table 5.11). Samples from 
general practices were further investigated by comparing VE estimated between 
sentinel and non-sentinel practices. Similar sentinel practice VE was found, but no 
significant VE for non-sentinel practices due to small number of samples and the 
higher vaccine uptake in cases (see Table 5.12).   
 
A sensitivity analysis was also performed by excluding swab samples collected from 
sentinel general practices. 704 of the total 5,910 virological tests were collected from 
sentinel general practices. The VE was similar to the overall VE in our primary 












































55/146 37.7 304/727 41.8 16.7 39.1 
(7.2 to 60.1) 
49.3 
(18.4 to 68.5) 
Hospital 
266/628 42.4 2228/4382 50.8 12.5 50.4 
(40.1 to 58.9) 
55.4 
(45.2 to 63.7) 
Abbreviations: CI: confidence interval 
a  Adjusted for time (i.e. days) only 
b Adjusted for time (i.e. days), age, number of risk groups  

























35/102 34.3 249/602 40.2 14.5 46.2 
(13.2 to 66.7) 
45.6 
(7.9 to 67.9) 
Non-sentinel 
GPs 
20/44 45.5 55/125 44.0 26.0 -6.4  
(-160.9 to 56.6) 
27.5 
(-94.3 to 72.9) 
Abbreviations: CI: confidence interval; GP: general practice  
a  Adjusted for time (i.e. days) only 
b Adjusted for time (i.e. days), age, number of risk groups  
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GP & hospital 
326/781 41.7 2548/5129 49.7 13.2 48.6 
(39.2 to 56.6) 
55.0 
(45.8 to 62.7) 
No sentinel GPs 
291/679 42.9 2299/4527 50.8 13.0 48.5 
(38.2 to 57.0) 
54.1 
(44.0 to 62.4) 
Abbreviations: CI: confidence interval; GP: general practice 
a Adjusted for time (i.e. days) only   
b Adjusted for time (i.e. days), age and number of risk groups  
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5.4 Discussion  
Summary of main findings  
During 14 influenza seasons (2000/01 to 2015/16), influenza vaccination reduced 
laboratory-confirmed influenza in those people presenting to and being swabbed in 
general practice and hospital settings by 49.4% (95% CI: 39.7 to 57.7) in 5,824 
children and adults with asthma. A similar overall protection (55.0%) was also 
observed during the post-pandemic seasons (2010/11 to 2015/16) in the asthma 
population. Higher protection was observed during seasons with good vaccine 
antigenic match and where the A(H1N1) strain dominated. VE was moderate in cases 
of influenza A(H1N1) (47.0%) and influenza B (62.0%) and was low in cases of 
influenza A(H3) (29.0%). Moderate and significant protection for all influenza strains 
was detected in the young adults (aged 18-54 years old). The highest VE (96.0%) was 
detected against influenza B in children <17 years old with a LAIV administration 
during the 2013/14 to 2015/16 influenza seasons.  
 
Comparisons with existing literature 
In this study, the highest VE was observed in the 2010/11 season which was 
characterised by high influenza activity predominated by the influenza A(H1N1) and 
B strains in the UK.(258) There was a good match between the circulating and vaccine 
strains justifying the high and significant protection against predominant circulating 
strains.(259) In contrast, low and non-significant VE was detected in the 2011/12 
season probably due to low and late activity of the predominant A(H3N2) strain and 
its antigenic distance from the vaccine strain.(260) In addition, intra-seasonal VE 
waning against the A(H3N2) was observed in the UK resulting in an even lower VE 
estimate over the course of the season.(261) The 2012/13 season was a mixed season 
with all common strains co-circulating. However, high and significant protection was 
only found against the A(H1N1) strain. A finding also seen in another UK study in the 
same season.(262) The antigenic drift observed for the circulating influenza B in the 
UK and the substantial decline in the VE against the influenza A(H3N2) in the second 
trimester following the vaccinations could justify the absence of protection for these 




The influenza activity during the 2013/14 season was low and prolonged. Influenza 
A(H1N1) dominated with a good match with the respective vaccine strain.(264) A 
moderate overall protection was observed in this study, but no protection was seen for 
specific influenza A and B strains. This was mainly due to extremely overall low 
number of positive for influenza swabs. In the 2014/15 season significant overall VE 
was observed in this study despite the observed mismatch between the predominant 
A(H3N2) strain with the strain included in the vaccine.(265) Our stratified analysis by 
influenza type and sub-type showed that the overall significant VE was due to high 
VE against influenza B. A similar finding also observed in the UK-wide study 
assessing the VE in 2014/15.(265) Moderate overall protection was seen in 2015/16. 
This result was consistent with the VE of 55% seen in the UK in the same season.(266) 
No protection was seen against the dominant circulating A(H1N1) strain, which 
antigenically matched the vaccine strain.(267) This is in contrast to the overall UK 
findings where the highest VE (55%) was found against A(H1N1).(266) Significant 
VE was observed against influenza B for the same season and this was confirmed also 
in the UK study (266)  despite lineage mismatch with the vaccine strain.(266)  
The LAIV showed consistently high VE against influenza B in this study. The high 
VE of the live vaccine has also been observed in other studies.(159)(197) No 
significant VE was observed for any of the influenza A type and its A(H1N1) and 
A(H3) sub-types. The number of swab samples was too small in this subgroup analysis 
to show any protection. Therefore,  replication of these findings is required in a larger 
study with more than three seasons.  
Our finding of a significant pooled VE when the A(H1N1) dominated could be 
explained by the absence of vaccine mismatch over the three seasons.(259)(264)(267) 
While the lower pooled VE when the A(H3N2) dominated could be due to vaccine 
mismatch in the two out of the three seasons and the intra-seasonal VE 
waning.(262)(264) It is common the vaccine protection against influenza A(H3N2) to 
be lower than influenza A(H1N1) and B.(84)(269)  
Amongst children (<17 years old) significant protection was found only against B, 
while protective effects have been observed for both influenza B and A(H1N1) in other 
studies.(165)(173) A recent TND study in Canada also found a similar VE of 43.3% 
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in children 6-59 months old with asthma from 2010/11 to 2013/14.(235) Higher VE 
for all influenza strains was found in young adults 18-54 years old. Amongst older 
adults (aged >55 year old), no protection was found against any of the influenza A(H3) 
and A(H1N1) sub-types. Similarly, no protection was seen in a recent hospital-based 
study in older patients with asthma aged 65 years and above.(236) Although, no strain 
specific estimates were provided to allow comparison. The lack of significant positive 
VE amongst adults aged 55 and above may indicate immunosenescence, but further 
research is needed due to sample power issues in this study.  
The effect of previous influenza vaccination on current VE has been assessed in 
previous studies due to conflicting evidence.(185)(270-273)In this study the point VE 
estimate was higher for those without a previous season vaccination compared to those 
with a vaccination in both seasons. This finding could be indicative of a negative 
impact of previous immunity on current VE. On the other hand, unmeasured 
confounding or patient characteristics (e.g. more severe asthma) could explain the 
lower VE in individuals with regular vaccination pattern.  
Strengths and limitations 
Strengths of this study include the objective marker for influenza diagnosis using the 
RT-PCR laboratory test minimising the risk of information bias. In addition, the TND 
minimises the risk of selection bias which may arise due to differential healthcare 
seeking behaviour between cases and controls by assessing only the prevention of the 
vaccine against medically-attended influenza infection. By pooling the VE assessment 
over six seasons the power of the study was increased, which allowed the provision of 
VE estimates for different virus sub(types), vaccine types and patient characteristics.  
 
There also several limitations in this study. In this study the cohort of people with 
asthma was based on general practice ever asthma diagnosis. Therefore, the vaccine 
uptake was probably underestimated since it is only recommended to people with 
asthma on inhaled or oral medication or previous history of asthma exacerbations 
requiring hospital admission. The VE in this study assessed only the prevention of 
influenza which was determined by RT-PCR viral swab. However, vaccinated 
individuals may have also been benefited by having less severe influenza illness and a 
subsequent lower risk of a severe asthma attack. A single swab may not identify all 
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cases of true influenza and viral shedding can be variable and is affected by age, the 
site of the swab, and the point in the illness at which the swab is taken. Thus, vaccine 
protection provided by any decrease in influenza severity cannot be quantified using 
this study design.(126) There was inadequate power for some sub-group analyses (e.g. 
by vaccine type and some age groups) despite the inclusion of data on six seasons. 
Thus, results from these relatively underpowered subgroup analyses need to be 
interpreted with caution. Results from the post-hoc analyses also need careful 
interpretation since they were not pre-specified in the protocol of this study. Measured 
confounders (e.g. asthma severity status) and other unmeasured confounders could still 
have influenced the VE estimates. The confounding effect on VE derived from TND 
studies needs to be assessed in future research work. There could be miscoding of 
LAIV administration as LAIV may have been coded using an influenza vaccine parent 
code. This would mean LAIV would be labelled as TIV. This is due to the parent code 
being the most widely used code by GPs (i.e. before the introduction of the LAIV in 
2013). In this scenario, the power to detect LAIV VE is reduced. Thus, the true VE of 
the LAIV should be assessed in future studies including more than three seasons.  
 
Implications and conclusion  
This study showed that the vaccination can prevent influenza infection in people with 
asthma. Although variation in VE amongst people with asthma was observed for 
circulating strains, vaccine types and across age group. These findings may inform 
vaccine research and the current vaccination programme. Healthcare providers and 
asthma patients will now have a better understanding of the benefits of the seasonal 
influenza vaccination which may lead to higher acceptance and adoption (in particular 
for those groups with better evidence of protection). Thus, evidence from this study 
reinforces the recommendation for annual seasonal vaccination for people with 
asthma. Progress may be being made towards vaccines with better potency, durability 
which convey better protection.(110) Monitoring of VE should still be continued. 
Better sample size and sufficiently long follow-up periods though are required, 




To conclude, this study provided compelling national evidence over a number of years 
that influenza vaccination can reduces the risk of influenza in people with asthma. 
Specifically, vaccinated individuals would have about 50% less risk of influenza 
infection compared to unvaccinated individuals. In addition, higher VE was observed 
in seasons with good antigenic match between the circulating and vaccine strains and 
against the A(H1N1) and B influenza strains.  
5.5 Summary to Chapter 5  
This study has shown that the influenza vaccines can prevent an important proportion 
of laboratory-confirmed influenza infection in people with asthma. The protection of 
the vaccines against clinical outcomes due to influenza infection also needs to be 
assessed. However, an exploratory analysis regarding differences in demographics 
between the vaccinated groups is necessary. The exploration of baseline differences 
between the vaccinated and unvaccinated individuals could discover significant 
differences and guide accordingly any planned analyses especially related to VE 
against clinical outcomes given the high presence of bias and confounding in these 
studies (see Chapter 4). Thus, in the following chapter a descriptive analysis of the 
characteristics of the asthma population derived from a primary care setting will be 
conducted in relation to vaccine uptake. Additionally, demographic differences 
between the immunisation groups will be explored for those having an emergency 
















Chapter 6. Demographic and clinical characteristics of influenza 
vaccinated and unvaccinated individuals with asthma in primary and 
secondary-care settings in Scotland: a vaccine uptake analysis   
In the previous chapter, demographic and other differences between the study groups 
were described. However, the main aim of the study in Chapter 5 was to assess the 
association between the influenza vaccination and influenza infection. Thus, the 
description of the demographic or other characteristics of the asthma population was 
not fully explored. The aim of this chapter is to explore demographic characteristics 
of both vaccinated and unvaccinated people with asthma.  
6.1 Introduction  
People with chronic respiratory conditions such as asthma are eligible for influenza 
vaccination in most countries with an immunisation programme for influenza 
infection.(36) According to the UK guidelines people with “asthma that requires 
continuous or repeated use of inhaled or systemic steroids or with previous 
exacerbations requiring hospital admission” are eligible for influenza vaccination 
without cost to the individual.(36) Adults with asthma can be vaccinated with the 
trivalent split-virus inactivated vaccine, which is administered parenterally. Children 
with asthma aged 2-17 years are eligible for a quadrivalent LAIV which is 
administered nasally as a spray.(36) However, the “LAIV is not recommended for 
children and adolescents with severe asthma or active wheezing, for example those 
who are currently taking oral steroids or who have been prescribed oral steroids in 
the last 14 days for respiratory disease”.(36) The benefits of the LAIV include: a) the 
ease of administration and acceptance by children and adolescents, b) better protection 
against influenza B strains (as it includes two influenza B strains) in naïve children 
with no previous exposure to variants of influenza B, c) cross-protection against new 
influenza B strains, d) immediate protection via innate immunity generated by local 
upper respiratory infection and e) indirect protection of the community by reducing 
the transmission of influenza to adults and particularly those with at-risk conditions 
for influenza.(274) In addition, a large UK study found that the LAIV administration 
in children would decrease the number of influenza infections in low-risk individuals 
than the vaccination of this low-risk individuals.(275) In the UK, despite long-standing 
influenza recommendations (over 30 years) for asthma and the introduction of 
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financial reimbursements to GPs that meet government immunisation targets, the 
uptake levels are still not in line with the WHO target of 75% vaccine uptake for all 
at-risk groups for influenza.(276) Suboptimal uptake trends have also been reported 
from across 44 European countries over a seven-year period. Vaccine uptake in 
patients with specific chronic conditions including asthma has been below 40% in most 
of these countries.(277)  
In Scotland, the vaccine uptake in those <65 years and with conditions making at-risk 
to serious influenza illness has dropped over the years with the lowest uptake of 44.9% 
recorded during the season 2016/17.(278) However, the uptake in older people (aged 
>65 years old) is considerably higher with rates over 70.0%.(278) Similarly, an 
increased uptake pattern has been observed in children especially since the 
introduction of a universal childhood immunisation programme with the live vaccine 
in 2013. In primary school children (aged 4-11 years old) the uptake of the LAIV is 
even higher with a notable 73.0% coverage in 2016/17 in Scotland.(278) Thus, the 
observed low uptake in asthma, especially in adults less than 65 years compared to 
other age groups needs to be investigated.  
The comparison of socio-demographic and clinical characteristics between vaccinated 
and unvaccinated groups could reveal which characteristics of the asthma population 
affect the propensity of being in either group. Thus, this analysis could help to improve 
the vaccine uptake by identifying the factors related to vaccination in the asthma 
population and maximise the impact of the influenza vaccination programme in 
Scotland. In addition, a detailed exploration of the characteristics in this population 
can guide the estimation of the VE especially against clinical outcomes, which suffer 
considerably from confounding and other bias.(279)  
To the best of my knowledge, this is the first analysis in Scotland that aimed to explore 
characteristics between vaccinated and unvaccinated groups in the asthma population 
based on administrative data from general practice and emergency department hospital 
settings across 16 influenza seasons. 
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6.2 Methods  
6.2.1 Study design 
A vaccine uptake analysis was conducted to assess differences between vaccinated and 
unvaccinated individuals with asthma in the community and an emergency hospital 
admission due to influenza or pneumonia. Patients with asthma were identified from 
223 primary care practices across Scotland (see sections 5.2.1 and 5.2.2 of Chapter 5). 
In this study, data from 194,319 patients (or 1,830,772 patient-seasons) were included 
from 16 influenza seasons (2000/01 to 2016/17). Data from each patient were analysed 
as person-time (see Table 6.1). It appears that the number of people with asthma 
increases from 2000/01 to 2016/17. This could simply reflect the nature of the cohort 
since a person that appears in 2000/01 can re-appear multiple times in the following 
years. In addition, this could be a combination of the asthma cohort surviving longer 
and due to an accumulation of people in the dataset with an asthma diagnosis as you - 
as you progress in years, the number of asthma patients increases and it almost doubles 
from 20001/01 to 2016/17 (see Table 6.1).  
Table 6.1: Number of patients with an asthma diagnosis in the community per influenza season in 
Scotland 





















People with an asthma diagnosis in the community were also followed up in secondary 
healthcare settings to explore their demographic and health-related characteristics in 
relation to vaccine uptake. Specifically, there were in total 218,455 emergency hospital 
admissions during 16 influenza seasons in Scotland. Out of the 214,455 emergency 
admissions 5.3% were due to influenza or pneumonia (11,605/214,455). In this study 
the outcome of admission due to influenza or pneumonia was included rather than 
admission due to influenza only or influenza with an additional diagnosis of 
pneumonia because there was a low number for these types of admissions. Thus, the 
assessment of differences between vaccination groups would have been less 
informative if the admission was restricted to influenza only. Asthma was the main 
primary condition (or reason of admission) in 318 (2.7%) out of the 11,605 admissions 
due to influenza or pneumonia. However, asthma (or reason of admission) was a 
secondary condition in 23.2% (2,686) out of the 11,605 admissions for influenza or 





















Table 6.2: Emergency hospital admissions of asthma patients and in relation to influenza or 
pneumonia, Scotland, 2000/01 to 2016/17 
 
 
Demographic and other characteristics related to vaccine uptake were determined in 
8,231 admissions out of the 11,605 admissions. This is because only these 8,231 
admissions were registered with a general practice in the same season of 
hospitalisation (the rest of the admissions being a patient is registered at a non-











admissions due to 
influenza or 
pneumonia with 
asthma as the 
main condition 
Emergency 
admissions  due to 
influenza or 
pneumonia with 










2000/01 8,600 223/8,600 (2.6%) 5/223 (2.2%) 33/223 (14.8%) 
2001/02 5,985 201/5,985 (3.4%) 6/201 (3.0%) 52/201 (25.9%) 
2002/03 6,137 223/6,137 (3.6%) 7/223 (3.1%) 45/223 (20.1%) 
2003/04 6,725 293/6,725 (4.4%) 10/293 (3.4%) 67/293 (22.9%) 
2004/05 7,026 299/7,026 (4.3%) 4/299 (1.3%) 83/299 (27.8%) 
2005/06 7,341 323/7,341 (4.4%) 4/323 (1.2%) 103/323 (31.9%) 
2006/07 8,092 343/8,092 (4.2%) 7/343 (2.0%) 113/343 (32.9%) 
2007/08 8,385 405/8,385 (4.8%) 4/405 (1.0%) 105/405 (25.9%) 
2008/09 8,610 445/8,610 (5.2%) 4/445 (0.9%) 108/445 (24.3%) 
2009/10 8,605 506/8,605 (5.9%) 21/506 (4.2%) 129/506 (25.5%) 
2010/11 9,446 616/9,446 (6.5%) 21/616 (3.4%) 153/616 (24.8%) 
2011/12 10,051 676/10,051(6.7%) 12/676 (1.8%) 161/676 (23.8%) 
2012/13 10,305 716/10,305(6.9%) 14/716 (2.0%) 154/716 (21.5%) 
2013/14 10,536 663/10,536(6.3%) 13/663 (2.0%) 134/663 (20.2%) 
2014/15 10,766 862/10,766(8.0%) 32/862 (3.7%) 223/862 (25.9%) 
2015/16 11,358 953/11,358(8.4%) 34/953 (3.6%) 222/953 (23.3%) 
2016/17** 4,979 484/4,979 (9.7%) 18/484 (3.7%) 124/484 (25.6%) 
* A patient with asthma can have more than one admission within the same season 
** Data were not available for the full 2016/17 season as depicted by the lowest number of 
hospital admissions compared to previous seasons 
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6.2.2 Population characteristics 
Various demographic and clinical-related characteristics were assessed between 
vaccinated and unvaccinated asthma patients. Sex was considered as a dichotomous 
variable (female [baseline] versus male). Age was split into eight groups based on 
vaccine eligibility and other relevant information (see previous chapter for details).  
Socioeconomic status was assessed using the SIMD quintile. Urban/rural eight-fold 
score was also used (see previous chapter for details).   
A number of other at-risk clinical conditions eligible for an influenza vaccine were 
also provided such as COPD, chronic heart disease, chronic liver disease, chronic 
neurological disease, diabetes and immunosuppression. The number of risk groups 
(comorbidities) was also provided in six categories. Where ‘1’ was assigned to asthma 
patients with at least one comorbidity and ‘>5’   to asthma patients with more than five 
comorbidities. Previous history of influenza vaccine for one season earlier was 
provided into a binary format (yes or no). The receipt of pneumococcal in the previous 
season was also provided into a binary format (yes or no). Smoking status was 
presented into four categories. Patients with no data on smoking status were included 
into the ‘Not recorded’ category. In addition, if a patient’s smoking status was recorded 
for one season, but not in the follow-up seasons we assumed that the same status will 
exist in the future. Thus, the smoking status in the current year was carried over in the 
future seasons. Finally, when a patient appeared to have more than one smoking status 
within the same season priority was given to the smoking status that represents either 
current or previous history of smoking. For example, if a patient was a non-smoker 
and current smoker in the same season was assigned as a current smoker. Similarly, if 
a patient was current smoker and ex-smoker or non-smoker in the same season was 
assigned as a current smoker.  
The Charlson Comorbidity Index in our data represents the weighted comorbidity 
score based on secondary care data in the previous five years.(280) The score for a 
patient was more reliable from the season 2006 and onwards as there was a five year 
history of data compared to the seasons before 2006. Thus, a patient with no 
comorbidities in the previous five years was assigned a zero score. The Charlson score 
in this study differs from the widely used Charlson Comorbidity Index which is 
produced based on a combination of the number and the severity or weight of each 
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comorbidity.(280) The number of consultations at a general practice for acute 
respiratory illness were also counted and presented in seven categories based on data 
in the previous season. Thus, patients with no previous year consultations were 
assigned into the zero category and those with a history of more than five consultations 
were assigned into the ‘>5’ category. The number of previous season emergency 
hospital admissions was also provided into seven categories following a similar 
rigorous with the GP consultations.  
The chronic underlying condition of the patients (asthma) would have been ideally 
explored through an asthma severity status. According to the British Thoracic Society 
(BTS) guidelines, asthma severity can be inferred by the amount of prescriptions 
needed to maintain good control of asthma-related symptoms (e.g. day-time, night-
time and activity related symptoms) and maximise lung function.(281) Thus, the 
determination of the asthma severity status should be based on a holistic view of 
asthma status, which can be provided through a combination of information (e.g. 
asthma-related symptoms, asthma exacerbations, use of short-acting bronchodilators 
and tests to assess airway function and inflammation). However, most data in this 
study were available for asthma-related prescriptions such as bronchodilators, inhaled 
and oral corticosteroids. Thus, a variable reflecting a combination of asthma treatment 
options guided from the BTS 2016 guidelines was created as an indicator of asthma 
manifestations.(282) In the SIVEII study, medications for asthma were only available 
in a free-text format, which prohibited the manipulation of the data and the provision 
of the five treatment level options (previously referred as BTS steps) suggested in the 
BTS 2016 guidelines.(282) For example, some of the inhaled corticosteroids (ICS) 
doses were either missing or insufficiently recorded by the physicians. Thus, it was 
impossible to infer the exact dose for all ICS in our dataset and specify the dose of an 
ICS as low, medium or high.  
We decided to treat the doses of the ICS in a binary format. A patient was assigned as 
having a ‘high’ versus ‘not high’ dose or a ‘medium’ versus ‘not medium’ dose based 
on a combination of age (<18 or >18 years old) and ICS formulation. Specifically, a 
patient not on Steps 1-3 was assigned to Step 0, children with a ‘not medium’ or ‘not 
high’ dose (e.g. older children) and adults with a ‘not high’ dose were assigned to Step 
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1, children with a ‘medium’ or ‘high’ dose (e.g. older children) and adults with a ‘high’ 
dose were assigned to Step 2 and children or adults that appeared in any of the previous 
three steps (Steps 0-2) and were also on oral steroids comprised Step 3.  
 
The creation of the BTS step variable derived from GP free-text prescriptions issued 
in patients with asthma that were for asthma or other conditions. Thus, if a patient had 
multiple prescriptions within the same season priority was given to the highest BTS 
step and he was assigned to the highest BTS step. The BTS step variable in this study 
was thus created by combining steps suggested in the BTS 2016 guidelines (see Table 
6.3 & 6.4).   







(or steps)  
Asthma medications 
Step 0  Consider monitored initiation of treatment with low-dose ICS 
Step 1 Low-dose ICS 
Step 2 Add inhaled LABA to low-dose ICS 
Step 3 Increased dose of ICS (low for children, medium for adults) & continue LABA & may 
add in other therapy (LTRA, theophylline, LAMA) 
Step 4 Increased dose of ICS (medium for children, high for adults), add a fourth drug 
(LTRA, theophylline, beta agonist tablet, LAMA) 
Step 5  Increased dose of ICS (medium for children, high for adults) and add OCS  
(frequent or continuous use, but consider other treatment to minimise use of OCS) 
Abbreviations: BTS: British Thoracic Society; ICS: inhaled corticosteroids; OCS: oral 
corticosteroids; LTRA: leukotriene receptor antagonists; LAMA: long-acting muscarinic 
antagonists; LABA: long-acting beta agonists  
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   Table 6.4: BTS steps creation in this study based on the BTS 2016 guidelines 
 
6.2.3 Data sources  
Using the CHI number, individual-patient data were extracted from the 223 Scottish 
primary care practices and linked to a number of databases including primary care, 
vaccination records from SIRS and hospitalisation records. Details on the primary care 
and SIRS data are provided in sections 5.2.1 and 5.2.2 of Chapter 5. All linked 
databases and statistical analyses were hosted in the eDRIS (see Chapter 5 for further 
details).  
Primary care: A separate dataset of prescriptions issued by GPs was used for the 
creation of the BTS step variable. The vaccine uptake status was determined only for 
those prescriptions issued to patients with an established asthma diagnosis in the 
community. The unit of analysis was the number of prescriptions per person (and not 
number of patient-seasons) between vaccinated and unvaccinated asthma patients for 
each BTS step across 15 seasons. My initial attempt to add the BTS step variable into 
the primary care cohort and the emergency hospital admissions datasets was 
abandoned due to high level of missing data. This was mainly due to a large number 
of unmatched records by patient ID and season. Specifically, many patient IDs from 
the dataset containing all the prescriptions could not be identified in the same season 
in the primary care or in the hospital dataset. As a result, more than 50% of 
prescriptions could not be allocated in the relevant BTS step. In addition, there were 
BTS steps Study 
BTS 
steps 
Asthma medications  
Step 0  Step 0  A person not in the other steps (e.g. bronchodilators only)  
Steps 1, 2 & 3 Step 1 Not medium dose of ICS for children; 
Not high dose of ICS for adults or children (e.g. older)   
Step 4 Step 2 Medium dose of ICS for children; 
High dose of ICS for adults or children (e.g. older)  
Step 5 Step 3 Step 0 & OCS;   
Step 1 & OCS;  
Step 3 & OCS;  
OCS only  




no prescriptions data for the first two influenza seasons (2000/01 and 20001/02), while 
the primary care and hospital datasets included data from 2000 and onwards.  
Scottish Morbidity Database: Individual-patient data from GPs were linked to the 
Scottish Morbidity Record (SMR), which contains episode level data on acute hospital 
admissions and death records of the Scottish population.(283) Specifically, the 
database contained four major linked datasets containing data on acute hospital 
admissions, psychiatric admissions, cancer registrations and death records from 1980 
and onwards. The SMR01 dataset contains data on all general/acute inpatient and day 
cases.(284) The SMR01 dataset was constantly updated and held over 37 million 
records. All diseases and health problems were recorded in this database based on the 
10th revision of the International Statistical Classification of Diseases and Related 
Health Problems (ICD-10) diagnostic code since 1996.(284) Regular quality 
assessments are carried out in both SMR01 hospital dataset. The quality of SMR01 
data was high according to a recent report, where the accuracy rate was found over 
90% during a 25 year data quality assessment.(285)  
6.2.4 Statistical analysis   
All demographic and clinical descriptive data were provided for both vaccine groups 
as percentages in tabulated format. Overall vaccine uptake between vaccinated and 
unvaccinated groups for each descriptive characteristic was also provided as a 
percentage. A univariate logistic regression analysis was performed to estimate any 
significant differences in vaccine uptake for each category of patients’ characteristics. 
Adjusted ORs and their 95% CIs were provided for all categories. For the univariate 
logistic regression analysis, reference groups were usually those with the highest 
number. Missing values for each characteristic were also provided.  
A multivariate correlation logistic regression model was performed to provide adjusted 
vaccine uptake effects from the influenza season 2000/01 to 2016/17. Specifically, the 
model aimed to provide ORs and 95% CIs estimates for each predictor of vaccine 
uptake adjusted for the effects of other covariates. The correlation model was able to 
adjust for the within patient correlation which occurred in the data. This is because the 
observations in this dataset were not independent as one asthma patient could appear 
in more than one season resulting in multiple observations of the same patient. Thus, 
170 
 
the observations from the same patient were correlated or dependent. I used a 
correlation regression model which takes the correlated observations into account 
when it estimates sampling variation such as regression-coefficient standard errors. 
This tends to provide larger standard errors in order to adjust for multiple observations 
derived from the same patient. Consequently, p-values of the predictor variables in the 
model are also larger.(286) The model was fitted using a backward stepwise selection 
procedure. In the first step all variables that were significant at the p=0.05 level in the 
univariate analysis were entered into the multivariate model. In the second step, 
variables not statistically or clinically significant with the vaccine uptake were 
eliminated from the model. Observations from asthma patients (13,368/194,314) with 
a death record were removed from the analysis. The level of statistical significance 
was set at p=0.05 and all statistical tests were two-sided. The analyses were performed 





Primary care cohort dataset  
In total, 614,182 (33.6%) influenza vaccinations were administered during 1,830,772 
person-seasons of observation across 16 influenza seasons. Overall high influenza 
vaccine uptake was observed for females (38.7%), school-aged (5-11 years old) 
children (24.5%) and older adults (>75 years old) (82.8%), people with a higher 
socioeconomic status (33.9%), people living in remote rural areas (41.6%), people 
with COPD (75.6%), chronic heart disease (76.3%), chronic liver disease (56.7%), 
chronic neurological disease (75.2%), diabetes (76.7%), immunosuppression (61.2%), 
people with >5 medical conditions (83.2%), people with an influenza (80.5%) and 
pneumococcal (79.6%) vaccination history in the previous season, in ex-smokers 
(63.7%), people with a Charlson score 5 (78.0%), people with >5 primary care 
consultations for acute respiratory illness in the previous season (70.4%) and people 
with 4 emergency hospital admissions in the previous season (60.0%).(see Table 6.5) 
 
After adjustment, the OR for vaccine uptake was high in females, adults aged > 65 
years old, people living in remote rural areas, people with chronic conditions (COPD, 
chronic heart disease, chronic liver disease, chronic neurological disease, diabetes and 
immunosuppression), people with a previous influenza or pneumococcal vaccination, 
ex-smokers, people with five primary care consultations in the previous season and 
people with two emergency admissions in the previous season.(see Table 6.6) No 
differences in adjusted ORs for vaccine uptake was found amongst people in different 









Table 6.5: Vaccine status by demographic and other clinical characteristics for 194,314 asthma 













Vaccine uptake  
unadjusted OR  
(95% CI) 
Gender 
Female (reference) 59.5 47.5 38.7 NA 
Male 40.5 52.5 28.0 0.615 (0.61 to 0.62) 
Age group (years) 
0-1 0.01 0.1 10.1 0.023 (0.020 to 0.030) 
2-4 0.6 1.0 24.1 0.066 (0.060 to 0.070) 
5-11 5.3 8.2 24.5 0.067 (0.066 to 0.070) 
12-17 4.9 12.2 17.0  0.043 (0.040 to 0.044) 
18-44 24.9 56.1 18.3    0.046 (0.045 to 0.050) 
45-64 32.6 18.8 46.7    0.180 (0.178 to 0.185) 
65-74 17.8 2.2 80.2    0.840 (0.820 to 0.860) 
>75 (reference) 13.9 1.5 82.8 NA 
Deprivation quintile 
1a (reference)  18.1 17.9 33.7 NA 
2 21.5 21.0 34.1 1.02 (1.01 to 1.03) 
3 19.5 19.4 33.6 1.00 (0.99 to 1.01) 
4 20.5 20.2 33.9 1.01 (1.00 to 1.02) 
5 18.9 19.5 32.9 0.96 (0.95 to 0.97) 
Urban/rural score 
1 (reference)  35.4 37.5 32.3 NA 
2 33.4 34.2 33.0 1.03 (1.02 to 1.04) 
3 9.2 8.6 34.9 1.12 (1.11 to 1.14) 
4 2.3 1.9 37.9 1.28 (1.25 to 1.31) 
5 1.5 1.4 35.1 1.13 (1.10 to 1.16) 
6 10.8 10.3 34.7 1.11 (1.10 to 1.13) 
7 2.9 2.3 39.4 1.36 (1.34 to 1.39) 
8b 3.6 2.5 41.6 1.50 (1.47 to 1.52) 
COPD 7.2 1.2 75.7 6.56 (6.43 to 6.69) 
Chronic heart disease 11.1 1.8 76.3 7.04 (6.93 to 7.15) 
Chronic liver disease 0.6 0.2 56.7 2.60 (2.48 to 2.73) 
Chronic neurological 
disease 
4.4 0.7 75.2 6.23 (6.08 to 6.38) 
Diabetes 8.8 1.4 76.7 7.07 (6.94 to 7.19) 
Immunosuppression 0.5 0.2 61.2 3.14 (2.97 to 3.32) 
Number of risk groups  
1 (reference)  70.9 93.4 27.7 NA 
2 17.2   5.0 63.6     4.56    (4.51 to 4.61) 
3    8.2    1.2 77.0     8.72    (8.56 to 8.88) 
4    2.9    0.3 81.1 11.18 (10.81 to 11.57) 





>5     0.1    0.01 83.2 12.95 (10.72 to 15.63) 
Influenza vaccine in the previous season 
Yes 76.1    9.3 80.5 30.88 (30.62 to 31.14) 
No (reference)  23.9 90.7 11.8 NA 
Pneumococcal vaccine  
Yes     4.2    0.6 79.6 8.05 (7.83 to 8.27) 
No (reference)    95.8  99.5 32.7 NA 
Smoking status  
Non-smoker 
(reference) 
30.6 16.8 47.9 NA 
Ex-smoker 18.9   5.5 63.7     1.90 (1.88 to 1.94) 
Current smoker 13.6   9.8 41.2      0.76  (0.75 to 0.77) 
Not recorded 36.9 68.0 21.5 0.30 (0.295 to 0.31) 
Charlson score 
0 (reference)    7.5 7.6 33.2 NA 
1 14.4 6.0 55.0 2.46 (2.42 to 2.49) 
2    4.9 0.9 73.6 5.61 (5.47 to 5.75) 
3    2.0 0.3 76.6 6.58 (6.33 to 6.84) 
4    0.8 0.1 77.4 6.89 (6.48 to 7.31) 
5    0.4 0.1 78.0 7.11 (6.50 to 7.78) 
>5    0.7 0.2 67.5 4.18 (3.96 to 4.41) 
Primary care consultations for acute respiratory illness  
0 (reference)  82.0 87.7 32.1 NA 
1 10.6   5.8 48.1 1.96 (1.94 to 1.98) 
2   2.8    1.1 56.7 2.78 (2.71 to 2.84) 
3   1.1    0.3 60.9 3.30 (3.18 to 3.43) 
4   0.5    0.1 63.7 3.72 (3.50 to 3.95) 
5   0.3    0.1 68.6 4.63 (4.24 to 5.06) 
>5   0.4    0.1 70.4 5.05 (4.67 to 5.45) 
Emergency hospital consultations 
0 (reference)  89.3 91.5 33.0 NA 
1   6.3   3.0 51.8 2.18 (2.15 to 2.21) 
2   1.3   0.5 58.0 2.80 (2.70 to 2.90) 
3   0.4   0.1 58.5 3.04 (2.85 to 3.23) 
4   0.2   0.1 60.0 3.04 (2.76 to 3.35) 
5   0.1   0.03 58.5 2.86 (2.47 to 3.32) 
>5   0.1   0.04 52.8 2.27 (2.01 to 2.56) 
Abbreviations: OR: odds ratio; CI: confidence interval; NA: not applicable;  
a Most socioeconomically deprived  
b Remote rural areas 
Missing data (available data): Deprivation quintile 2.0% (1,796,253 patient-seasons);  
Urban/rural score 1.0% (1,808,751 patient-seasons);  
Charlson score 79.7% (372,403 patient-seasons);  
Primary care consultations for acute respiratory illness 4.0% (1,756,516 patient-season); 
Emergency hospital admissions 4.0% (1,756,516 patient-season)  
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Table 6.6: Vaccine status by demographic and other clinical characteristics for 180,951 asthma 
patients (1,732,799 patient-seasons), Scotland, 2000/01 to 2016/17 
Characteristic Adjusted OR Adjusted 95% CI 
Gender  
Female (reference) NA NA 
Male 0.79 0.78 to 0.80 
Age group (years)  
0-1 0.21 0.16 to 0.28 
2-4 0.36 0.34 to 0.38 
5-11 0.32 0.31 to 0.33 
12-17 0.18 0.175 to 0.19 
18-44 0.19 0.18 to 0.20 
45-64 0.41 0.39 to 0.43 
65-74 1.04 1.00 to 1.08 
>75 (reference) NA NA 
Deprivation quintile  
1a NA NA 
2 1.00 0.98 to 1.02 
3 0.98 0.96 to 1.00 
4 0.97 0.95 to 0.99 
5 0.98 0.96 to 1.00 
Urban/rural score  
1 NA NA 
2 0.96 0.95 to 0.98 
3 0.97 0.95 to 0.99 
4 1.08 1.03 to 1.12 
5 0.97 0.92 to 1.02 
6 0.98 0.95 to 1.00 
7 1.08 1.04 to 1.13 
8b 1.12 1.08 to 1.16 
COPD 1.21 1.15 to 1.26 
Chronic heart disease 1.48 1.42 to 1.54 
Chronic liver disease 1.41 1.28 to 1.55 
Chronic neurological disease 1.22 1.15 to 1.29 
Diabetes 1.80 1.73 to 1.87 
Immunosupression 1.75 1.55 to 1.97 
Influenza vaccine in previous season  
Yes 17.81 17.57 to 18.06 
No NA NA 
Pneumococcal vaccine in previous season  
Yes 1.20 1.16 to 1.25 
No NA NA 
Smoking status   
Non-smoker NA NA 
Ex-smoker 1.06 1.04 to 1.08 
Current smoker 0.86 0.84 to 0.87 
Not recorded 0.55 0.547 to 0.56 
Primary care consultations for acute respiratory illness in previous season 
0 NA NA 
1 1.53 1.50 to 1.55 





3 1.84 1.73 to 1.96 
4 1.93 1.75 to 2.13 
5 2.30 1.97 to 2.66 
>5 2.14 1.88 to 2.45 
Emergency hospital consultations in previous season  
0 NA NA 
1 1.31 1.27 to 1.34 
2 1.41 1.32 to 1.51 
3 1.30 1.14 to 1.47 
4 1.14 0.92 to 1.42 
5 1.31 0.94 to 1.82 
>5 1.24 0.94 to 1.64 
Abbreviations: OR: odds ratio; CI: confidence interval; NA: not applicable;   
a Most socioeconomically deprived  
b Remote rural areas 
Missing data (available data): Gender 0.01% (1,732,792); Deprivation quintile 1.84% (1,700,951 
patient-seasons); Urban/rural score 1.15% (1,712,934 patient-seasons); Primary care consultations 
for acute respiratory illness 3.80% (1,666,931 patient-season); Emergency hospital admissions 
3.80% (1,666,931 patient-season);  
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Emergency hospital admission dataset  
There were 8,231 emergency hospital admissions due to influenza or pneumonia out 
of 6,232 patients with an asthma diagnosis in the community over 16 influenza 
seasons. The vaccine uptake out of the total admissions was 65.9% (5,422/8,231). The 
coverage in females was higher but not significantly different from males. Higher 
uptake was observed in older age groups with those > 75 years old having an uptake 
of 31.0%.  
 
The coverage was higher from admissions with low socioeconomic status. Higher 
uptakes were observed from large urban areas; however, the differences were not 
statistically significant. Admissions from people chronic medical conditions were 
more likely to be vaccinated. Highest uptake was detected amongst admissions were 
COPD as a comorbidity. The uptake was higher in admissions where patients had more 
than one at-risk condition. The receipt of an influenza vaccine in the previous season 
increased the propensity of being vaccinated, while having a pneumococcal vaccine in 
the past decreased the propensity of being vaccinated against influenza. Non-smokers 
and ex-smokers were more likely to have been vaccinated than current smokers. 
Charlson score showed a decrease in vaccine uptake as the number of at-risk 
conditions increased. Significantly higher coverage was observed only in those with 
two or three primary care consultations for acute respiratory illness in the previous 
season. Highest uptake was found in those with no previous consultations however the 
number of admissions in the unvaccinated when compared to the vaccinated. 
Similarly, the highest uptake was observed in those with no previous season 
emergency admission but most admissions came from unvaccinated individuals. 
Significant higher uptake levels were observed in those with one or more emergency 
admissions in the previous year, except in those with three admissions with 




Table 6.7: Baseline characteristics by vaccine status of emergency admissions due to influenza or     













Vaccine uptake  
adjusted OR  
(95% CI) 
Gender 
Female (reference) 3,043 (56.1) 1,619 (57.6) 37.0 NA 
Male 2,379 (43.9) 1,190 (42.4) 28.9 1.06 (0.97 to 1.17) 
Age group (years) 
0-1        5   (0.1)     5    (0.2)   0.1 0.27 (0.08 to 0.92) 
2-4      26   (0.5)   79    (2.8)    0.3 0.09 (0.06 to 0.14) 
5-11      69   (1.3) 130    (4.6)   0.8 0.14 (0.10 to 0.19) 
12-17      46   (0.9)   74    (2.6)   0.6 0.17 (0.11 to 0.24) 
18-44    362   (6.7) 730  (26.0)   4.4 0.13 (0.11 to 0.15) 
45-64 1,149 (21.2) 760  (27.1)  14.0 0.40 (0.36 to 0.46) 
65-74 1,211 (22.3) 350  (12.5)  14.7 0.92 (0.80 to 1.07) 
>75 (reference) 2,554 (47.1) 681  (24.2)  31.0 NA 
Deprivation quintile 
1a 1,209  (22.3) 753 (26.8) 15.0 NA 
2 1,419  (26.2) 674 (24.0) 17.0 1.31 (1.15 to 1.49) 
3     974 (18.0) 480 (17.1) 12.0 1.26 (1.10 to 1.46) 
4     971 (17.9) 444 (15.8) 12.0 1.36 (1.18 to 1.57) 
5     743 (13.7) 364 (13.0)   9.0 1.27 (1.09 to 1.48)  
Urban/rural score 
1 2,198 (40.5) 1,115 (39.7) 27.0 NA 
2 1,749 (32.3)    958 (34.1) 21.1 0.93 (0.83 to 1.03) 
3     458  (8.5)     228  (8.1)   5.6 1.02 (0.86 to 1.21) 
4     107  (2.0)       57  (2.0)      1.3 0.95 (0.69 to 1.32) 
5       83  (1.5)       45  (1.6)   1.0 0.94 (0.65 to 1.36) 
6     521  (9.6)     223  (7.9)   6.3 1.19 (1.00 to 1.41) 
7     101  (1.9)       39  (1.4)   1.2 1.31 (0.90 to 1.91) 
8b     133  (2.5)       62  (2.2)   1.6 1.09 (0.80 to 1.48) 
COPD 1,707 (31.5)     552 (19.7)  20.7 1.88 (1.68 to 2.10) 
Chronic heart disease 1,684 (31.1)     453 (16.1) 20.5 2.34 (2.09 to 2.63) 
Chronic liver disease     113  (2.1)        66  (2.4) 1.4 0.89 (0.65 to 1.20) 
Chronic neurological 
disease 
    778 (14.4)      259  (9.2) 9.5 1.65 (1.42 to 1.91) 
Diabetes  1,001 (18.5)       272 (9.7) 12.2 2.11 (1.83 to 2.44) 
Immunosuppression     111   (2.1)         63 (2.2) 1.4 0.91 (0.67 to 1.25) 
Number of risk groups  
1 1,550  (28.6) 1,542 (54.9) 18.8 NA 
2 1,343  (24.8)    497 (17.7) 16.3 2.69 (2.37 to 3.05) 
3 1,436  (26.5)    461 (16.4) 17.5 3.10 (2.73 to 3.52) 
4     804 (14.8)    206   (7.3)   9.8 3.88 (3.28 to 4.60) 






>5       59   (1.1)       14   (0.5)   0.7 4.19 (2.33 to 7.54) 
Influenza vaccine in the previous season 
Yes 4,677  (86.3)     831 (29.6) 56.8 14.94 (13.36 to 16.71) 
No     745 (13.7)  1,978  (70.4)   9.1 NA 
Pneumococcal vaccine  
Yes     269  (5.0)       26  (0.9)   3.3 5.59 (3.73 to 8.38) 
No 5,153 (95.0) 2,783 (99.1) 62.6 NA 
Smoking status  
Non-smoker 1,051 (19.4)     350 (12.5) 12.8 NA 
Ex-smoker 1,798 (33.2)     375 (13.4) 21.8 0.58 (0.49 to 0.68) 
Current smoker 1,012 (18.7)     583 (20.8) 12.3 1.60 (1.36 to 1.88) 
Not recorded 1,561 (28.8) 1,501 (53.4) 19.0 0.35 (0.30 to 0.40) 
Charlson score 
0     356   (6.6) 253    (9.0)   4.3 NA 
1 1,386  (25.6) 629  (22.4) 16.8 1.57 (1.30 to 1.89) 
2     856 (15.8) 277    (9.9) 10.4 2.20 (1.78 to 2.71) 
3     565 (10.4) 177    (6.3)  6.9 2.27 (1.80 to 2.87) 
4     309   (5.7) 112    (4.0)  3.8 1.96 (1.50 to 2.57) 
5     187   (3.5)   57    (2.0)   2.3 2.33 (1.66 to 3.27) 
>5     238   (4.4) 102    (3.6)  2.9 1.66 (1.25 to 2.20) 
Primary care consultations for acute respiratory illness in previous year  
0 4,276  (78.9) 2,252  (80.1) 52.0 NA 
1     583 (10.8)     276    (9.8)   7.1 1.11 (0.96 to 1.30) 
2     205   (3.8)       78    (2.8)   2.5 1.38 (1.06 to 1.81) 
3     110   (2.0)       31    (1.1)   1.3 1.87 (1.25 to 2.79) 
4       45   (0.8)       26    (0.9)   0.5 0.91 (0.56 to 1.48) 
5       38   (0.7)       11    (0.4)  0.5 1.82 (0.93 to 3.57) 
>5       54   (1.0)       24    (0.9)   0.7 1.18 (0.73 to 1.92) 
Emergency hospital consultations in previous year  
0 3,254  (60.0) 1,834  (65.3) 39.5 NA 
1 1,112  (20.5)     428 (15.2)  13.5 1.46 (1.29 to 1.66) 
2     478   (8.8)      206   (7.3)   5.8 1.31 (1.10 to 1.55) 
3     197   (3.6)         99  (3.5)    2.4 1.12 (0.88 to 1.44) 
4     128   (2.4)        41  (1.5)    1.6 1.76 (1.23 to 2.51) 
5        56  (1.0)         17  (0.6)    0.7 1.86 (1.08 to 3.20) 
>5        86  (1.6)         72  (2.6)    1.0 0.67 (0.49 to 0.93) 
Abbreviations: OR: odds ratio; CI: confidence interval; NA: not applicable  
a Most socioeconomically deprived  
b Remote rural areas 
Missing data (available data): Deprivation quintile 2.4% (8,031 admissions); 
 Urban/rural score 1.9% (8,077 admissions);  
Charlson score 33.1% (5,504 admissions);  
Primary care consultations for acute respiratory illness 2.7% (8,008 admissions); 
 Emergency hospital consultations in previous year 2.7% (8,008 admissions) 
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Primary care prescriptions dataset  
GPs prescribed 8,006,171 medications in 134,941 patients with asthma over 15 
influenza seasons (2002/03 to 2016/17).  The number of prescribed medications 
increased from 173,449 in 2002/03 to 652,585 in 2016/17 (see Appendix A15; p 330). 
There were 57.1% of asthma-related medications (e.g. bronchodilators, inhaled and 
oral corticosteroids) issued out of the total number of prescriptions (see Appendix A16; 
p 330). The number of prescriptions in each BTS step developed in this study was also 
calculated. The highest number of prescriptions was observed in Step 1 (35.3%) while 
Step 2 included the least prescriptions (14.5%) (see Appendix A17; p 330). The low 
vaccine uptake in Step 2 could be due to patients with medium or high dose of ICS 
being assigned to Step 3 rather than to Step 2 when they also had OCS prescriptions 
during a season.  
The vaccine status was identified for 7,271,777 out of the 8,006,171 prescriptions 
based on the primary care cohort. Out of the total 7,271,772 prescriptions 65.2% 
(4,742,979) derived from asthma patients with an influenza vaccination. The highest 
vaccine uptake was observed in Step 1, which included lower doses of ICS for children 
and adults with asthma. The lowest uptake was found in patients with prescribed 
medications other than inhaled or oral steroids (see Table 6.8).  















Vaccine uptake  
adjusted OR  
(95% CI)  
Step 0    638,860  (13.5) 733,019  (29.0) 8.8 0.317 (0.315 to 0.318) 
Step 1 1,844,842  (38.9) 977,985  (38.7) 25.4 0.685 (0.683 to 0.688) 
Step 2    851,879  (18.0) 306,414  (12.1) 11.7 1.01 (1.00 to 1.02) 
Step 3 1,407,398  (29.7) 511,380  (20.2) 19.4 NA 
Abbreviations: BTS: British Thoracic Society; OR: odds ratio; CI: confidence interval 
Step 0: no other step;  
Step 1: no medium or high dose of ICS;  
Step 2: medium or high dose of ICS;  
Step 3: step 2 & OCS or OCS only or OCS & step 0 or OCS & step1  




Summary of main findings  
This is the first analysis to explore demographic and clinical characteristics of 
influenza vaccine groups in individuals with asthma across multiple influenza seasons 
in Scotland. In people with asthma the overall vaccine coverage was below the 
desirable level. Females, adults aged >65 years old, individuals living in remote rural 
areas, with comorbidities, with history of influenza or pneumococcal vaccination, ex-
smokers and with history of five primary care visits and two emergency hospital 
admissions were more likely to have been vaccinated in the current season. Individuals 
with prescribed medications were also more likely to have been vaccinated. 
Particularly, asthma-related prescriptions including inhaled or oral steroids were 
associated with vaccination. 
 
Comparisons with existing literature  
In this analysis, females were more likely to be vaccinated than males, a finding also 
observed in previous studies.(287)(288) The uptake pattern differed between children 
and adults. Specifically, the higher coverage found in younger children and in older 
adults, confirmed previous findings.(104)(289)(290) However, only adults over 65 
years old were significantly more likely to be vaccinated compared to younger age 
groups. This pattern could be explained by the recommendation that older adults 
(especially over 65 years old) are vaccinated irrespective of other risk factors such as 
asthma.  
 
Individuals with lower socioeconomic status who were admitted to hospital were more 
likely to have been vaccinated. Previous studies have also shown that lower 
socioeconomic status was associated with higher chance of vaccination.(291-294) 
There is, however, conflicting evidence, particularly for children. Specifically, others 
have found that vaccine uptake was lower in children of parents with lower income or 
with less than a high school education.(295-297) However, the adjusted vaccine uptake 
ORs in this study showed no difference for the primary care population.  No substantial 
differences were observed in vaccine uptake between individuals living in large urban 
and small remote areas. The presence of asthma co-morbidities increased the uptake 
of the vaccine. People with additional chronic conditions tend to have more healthcare 
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visits which, by extension, increases the probability of being recommended annual 
vaccination and receiving one opportunistically during a health care visit for another 
reason.(288)(291)(298) The receipt of influenza or pneumococcal vaccination in the 
previous year was strongly related with current year vaccination. A person with asthma 
who is regularly vaccinated may be more likely to continue vaccination potentially 
reflecting their personal belief in the importance of the vaccination or strong physician 
recommendation due to the severity of their underlying condition. This has also been 
shown in the case of the 2009 H1N1 pandemic where the receipt of the seasonal 
vaccine was a significant predictor of the pandemic vaccine.(298)(299) Thus, 
individuals that tend to get vaccinated may be more likely to accept additional 
vaccinations even in the same year for the same infection.(298)(299) This study found 
that current smokers were less likely to receive vaccination compared to non- or ex-
smokers. Previous studies have shown the association of no vaccine receipt in current 
smokers not only in asthma, but also in other chronic respiratory 
conditions.(186)(289)(292) This is an important finding as the combination of 
smoking and no vaccine protection against influenza puts people with asthma or other 
respiratory conditions at an increased risk of respiratory exacerbations. Patients with 
primary care or hospital care related visits in the previous season had a higher 
possibility to be vaccinated. A reverse pattern of vaccination was seen between 
primary and secondary healthcare visits. The increase of primary care consultations 
was associated with a vaccine uptake increase while no difference in vaccination was 
found in individuals with four or more hospital admissions. Regular primary healthcare 
visits could reflect a person’s healthy lifestyle or recognition of the need for protection 
by the healthcare providers and patients resulting in increased likelihood of 
vaccination.(300)(301) In this analysis, vaccinated individuals with asthma were more 
likely to have received a prescribed medication. The prescription of preventive asthma-
related medications such as bronchodilators and inhaled corticosteroids was 
particularly strongly associated with vaccine uptake. Other studies have hypothesised 
that the use of asthma medications reflects more severe asthma and increased number 
of healthcare encounters.(288)(300) Thus this could be associated with higher chance 




Strengths and limitations  
The main strength of this analysis is the use of a large primary care dataset including 
194,319 people with asthma in over a decade of observational data. Thus, the external 
validity of this analysis is probably high, and the study’s findings are likely 
generalisable to the asthma population in Scotland. Furthermore, the inclusion of 
different patient characteristics (e.g. demographics, socio-economic status and clinical 
information) allowed for an exploration of differences of vaccine uptake between 
groups. However, there are several limitations in this analysis. First, unmeasured 
confounding could still have biased the vaccine uptake estimates in this analysis. 
Second, some individuals’ characteristics were less completely ascertained due to 
insufficient data in early seasons (e.g. Charlson score) or no regular recording of these 
type of information (e.g. smoking status) by the GPs. Finally, the asthma severity 
status was not available to this analysis. This was due to insufficient data on asthma 
symptoms, pulmonary function tests and the use of GP asthma prescriptions where 
doses and other related information are recorded as free-text and could not be 
accurately determined for all patients. 
 
Implications and conclusion  
In Scotland, the influenza vaccine is given free of charge to all patients with asthma 
who are on continuous or repeated inhaled or oral corticosteroids or have a history of 
hospital admission due to asthma attack in the last 12 months. This study also found 
higher vaccine uptake in people with asthma prescriptions and a history of emergency 
admission in the last season. However, overall uptake rates based on annual national 
reports and also confirmed in this analysis remain suboptimal. On the other hand, age-
based immunisation strategies seem to be more effective than at-risk strategies based 
on the increased or desirable uptake levels in older adults (>65 years old) found in this 
study.(302).Healthcare providers should also be more informed regarding the latest 
evidence on VE, safety and burden of the infection in the asthma population.(104) 
Thus, providers are more likely to recommend the vaccine based on clear and timely 
evidence. Finally, healthcare providers should promote influenza vaccination 
particularly in males, younger age groups, active smokers and those with no 
vaccination history for influenza as they are less likely to be vaccinated. In conclusion, 
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more work is needed to improve the current low vaccination rates in the Scottish 
asthma population. Specifically, vaccination strategies should aim to improve the 
coverage in males, in younger age groups, in smokers and in those without a previous 
history of vaccination.  A qualitative study could be performed to explore the barriers 
and motivators for vaccination between males and females, in younger adults, in 
smokers and in those without regular vaccination histories for influenza. The focus on 
these subgroups would probably increase the overall uptake in the asthma population 
since these subgroups are less likely to follow the influenza vaccine recommendations. 
Thus, the gap between vaccination policy and implementation in the clinical settings 
is likely to be bridged.  
6.5 Summary to Chapter 6 
In Scotland, the influenza vaccine coverage in the asthma population is below the 75% 
WHO recommended target. Individuals with characteristics including males, children 
and young adults, current smokers, no history of previous vaccination, no regular 
health visits, not on asthma medications (e.g. inhaled or oral steroids) were more often 
found in the unvaccinated group. Uptake rates could be increased if the vaccination 
programme focuses on these groups of the asthma population. Thus, this will improve 
the implementation of the current vaccination guidelines at the clinical practice.  
Findings from this analysis and from studies in previous chapters will now be 
discussed in the following chapter. Specifically, all findings in this thesis will be 
discussed in terms of strengths and weaknesses and compared with other literature. 
Finally, the chapter will aim to identify all implications and conclusions resulting from 
this thesis that are applicable to vaccination policy, research community, healthcare 






Chapter 7. General discussion  
The aim of this final chapter is to provide an overall description, evaluation and context 
of my research findings in relation to current literature. Recommendations and future 
work arising from this thesis will also be provided. Specifically, in this chapter, I will 
summarise the findings from my research work in Chapters 3, 5 and 6. Strengths and 
weaknesses from the aforementioned chapters will also be discussed. Then I will 
reflect and integrate the findings of this thesis in relation to existing research evidence. 
Implications to policy, research and practice as a result of this thesis will also be 
considered. Finally, I will provide all conclusions that can be derived from this thesis. 
More detailed discussions for the research work undertaken in this thesis have been 
already provided in previous individual chapters.  
7.1 Summary of main findings  
The systematic review (Chapter 3) showed that influenza vaccines offered protection 
for people with asthma from influenza infection and other influenza induced 
complications. An overall VE of 45.0% was observed against laboratory-confirmed 
influenza infection. Protection against asthma related hospitalisation was also found 
which ranged from 59.0% to 78.0%. Finally, vaccines were safe and well tolerable in 
people with asthma.  
The TND case-control study (Chapter 5) found an overall VE of 48% against influenza 
infection in children and adults with asthma in Scotland. Significant positive VE was 
also seen in years with good antigenic match between the circulating and vaccine 
strains and for particular strains such as A(H1N1) and B. In addition, vaccination 
offered protection for all circulating influenza strains in adults less than 55 years old. 
While the LAIV offered substantial protection against influenza B in children with 
asthma.  
The univariate analysis on vaccine uptake (Chapter 6) found characteristics of people 
with asthma which increase the likelihood of vaccination. Specifically, individual 
characteristics including females, younger children and older adults, co-morbidity, 
vaccination history, recent healthcare visit history and asthma prescription were 
related with higher influenza vaccine uptake.  
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7.2 Strengths of the research program 
This research work added new evidence regarding the protective effects of the seasonal 
influenza vaccination in the asthma population. The uniqueness of this PhD thesis lies 
upon the explicit focus on the asthma population. The main strength of this work 
derives from the conduct of a large review of the literature and two large primary 
studies which enabled the exploration of research questions on vaccine effectiveness 
and safety in children and adults with asthma. Lack of substantial immunological, 
clinical and research personal experience on this topic was addressed by the 
independent journal peer-review of my systematic review work, carrying out my 
primary work analyses within the SIVE II project dataset and the overall support from 
the SIVE II project team and the AUKCAR.  
Specifically, I used a systematic review to synthesise any available evidence of the 
protective and adverse events of seasonal influenza vaccination in asthma. The use of 
a systematic review instead of a narrative review aimed to reduce any bias during the 
review process by using pre-specified systematic and reliable methods. My review 
findings were also statistically synthesised (e.g. via meta-analyses), increasing the 
strength of evidence by providing pooled estimates on vaccine protection. In addition, 
the journal publication (BMJ Open) and the registration in PROSPERO 
(CRD42016037219)(303) of my systematic review protocol standardised and guided 
the process of systematic review.(146) Thus, any deviations between my 
predetermined systematic review protocol and the completed systematic review were 
kept to a minimum by reducing any potential reviewer bias which can happen when 
the knowledge of the systematic review findings shapes the review process. The 
completed review also underwent an independent journal peer-review (Clinical 
Infectious Diseases) which improved the interpretation and presentation of my 
work.(234) As a first-time author of a systematic review, I also built a large and 
multidisciplinary review team who guided and made me aware of any errors during 
the review process.  
 
This PhD work program also adds new valuable information on the preventive capacity 
of the seasonal influenza vaccine in children and adults with asthma against laboratory 
confirmed influenza. An exploration of the vaccine uptake patterns in the asthma 
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population was also carried out in this PhD, evidence from which could help to tackle 
the sub-optimal coverage rate seen in the asthma population at national level by 
targeting patients with asthma not receiving the vaccination. My main primary work 
was part of the wider SIVE II project which aims to assess the effectiveness and safety 
of the influenza vaccination amongst at-risk groups.(128) The SIVE II project was led 
by an expert team (an led by my supervisor Prof. Colin Simpson), with a record of 
previous published work on the area of influenza vaccines and asthma research. The 
SIVE II project also determined all its epidemiological methods and statistical analyses 
in their protocol published in BMJOpen, which I contributed to.(128) My statistical 
analyses were guided and assessed by the SIVE II statistical team ensuring the 
soundness of my work and the subsequent outputs. The large sample size of my case-
control study and univariate analysis enabled me to explore additional research 
questions not pre-determined in the SIVE II project.  
The main strength of the TND case-control study in this thesis was that it used data 
from the national GP Scottish routine sentinel surveillance program which reduced 
concerns regarding the validity of the VE estimates produced (although I still carried 
out validation work comparing sentinel GP vs. non-GP sentinel results).(304) In 
addition, cases and controls were more comparable since both groups were retrieved 
from the same population (patients with ILI seeking care) - a major advantage of the 
nested TND case-control study over traditional case-control studies. Another strength 
of this study design lies in the fact that all data on vaccine exposure and other baseline 
characteristics were determined before the allocation of the patients into cases or 
controls. Thus, this should have minimised any recall bias from the asthma patients or 
observer bias derived from the research investigators.  
7.3 Limitations of the research program 
There were also several limitations related to the methodology and the datasets that 
were used in this research work.  
 
Pitfalls with the evidence search and synthesis in the literature review  
During my systematic review many studies assessed the effectiveness of the vaccines 
in individuals with chronic respiratory diseases and not explicitly in asthma. Thus, I 
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had to contact many authors to identify any separate analyses on the asthma 
population. However, some authors either did not reply to my requests for 
collaboration, or I was not able to find any contact details. In addition, some authors 
did not have access to their data any longer and could not confirm to me any analyses 
in the asthma subgroup. Thus, it is possible my systematic review failed to include 
some eligible studies. Another issue regarding my systematic review is availability of 
agreed rigorous criteria for the provision of pooled estimates deriving from 
epidemiological or clinical heterogeneous (e.g. participants, interventions, outcome 
measures and study designs) studies. As a result, I pooled results from two studies in 
each of my three meta-analyses as they were homogenous in terms of study design, 
intervention and outcome measure. However, this approach prohibited meta-analyses 
using results from more than two studies. Thus, the estimated effect size and the 
precision of the VE estimates in this review can be still questioned. According to 
previous work by Beyer et al protective effects of the influenza vaccines can be hidden 
when data from original studies are meta-analysed based on multiple criteria (e.g. 
vaccine types, study designs, populations and type of outcomes, virus circulation and 
vaccine mismatch) that are not related to the vaccine.(305)  
 
Confounding and bias in the primary research work  
The TND is now the most widely used study design used to answer the question of VE 
against confirmed influenza infection. However, we need to bear in mind that this is 
still an observational, analytic study design which cannot directly determine causation 
between vaccine exposure and influenza prevention. Thus, the internal validity of the 
TND study may still be questioned. Measured and unmeasured confounding could still 
have affected the VE estimates in this study given that their effect on the magnitude 
and direction of the VE estimates were not determined. In my TND study, swab 
samples were also taken from hospital settings. Thus, there could be individuals with 
more severe influenza-related outcomes e.g. hospitalisations due to influenza. 
However, if a large number of individuals are hospitalised and at a second time 
swabbed for influenza when the virus was no more detectable this could have led to 
false negative results.(231) Viral interference is another potential issue that could have 
undermined the validity of the TND, and happens when transient non-specific immune 
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protection against acute respiratory illness occur after a previous exposure to a 
respiratory infection. According to Foppa et al, children who received the inactivated 
trivalent vaccine had higher risk of having a non-influenza illness compared to the 
placebo group.(231) If this pattern between the vaccine and the likelihood of a non-
influenza illness indeed exists could threaten the validity of the TND resulting to 
overestimation of the true VE when it comes to impact on all ILI (rather than true 
influenza alone).  
In the TND study, I measured the effectiveness of the vaccine in preventing confirmed 
influenza illness. Nonetheless, the vaccine could also modify the expression of the 
influenza symptoms when an immunised individual is infected with the virus. This 
phenomenon could bias the ORs from the TND study as the ORs would not only 
represent the risk of infection but could also represent the risk of having more severe 
symptoms compared to an unvaccinated individual. However, it remains unclear how 
the modification of influenza symptoms followed by the vaccination will influence the 
VE estimates.(231) A potential confounder that can also affect the VE estimates of the 
TND study is the rate that the individuals in my study came into contact with other 
influenza infected individuals.(230) For example, female patients were more likely to 
get vaccinated in the TND and the univariate analysis, but at the same time mothers of 
young children are more likely to be in contact with children who are more likely to 
get infected (see section 1.3.1 in Chapter one). It was however difficult to find a 
relevant variable that could assess the existence of such a confounding effect.  
Bias could also be introduced in the TND study if the influenza vaccination had 
indirect effects, other than preventing the influenza virus. According to Lipsitch et al, 
if this is the case, the direct protective effect of the vaccine on the influenza could have 
been imitated or hidden by those indirect effects leading to under- or over-estimation 
of the VE estimates.(306) The first potential bias could occur if the vaccine has a 
protective effect on non-influenza ILI. This potential bias mechanism does not fit with 
claim by the Foppa et al regarding the higher risk of non-influenza ILI among 
vaccinated children.(231) This potential bias means that the vaccine might also 
decrease the likelihood of an individual being infected with a non-influenza virus 
compared to the general population. Thus, individuals that are swabbed for ILI 
189 
 
symptoms are more likely to be tested positive for influenza or less likely to be tested 
negative for influenza than an individual in the general population. If this had occurred 
in my study, it could have biased and underestimated the VE estimates since some of 
the direct protective effect of the vaccine could have been masked from the beneficial 
effect against other non-influenza ILI.(306) A second potential bias could have 
occurred if the influenza infection induced a non-specific immune protection against 
non-influenza illnesses.(306) Lipsitch et al hypothesised that in this scenario the 
influenza vaccine will increase the risk of a non-influenza ILI and the chance of being 
tested negative for influenza infection.(306) Consequently, the VE estimates will be 
overestimated since vaccinated individuals will be more likely to be controls than in 
the general population.(306) The final potential bias could result from the fact that 
individuals at higher risk for influenza infection are more likely to contract the 
infection earlier in the season and be protected for a second infection during that 
season. Similarly, higher risk individuals will be vaccinated more rapidly during the 
influenza season. However, the presence of within-season decline in immune 
protection provided by either past infections or vaccination will eventually decrease 
the VE estimates over the course of the season.(306)  
The main widely accepted methodological advantage of the TND study over the 
traditional case-control study is the exclusion of bias derived from confounding by 
healthcare seeking behaviour.(239) This behaviour refers to the likelihood of an 
individual seeking care when in the presence of respiratory infection symptoms. Thus, 
the healthcare seeking behaviour is treated by the TND studies as a binary variable 
whereby an individual will either seek or not seek care. However, the propensity of 
seeking care is dynamic and changes constantly based on other behaviours (e.g. hand 
washing) or characteristics such as age or high-risk status. Therefore, it is an 
oversimplification to adjust for healthcare seeking behaviour by using a binary 
indicator and it will still remain partially unobserved. Consequently, according to 
Sullivan et al the TND study will not completely account for the effects of this 
confounder.(239)  
Another limitation is the use of data from medical records for the ascertainment of 
exposure, outcome and baseline characteristics. The accuracy of these data is higher 
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than in studies based on self-report and introducing subsequently recall bias.(239) 
However, misclassification bias in study variables is still possible particularly given 
the retrospective nature of the primary studies in this thesis. Nonetheless, any errors in 
the medical records are likely to be random and thus have a smaller effect on VE 
estimates. Another limitation is related to the definition of the influenza-like illness 
symptoms, for which there are widely agreed criteria in use in Scotland. Therefore, 
GPs or other healthcare providers may have been more likely to take swab samples 
from people with at-risk conditions such as asthma. In my TND study, I found that in 
patients with asthma, the odds of being swabbed for influenza were 1.76 (95% CI: 1.60 
to 1.94) higher than in non-asthma patients (see Appendix A18; p 331). However, the 
odds of being infected with influenza were also higher and up to 1.28 (95% CI: 1.17 
to 1.41) in patients with asthma compared to non-asthma patients (see Appendix A19; 
p 332).  
 
A central assumption of the TND that there is only direct protection afforded by the 
vaccine may be violated in the following scenario. Vaccines that alter viral shedding 
may reduce transmission of infection by generating an indirect protection which is 
additive to the direct protection. So when a TND is used in a population vaccinated 
with a live influenza vaccine we may underestimate the overall effect of the 
vaccine.(239)  Another potential issue can occur if the vaccine alters ‘viral shedding’ 
which may lead to higher number of false negative tests for influenza amongst the 
vaccinated than unvaccinated individuals. This incidence will violate the assumption 
of the TND that the rate of non-influenza acute respiratory infections is equal between 
vaccine groups, and thus will alter VE effect size. However, the inclusion as controls 
those with a negative test for influenza, but positive for non-influenza respiratory 
infection aims to remove this potential bias.  
 
The external validity of the TND study can also be questioned since, by definition, it 
focuses on individuals with acute respiratory illness who then seek healthcare for their 
symptoms and are swabbed. Thus, according to Westreich et al it is unclear to what 
extent the results for this study can be generalised to the general population and to 
those that do not seek care.(307) This PhD work provided evidence on the VE against 
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influenza infection however the protective effects of the vaccine against clinical 
outcomes are also important for asthma patients - asthma attacks leading to healthcare 
consultations or hospital admissions however were not assessed as part of this thesis. 
One of the initial objectives of this PhD was to assess the VE against clinical outcomes 
using a retrospective cohort study. However, these data sources from the SIVE II 
project were only accessible in the third year of my PhD project thus this delay 
prohibited the assessment of the clinical outcomes in a timely manner. Nevertheless, I 
still intend to conduct the cohort study and publish these results.  
7.4 Integration and reflection of the findings in comparison to existing 
research activity  
The findings in this PhD thesis can be relevant to various national and international 
research activities which are related with acute or chronic respiratory diseases and 
preventive strategies. At national level, HPS is a public organisation established by the 
Scottish Government for the provision of specialist services at national levels such as 
on respiratory and vaccine preventable diseases including influenza infection.(308) 
HPS collects data for surveillance purposes on influenza for the monitoring of the 
influenza activity, vaccine uptake and VE. However, the annual reports on influenza 
VE estimates produced by Scotland and the UK are not explicitly for asthma, but rather 
relate to a combined at-risk group (e.g. chronic heart or respiratory 
diseases).(265)(266) The results of this TND study can provide valuable evidence on 
the protection that the current influenza vaccines provide in the asthma population. In 
addition, the close collaboration of the HPS with academic partners involved in the 
SIVE II project will help to inform them to monitor and identify any gaps on vaccine 
protection and uptake in specific populations such as asthma. Specifically, the SIVE 
II project and my study on the asthma population have been used data by HPS with 
any valuable findings or gaps being reported back to HPS via Dr Jim McMenamin. 
The AUKCAR is another organisation where the findings of this PhD work are 
relevant. Specifically, the SIVE II project on asthma is part of AUKCAR’s portfolio 
of work, which aims to reduce asthma exacerbations and prevent asthma-related 
deaths.(309) New research work from the AUKCAR presented in the Annual 
Scientific Meeting in Bristol, UK in 2018 also highlighted the importance of the 
influenza prevention in asthma through influenza vaccination.(310) New research 
192 
 
work revealed that respiratory infections for people with asthma leads to worse asthma 
outcomes and increased asthma costs.(311) In addition, another research study 
reported the link between lower socioeconomic status and poor asthma-related 
healthcare outcomes in Wales.(312) Influenza infection can therefore be connected 
with both of these findings as it is a common pathogen that causes asthma attacks 
(details are included in Chapter 1) with higher influenza-induced asthma attacks have 
been found in socioeconomically deprived populations. Previous work by Sloan et al 
found an association between lower socioeconomic status and increased risk of 
hospitalisations due to influenza.(313) 
At an international level, the Influenza – Monitoring Vaccine Effectiveness (I-MOVE) 
network measures the VE annually in Europe where the University of Edinburgh is 
part of through previous and current work on VE.(126)(128)(314-316) I-MOVE 
includes a wide scientific community that works on different aspects related to 
seasonal and pandemic vaccine protection.  Specifically, some of the I-MOVE work 
includes recommendations for the use of the vaccine, provision of more precise VE 
estimates, improve vaccine composition and use of vaccine boosters (e.g. adjuvants) 
or booster doses. The findings from the review in this thesis have been already 
presented to the I-MOVE network during the 10th Annual Meeting in France in 2017. 
The primary work from this thesis will also give answers to evidence gaps and 
conflicting evidence on VE highlighted by influenza vaccine scientists from centres in 
Europe and North America. Specifically, it was agreed that large studies employing 
data from multiple seasons are required to enhance our current understanding on the 
protective capacity of the vaccination given the high variability of influenza seasons 
each year. The primary work in this thesis therefore used data from multiple seasons 
and enabled the exploration of differences on VE estimates within and across seasons. 
The methodological limitation of providing pooled VE estimates over multiple seasons 
was also discussed, arising due to differences in sample size by season and estimates 
particularly against the A(H3N2) strain (which is more likely to change annually 
compared to the A(H1N1) and B strains). Differences in VE estimates against the 
A(H3N2) were also observed in this PhD work.  
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More studies are also required (as expressed by a representative from the European 
Centre for Disease Prevention and Control (ECDC) and other scientists) comparing 
VE estimates between various vaccine types.  This is particular important since new 
vaccine types are introduced or stop being recommended such as the LAIV. The UK 
is one of the few European countries that it has adopted the LAIV into the childhood 
immunisation program while USA previously recommended LAIV but not during the 
2016/17 and 2017/18 seasons. However, US is now recommending the LAIV for use 
in children for the 2018/19 influenza season.(194) Evidence from this PhD showed 
high protection against the influenza B strain from the live vaccine. This adds to the 
current evidence of VE for LAIV and is supportive of the continuation of the LAIV in 
the UK. In addition, findings from this thesis can provide evidence on LAIV VE for 
counties such as US which stopped and have reactivated the LAIV programme.  
Role of prior influenza vaccination 
The impact of previous vaccination on current VE estimates is another controversial 
area with various possible explanations from researchers however without a clear 
answer. It is widely accepted in the scientific community that the impact of pre-
existing immunity acquired through either previous influenza infection or vaccination 
history needs to be assessed through large, long-term prospective studies using 
virology and immunological data. However, it has been acknowledged that there is a 
problem of getting enough sample size particularly to individuals with inconsistent 
vaccination patterns. This PhD work has found that individuals who were vaccinated 
in previous years were more likely to be re-vaccinated in the current year. Therefore, 
it is challenging to find an adequate number of individuals that are vaccinated in the 
current but not in the previous seasons. Researchers from the US and Canada have 
reported the phenomenon of decreased protection due to repeated vaccination.(317) 
Possible explanations included the antigenic distance hypothesis where during 
mismatched seasons (i.e. between the circulating and vaccine strains), the effect of 
previous vaccination on the current VE estimates is negative.(318) Another possible 
explanation is the phenomenon of cross-protective immunity that can be induced after 
a viral exposure and which has been particularly observed between influenza vaccine 
strains.(319)(320) Thus, the antibody memory from previous vaccinations may have a 
negative inference with future protection provided by current vaccination. The 
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infection-block hypothesis is another potential explanation of this negative effect of 
previous vaccination history. According to Skowronski et al “prior seasonal 
vaccination is conjectured to effectively block (protect against) seasonal influenza 
infection which might have otherwise provided effective heterologous cross-protection 
against the pandemic strain”.(321) Findings from this PhD work also found lower VE 
estimates among individuals with a vaccination history in the previous season. 
However, there was an overlap of confidence intervals with those individuals with 
current vaccination only. Finally, unmeasured confounders and characteristics related 
to patients with asthma could also explain the lower VE estimates among those with 
current and previous vaccination histories.  
 
Healthcare setting  
The healthcare setting where the swab samples are taken for the influenza illness is 
another area of research that could affect the VE estimates and needs to be investigated. 
In Scotland prior the 2009 H1N1 pandemic swab samples for influenza detection were 
predominantly collected in the general practice, however, after the pandemic the 
number of swabs from hospitals and other secondary health settings increased 
considerably. The patients’ clinical profile differs between outpatient and inpatient 
settings. Hospitalised patients are older with multiple medical conditions where the 
VE estimates could be lower due to immunoscenesence or immunosuppression. 
However, the influenza vaccination could reduce the severity of influenza symptoms 
and subsequently the number of severe influenza cases requiring hospital admission. 
The TND study in this thesis included swab samples from both inpatient and outpatient 
settings. This enabled the assessment of the vaccine protection in a more complete 
clinical spectrum related to both patients’ characteristics and influenza severity. The 
results in this thesis showed no difference in VE estimates between settings. A result 
also found during the same seasons (2010-2016) in Northern Spain in adults over 50 
years old.(322) Nevertheless, authors claimed that “in some instances of low VE, 
vaccination may still reduce the risk of hospitalisation in older adults with vaccine 
failure”.(322) This highlights the importance of annual immunisation even in 
mismatched seasons where the vaccination may not prevent the virus, but it may still 
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reduce the severity of the influenza infection and subsequently the number of hospital 
admissions.  
TND validation  
Observational, analytic studies are widely used in countries with influenza vaccination 
programmes as the study design of choice for the assessment of the vaccine protection. 
There has been a rapid increase in the number of TND case-control studies observed 
in the last decade. According to Sullivan et al “The chief advantages of this study 
(TND) over the case-control or cohort design are speed and economy, since it can be 
nested in routine surveillance, without elevated concerns about the validity of the 
estimates produced”.(239) Therefore, two main areas need to be evaluated since the 
TND study is becoming a reference standard for estimating VE, rather than other 
observational study designs. First, epidemiological assumptions related to the TND 
that could potential introduce bias or confounding need now to be assessed given the 
prominence of the TND study design and its influence on vaccine policy. I have 
already mentioned in the section 7.3 of this chapter a number of potential bias or 
confounding that could be inherited with the TND studies if certain assumptions are 
not satisfied and their potential impact on the VE estimates. Firstly, most of these 
assumptions are based on theoretical speculations and still need to be confirmed using 
real-world data. Secondly, the data used for the VE estimates also need to be validated 
in other studies to ensure the internal and external validity of a TND study. The 
database used for the primary studies in this thesis were also not validated in previous 
studies. In my primary studies, data capturing the definition of asthma severity, 
influenza related hospital admission and influenza related primary care visit was 
difficult to be determined due to either underuse of relevant codes or the absence of 
specific codes reflecting these definitions. A recent study found that for asthma 
diagnosis most clinicians used a large number of definitions and there were even no 
codes for asthma diagnosis in some instances, but instead asthma-related symptoms 
were used.(255) The need for standard definitions related to asthma, influenza-related 
outcomes and influenza vaccination is thus imperative given the extensive use of 
databases for the provision of the VE estimates. The use therefore of more standard 
definitions and codes (if possible) will increase the comparability of the VE estimates 
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at national and international level giving more consistent answers to gaps on VE 
estimates and increasing the reproducibility of the TND studies.(323)  
 
Vaccine uptake 
Another factor that can influence the assessment of the VE is the global low vaccine 
uptake levels observed in asthma and other at-risk groups. A study measured the 
influenza vaccine coverage levels based on the number of vaccine doses distributed in 
195 countries across all six WHO regions during a 10 year period (2004-2013).(234) 
According to the study authors, only the UK and Netherlands achieved the desired 
coverage rate but that was only for older people (>65 years old). In addition, while the 
overall distribution in vaccine doses increased up to 87% from 2004 to 2013 the 
respective increase, from the latter period 2008 to 2013, was only up to 12%. The 
second phase of this study revealed that barriers related to vaccination included: risk 
groups’ belief that they are not an at-risk group for influenza, lack or doubt about the 
evidence of vaccine protection and fear about the safety of the vaccination.(234) 
Suboptimal coverage rates in asthma were also observed in the primary studies in this 
thesis despite UK being one of the few countries globally achieving optimal uptake 
levels in the over 65 years old risk group. Evidence from the systematic review and 
the TND study in this thesis showed that protection from the vaccine can be achieved 
in the asthma population. In addition, the review in this thesis also confirmed the safety 
of the inactivated vaccine and the live vaccine especially in older children with asthma. 
The literature review in Chapter 1 also showed high rates of circulating influenza in 
the asthma population especially where there is high viral activity as was shown during 
the 2009 H1N1 pandemic. Additional post-hoc analyses in this thesis embedded in the 
TND study also found that the asthma population had a higher likelihood of being 
infected with influenza compared to the other at-risk groups in the TND study of the 
SIVE II project. Specifically, in patients with asthma, there was a significant odds ratio 
of being infected with influenza (OR:1.28) compared with (the reference group) non-
asthma patients (see Appendix A19; p 332). Potential explanations of this finding 
could be a) a majority of the swab samples in my TND study were from hospitals were 
patients will probably have more severe ILI symptoms thus higher chance of having 
an influenza positive test. In addition, secondary care attendance is more likely to be 
197 
 
sought from individuals living in the most deprived areas in Scotland (325) who may 
be particularly vulnerable to infectious diseases due to socio-economic reasons as 
explained below; b) Healthcare providers may recognise which symptoms are related 
to influenza and take accordingly swab samples which are more likely to be positive 
for the virus; c) socioeconomic status may also explain the association between asthma 
and influenza infection susceptibility. Individuals from socioeconomic deprived areas 
may be more likely to contract influenza due to reasons other than low vaccine uptake. 
For example, they may live in more crowded houses, be active smokers, living in 
households with smoking, have poor health literacy and not comply or follow 
preventive measures during winter seasons. According to the Scottish Public Health 
Observatory “A challenge for immunisation programmes is to find effective, simple 
and inexpensive population wide strategies to recruit hard to reach individuals and 
those more likely not to take up vaccination opportunities, for example, those who live 
in areas of greater deprivation, in groups identified as harder to reach and covered 
by the Equality Act protected characteristics”.(326) Thus, deprivation is a factor that 
can affect influenza vaccine uptake in the Scottish population and d) differences in the 
asthma lung epithelium and immune antiviral responses could make asthma patients 
more vulnerable to the influenza virus compared to other at-risk groups. As a result, 
findings from this thesis will add more evidence regarding the importance of influenza 
vaccination in the asthma population and potentially lead to higher uptake rates.   
7.5 Implications 
7.5.1 Implications for public health immunisation policy in Scotland and in the 
UK  
The UK provides an annual report on the three main parts of the influenza surveillance 
system which includes results of the monitoring of influenza burden, influenza vaccine 
uptake and influenza VE. End of influenza season results on the VE estimates are 
usually provided for various influenza strains, age groups and more recently for 
vaccine types. The vaccine uptake rates for individuals at-risk for influenza due to a 
chronic medical condition are provided as ‘at-risk <65 years old’. No specific 
information on the asthma population in relation to both the VE estimates and the 
vaccine uptake rates can be extracted by these annual reports on influenza. Therefore, 
the research work in this thesis fills a gap between policy and evidence on the VE in 
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asthma  and it also provides stratified and precise evidence on aspects of the influenza 
vaccine guidelines in the asthma population such as influenza VE estimates by 
common influenza strains, age groups, influenza vaccine types, swab location and 
vaccination history. The findings from this thesis will contribute to more effective 
policy planning by targeting aspects of the immunisation strategy in asthma that could 
both improve the protective effects of the vaccines and increase their uptake. The 
implications of this research on the current vaccination policy in the asthma population 
include: 
a) Evidence from the literature review and the primary study showed the vaccines 
can prevent laboratory-confirmed influenza in both children and adults with 
asthma. Therefore, this research work supports the continuation of vaccination 
recommendation in asthma by Scottish and UK immunisation programmes.  
b) Lower vaccine protection was observed for the highly mutated influenza 
A(H3N2) strain in all asthma age groups especially in seasons with antigenic 
mismatch between the circulating and vaccine strains. Thus, additional 
methods to supplement vaccine protection should also be adopted (e.g. 
antiviral prophylaxis, good hand hygiene, follow of an asthma action plan/self-
management to avoid attacks,(327) contact of the physician at the early stage 
of the influenza illness) in seasons that the vaccine fails to provide full 
protection.  
c) Given the high antigenic mutation of the A(H3N2) strain, influenza 
surveillance systems should use technologies such as genetic sequencing to 
detect these small mutations of this strain and recommend the right viral strains 
for inclusion in the vaccines next year.  
d) Higher VE estimates against influenza B was found for all age groups 
compared to influenza A. In addition, high protection of the LAIV was found 
against influenza B. This finding therefore justifies the introduction and the 
continuation of the UK LAIV programme in children.  
e) A decrease in the VE estimates was observed in people aged 55 and above. 
This finding is only indicative of the onset of the immune deterioration in older 
adults. Therefore, future research work is also needed to confirm this finding.  
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f) The safety of the TIV in asthma was also found in the literature review of this 
thesis. No safety concerns were also found for the LAIV vaccine in children 
with asthma. However, more evidence is required for the pre-school children 
with asthma.  
g) Lower vaccine uptake was observed in young adults and in those with less 
active asthma (i.e. with a past diagnosis for asthma but no active asthma 
prescriptions). The current guidelines recommend that influenza vaccines be 
offered for free to people with asthma. Specifically, the UK recommends 
vaccination for “asthma that requires continuous or repeated use of inhaled or 
systemic steroids or with previous exacerbations requiring hospital 
admission.”(36) Thus, asthma patients with fewer healthcare encounters and 
not on regular asthma prescriptions may not be targeted for vaccination by the 
healthcare providers or have irregular patterns of vaccination. Evidence on the 
protective effects in this asthma group could justify if people with mild or less 
severe asthma need to be vaccinated resulting in overall higher vaccine 
coverage and better protection of the asthma population.  
7.5.2 Implications for research  
This research has helped to reduce some of the uncertainty regarding the protective 
effects of the main prophylactic measure against influenza in asthma. In addition, new 
research questions have emerged from this thesis which resulted from assessing 
various aspects of the vaccine protection and inability to assess all aspects of the 
vaccine protection within the time framework of this PhD programme. Therefore, the 
following suggestions will help to fully explore how well the influenza vaccine works 
in asthma people in real time settings.  
a) Additional TND case-control observational studies including multiple 
influenza seasons are needed to confirm the findings of this research work. In 
addition, larger sample sizes should be enrolled in order to give more certain 
answers on the VE in various age groups and between the live and inactivated 
vaccines.  
b) Future TND studies should aim to minimise the effects of bias and unmeasured 
confounding given that assumptions of this study design are yet to be tested.  
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c) The severity of asthma status should be carefully defined and included in future 
VE studies as it is affecting both the propensity of vaccine receipt and 
influenza-related outcome.  
d) Further observational studies need to assess the protective effect of the vaccine 
in people with asthma that do not require inhaled or systemic steroids or with 
no history of hospital admissions due to exacerbations. The vaccine is not 
recommended in people with asthma not currently on ICS or OCS or without 
a history of previous hospitalisations related to asthma exacerbations in the 
UK. However, if in seasons with high influenza activity all asthma patients are 
affected regardless of the severity of their chronic condition, then the above 
recommendation needs to be re-assessed. Therefore, research that will show 
both the VE and the burden of the influenza in different asthma severity strata 
will be required.   
e) Retrospective cohort studies are needed to evaluate the VE also against clinical 
outcomes that are important for people with asthma such as asthma 
exacerbations leading to emergency visits or hospitalisation. These studies 
should also include multiple seasons to account for the variability of the 
influenza seasons and vaccine strains and be powered to fully explore factors 
that could affect the VE estimates in asthma. In addition, efforts to minimise 
measured and unmeasured confounding should be made for the provision of 
more reliable results.  
f) The determination of asthma clinical outcomes due to influenza (e.g. hospital 
admissions, emergency visits, primary care consultations) and asthma severity 
using electronic health records should be based on valid definitions and 
algorithms. Studies with no validation assessment of these asthma-related 
definitions should at least fully describe the process and the algorithms used 
for these definitions to allow the validity assessment by other researchers. In 
addition, the supplementary provision of all clinical codes used in the 
electronic databases is important for the replication of the research findings, 
validity assessment of the algorithms used and the determination of the best 
approach to define asthma-related outcomes or severity status based on the 
available electronic data.(323)  
201 
 
g) Large TND case-control studies should also follow up patients tested positive 
for influenza during the influenza season to examine the number and type of 
influenza complications triggered by the influenza virus.  
h) Other outcomes of the vaccine protection in asthma should also be evaluated 
in future studies such as the indirect protection provided particularly by the 
children to their family members, changes in quality of life and the cost-
effectiveness of the vaccine.  
i) Further studies to assess the safety of the LAIV in children of all age groups in 
comparison to the TIV should also be conducted. Concerns regarding the safety 
of the LAIV in asthma still exist given that the vaccine is not recommended in 
children with severe asthma or active asthma symptoms.  
j) Large cohort observational studies using appropriate statistical models need to 
be conducted in order to detect which characteristics among asthma people are 
more strongly associated with vaccine receipt. 
k) Qualitative studies are needed to investigate the knowledge, attitudes and 
beliefs towards influenza vaccination in people with asthma. This would be 
particularly important in people aged under 65 who reportedly have lower 
vaccine uptake rates.  
7.5.3 Implications for clinical practice  
The findings in this thesis provide evidence to healthcare professionals on the benefits 
of influenza vaccination in people with asthma. The safety of influenza vaccines was 
also proved in this research work. Findings in this PhD can be fed into risk 
communication tools that will help clinicians and their patients together make evidence 
based decisions. Therefore, vaccination will be achieved through a ‘shared decision 
making process’ which leads to patient centred medicine.  
a) Observational epidemiological studies in the literature and a case-control 
epidemiologic study using Scottish health-care data has shown that the 
inactivated and the live influenza vaccines can prevent influenza infection in a 
proportion of children and adults with asthma. The prevention of the influenza 
infection is particularly crucial in the asthma patients compared to healthy 
individuals because it will potentially trigger an asthma attack that, it in the 
worst-case scenario, could lead to a severe illness requiring intensive care unit 
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admission or even to death due to secondary complications such as bacterial 
pneumonia.  
b) Higher protection is observed during the seasons where the influenza 
circulating strains are similar with the strains included in the vaccines. 
However, the vaccine should still be administered because the inclusion of 
multiple viral strains means that some degree of protection can still be provided 
for the other matched concomitant circulating influenza strains.  
c) Overall the inactivated and live influenza vaccines appear safe in all age 
groups. However, more research is needed for the LAIV in younger children.  
More efforts to target young adults with asthma and less severe asthma are needed by 
clinicians as this category of asthma patients are less likely to get vaccinated and be 
protected against influenza infection and its complications. 
7.6 The future of influenza vaccination 
The effectiveness of the current influenza vaccines is moderate and ranges between 
40-60% during influenza seasons where the vaccine strains are similar to the viral 
circulating strains.(328)  
 
Although, this level of protection is still important for vulnerable groups of the 
population such as for those with asthma, more efforts for higher level of protection 
should be pursued by scientists. Before I list current and future developments in 
influenza vaccines at national and global level I will discuss some of the problems 
related to current suboptimal vaccine protection. Indicative factors related to lower 
protection include: (329)   
a) Mutations of the current circulating influenza strains are observed almost every 
year, which makes it difficult to predict which strains to be included in the 
vaccines for the next season. These mutations can also occur after the 
manufacture of the vaccines leading to low protection due to the antigenic 
distance between the circulating viral types and those including in the 
vaccine.(330)  
b) The current vaccines trigger immune responses by targeting mainly the virus’s 
surface antigen, HA. However, most mutations occur in the HA antigen. Thus, 
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the virus can escape any immune recognition by existing immune memory 
from previous or current season vaccination or previous infections.(331) 
c) Current inactivated and live vaccines are manufactured in egg cells. However, 
the virus can still mutate while it is growing in eggs, leading to a vaccine that 
cannot prevent any circulating strains from infecting a host’s cells.(329) In 
addition, the use of embryonated eggs for the production of these vaccines is 
slow and it can be a potential problem in future pandemics where demands for 
large quantities of vaccines in a timely manner is required. In addition, if the 
pandemic is related to new viral strains where their predominant host is poultry 
then an additional shortage in embryonated eggs will arise.(330)  
d) The immunologic history from multiple exposures to the virus every year from 
vaccine strains and wild-type circulating strains can also affect the immune 
response from the vaccine. Thus, immune memory by previous exposure to the 
virus may block the immune response to any new exposure to viral strains such 
as influenza B.(317)  
Nonetheless new advances in vaccine production and formulation have been reported 
for the traditional vaccines in the last decade until the long-term solution is achieved 
(for the above problems) which is translated into a universal influenza vaccine.(332) 
According to Lambert et al “The ideal influenza vaccine would be one that is safe, 
elicits humoral and cellular responses identical to those triggered by a natural 
infection, provides long-lasting and cross-strain protection, and can be manufactured 
rapidly in large amounts under well-controlled conditions.”(333) The universal 
vaccine is a potential vaccine that might replace all influenza vaccines as it is would 
provide all the qualities described earlier by Lambert at al.(333) The efficacy of a 
candidate  universal vaccine is currently being tested at a world-first clinical trial in 
the UK which involves people aged 65 and above eligible for vaccination.(334)   
 
However, it is likely to take 10 or more years to bring universal vaccines in the market 
and recommend them for all currently at-risk groups as they are still in pre-licensure 
clinical trial phases. Therefore, some of the short-term solutions to improve the 
protection of the currently licensed vaccines are already available for use.(335)  
Specifically, the UK is now going to add new vaccine types that could enhance the 
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efficacy of the current TIVs. In season 2018/19 younger adults aged 18-64 belonging 
in at-risk group will be offered a quadrivalent inactivated vaccine (QIV) and people 
over 65 years old will be offered adjuvanted TIV.(336) In Scotland, adults aged 75 
years and above were offered adjuvanted TIV due to limited vaccine supply compared 
to the rest of the UK.(337) The QIV aims to provide better protection by including two 
influenza B subtypes given that influenza B infection affects more younger age groups, 
while the adjuvant TIV aims to enhance the immune response in older people that is 
currently low by the traditional TIVs. New technologies related to the manufacture of 
the vaccines are also available mostly in the US. Specifically, in 2016 the U.S FDA 
approved the administration of a quadrivalent cell-based influenza vaccine named 
‘Flucelvac’ in individuals aged four years or older.(338)  
 
A cell-based vaccine technology uses mammalian cells for its manufacture which it is 
supposed to provide better protection than the egg-based vaccines and their production 
is rapid since they do not rely on egg supply. Their rapid production is particularly 
important for pandemics where large demand of the influenza vaccines at short period 
of times is usually the case.(335) In 2016 the US also approved the administration of 
a quadrivalent recombinant influenza vaccine named ‘Flublok Quadrivalent’  in adults 
aged 18 years or older.(339) The main advantages of this vaccine is that it does not use 
elements of the influenza virus and does not rely on eggs or mammalian cells during 
its manufacture process. In addition, the production of these vaccines is faster than the 
egg or cell-based vaccines.(335) These new developments seem to increase the 
efficacy of the vaccines based on the pre-licensure clinical trials. Therefore, the 
assessment of their effectiveness in real world settings through observational studies 
is now also imperative. The post-market monitoring of the VE and safety will not only 
establish the continuity of these new vaccines but it should also focus on to identify 
which at-risk groups will benefit the most of these new vaccine technologies. 
Therefore, more targeted immunisation recommendations should be aimed by 
assessing who will be benefited the most by which vaccine types and against which 
viral strains. To conclude, the efficacy of old and new licensed influenza vaccines is 
already determined based on their formulation and production process. However, the 
205 
 
effectiveness of the vaccines can still be improved if they are given under conditions 
that will maximise their protective abilities seen during the pre-licensure phases.  
7.7 Conclusions  
The systematic review in this thesis revealed for the first time the existence of evidence 
advocating the protective effects of the influenza vaccination in children and adults 
with asthma. The primary work in this research also added new evidence about 
influenza vaccine VE by using a methodologically robust observational study design 
(TND) and a long follow-up period allowing for various VE assessments. Both the 
literature and the primary work showed that the vaccines can prevent around 50% of 
influenza infections. In addition, the systematic review showed that the vaccines 
prevented 59% to 78% of emergency visits or hospital admissions related to asthma 
exacerbations. The primary work in this thesis also showed that influenza vaccines 
provide higher protection during matched seasons, when strains other than the 
A(H3N2) predominate, when the LAIV is given in place of the TIV in children and in 
younger age groups less than 55 years old. Evidence about the safety of the vaccination 
was derived from the literature review which confirmed the safety of the vaccines. 
Factors related to the vaccine uptake among individuals were also explored based on 
a 16-year follow-up period. Individuals’ characteristics such as females, younger or 
older age groups for children and adults respectively, co-morbidities, previous 
vaccination and medical visits history increased the propensity of a vaccine receipt. 
Therefore, my results suggest that the research community and policymakers should 
assess the effectiveness and factors related to the uptake of the vaccine explicitly in 
the asthma population and not as a risk-group due to a chronic medical condition or 
chronic respiratory disease. As a result, the extensive investigation of aspects related 
to VE and vaccine uptake in asthma will improve the vaccination programme’s goal 
to improve the health of the asthma population by preventing or reducing of viral-
trigger asthma exacerbations. In addition, the provision of better protection in asthma 
will also improve the protection of the risk group due to chronic respiratory conditions 
in general given that most individuals in this category have asthma and COPD and that 
both conditions can co-exist under the asthma COPD overlap syndrome (ACOS).(340)  
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The results from the primary work (Chapters 5 and 6) in this thesis also need to be 
validated and confirmed in other datasets. Future work in other UK or international 
datasets with similar vaccine recommendations can be used for similar studies in the 
asthma population. The protective effects of the vaccine against clinical complications 
related to influenza infections should also be evaluated in future research work. The 
vaccine protection measured by clinical endpoints is particularly meaningful for both 
clinicians and asthma patients that could result in higher acceptance and recognition 
of the value of the vaccination in asthma. In addition, more evidence on the vaccine 
protection in asthma may increase the current low vaccine coverage. People with 
asthma need to be annually vaccinated and have optimal vaccination levels in order 
substantially to reduce the risk of influenza triggered asthma exacerbations and 
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Chemokines They are signaling proteins secreted by cells. Their name 
is derived from their ability to induce directed chemotaxis 
in nearby responsive cells.  
Cytokines They are a number of substances, such as interferon, 
interleukin, and growth factors, which are secreted by 
certain cells of the immune system and have an effect on 
other cells. 
Immunosenescence It refers to age-related deterioration of the immune system 
leading to a decrease in a host’s capacity to respond to 
infections and develop a long-term immune memory, 



















A1. Search Strategies 
Medline 
1. (chronic disease* or chronic illness* or chronic medical condition*).mp.  
2. ((respiratory or pulmonary or lung) and (disease* or illness*)).mp.  
3. exp asthma/ or asthma*.mp. 
4. ((bronchial* or respiratory or airway or lung*) adj3 (hypersensitiv* or hyperreactiv* or allerg* or 
insufficiency)).mp.  
5. ((bronchial spasm* or bronchospasm* or bronch*) adj3 spasm*).mp.  
6. ((bronchoconstrict* or bronch*) adj3 constrict*).mp.  
7. or/1-6 
8. exp influenza vaccine/ 
9. ((influenza* or flu) and (vaccin* or immuni* or inocula* or efficacy or effectiveness)).mp.  
10. 8 and 9 
11. (vaccin* and (monovalent or bivalent or trivalent or quadrivalent or polyvalent or inactivated or 
live attenuated or recombinant or virosom* or whole or subunit or split)).mp.  
12. 10 or 11 
13. 7 and 12 
14. exp influenza/ 
15. (influenza* or flu).mp.  
16. exp Influenza A virus/ or exp Influenza B virus/ 
17. 14 and 15 and 16 
18. ((laboratory confirmed or laboratory diagnosed) and (influenza* or flu)).mp.  
19. (real time polymerase chain reaction or reverse transcript* polymerase chain reaction or RT-PCR 
or rapid influenza diagnostic test* or fluorescent antibody test* or serologic* test* or viral 
culture*).mp.  
20. (hospitaliz* or hospitalis*).mp.  
21. mortality.mp. 
22. asthma exacerbation*.mp. 
23. (influenza like illness or flu like illness or ILI).mp.  
24. (primary care visit* or primary care consultation* or GP visit*).mp.  
25. (vaccin* and (adverse event* or adverse effect*)).mp.  
26. or/17-25 
27. 13 and 26 
28. Animals/ 
29. Humans/ 
30. 28 not (28 and 29) 
31. 27 not 30 
32. limit 31 to yr="1970 -Current" 
 








1. (chronic disease* or chronic illness* or chronic medical condition*).mp.  
2. ((respiratory or pulmonary or lung) and (disease* or illness*)).mp.  
3. exp asthma/ or asthma*.mp. 
4. ((bronchial* or respiratory or airway or lung*) adj3 (hypersensitiv* or hyperreactiv* or allerg* or 
insufficiency)).mp.  
5. ((bronchial spasm* or bronchospasm* or bronch*) adj3 spasm*).mp.  
6. ((bronchoconstrict* or bronch*) adj3 constrict*).mp.  
7. or/1-6 
8. exp influenza vaccine/ 
9. ((influenza* or flu) and (vaccin* or immuni* or inocula* or efficacy or effectiveness)).mp.  
10. 8 and 9 
11. (vaccin* and (monovalent or bivalent or trivalent or quadrivalent or polyvalent or inactivated or 
live attenuated or recombinant or virosom* or whole or subunit or split)).mp.  
12. 10 or 11 
13. 7 and 12 
14. exp influenza/ 
15. (influenza* or flu).mp.  
16. exp influenza virus a/ or exp influenza virus b/ 
17. 14 and 15 and 16 
18. ((laboratory confirmed or laboratory diagnosed) and (influenza* or flu)).mp.  
19. (real time polymerase chain reaction or reverse transcript* polymerase chain reaction or RT-PCR 
or rapid influenza diagnostic test* or fluorescent antibody test* or serologic* test* or viral 
culture*).mp.  
20. (hospitaliz* or hospitalis*).mp.  
21. mortality/ or mortality.mp. 
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24. (primary care visit* or primary care consultation* or GP visit*).mp.  
25. (vaccin* and (adverse event* or adverse effect*)).mp.  
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29. human/ 
30. 28 not (28 and 29) 
31. 27 not 30 
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"(hospitaliz* or hospitalis* or mortality or 
asthma exacerbation* or influenza like 
illness or flu like illness or ILI or primary 
care visit* or primary care consultation* or 
vaccin* adverse event* or vaccin* adverse 
effect*)" 





"(real time polymerase chain reaction or 
reverse transcript* polymerase chain 
reaction or rapid influenza diagnostic test* 
or fluorescent antibody test* or serologic* 
test* or viral culture*)" 





"(laboratory confirmed or laboratory 
diagnosed) and (influenza* or flu)" 










(MH "Influenza A Virus+") OR (MH 
"Influenza B Virus") 






















S8 OR S9 Search modes - Find all my 
search terms 
68,204 
S9 "(vaccin*) and (monovalent or bivalent or 
trivalent or quadrivalent or polyvalent or 
inactivated or live attenuated or 
recombinant or virosom* or whole or 
subunit or split)" 
Search modes - SmartText 
Searching 
61,462 
S8 S6 AND S7 Search modes - Find all my 
search terms 
7,252 
S7 "(influenza* or flu) and (vaccin* or 
immuni* or inocul* or efficacy or 
effectiveness)" 
Search modes - SmartText 
Searching 
163,623 
S6 (MH "Influenza Vaccine") Search modes - Find all my 
search terms 
7,252 
S5 S1 OR S2 OR S3 OR S4 Search modes - Find all my 
search terms 
169,085 
S4 "(bronchoconstrict*) or (bronch* adj3 
constrict*)" 
Search modes - SmartText 
Searching 
285 
S3 "(bronchial* spasm* or bronchospasm*)" Search modes - SmartText 
Searching 
6,192 
S2 ""(bronchial* or respiratory or airway or 
lung*) and (hypersensitiv* or 
hyperreactivit* or allerg* or 
insufficiency)"" 
Search modes - SmartText 
Searching 
148,194 















1 TITLE-ABS-KEY (asthma*) 
2 TITLE-ABS-KEY  (bronchial* or respiratory or airway or lung*) W/3 (hypersensitive* or 
hyperreactiv* or allerg* or insufficiency) 
3 TITLE-ABS-KEY (bronchial spasm* or bronchospasm*) 
4 TITLE-ABS-KEY (bronch* w/3 spasm*) 
5 TITLE-ABS-KEY  (bronchoconstrict*) 
6 TITLE-ABS-KEY  (bronch* w/3 constrict*) 
7 TITLE-ABS-KEY  (or/1-6) 
8 TITLE-ABS-KEY  (influenza* or flu) and (vaccin* or immuni* or inocul* or efficacy or 
effectiveness) 
9 TITLE-ABS-KEY  (vaccine*) and (monovalent or bivalent or trivalent or quadrivalent or 
polyvalent or inactivated or live attenuated or recombinant or virosom* or whole or subunit 
or split) 
10 TITLE-ABS-KEY  (8 or 9) 
11 TITLE-ABS-KEY  (7 and 10) 
12 TITLE-ABS-KEY  (influenza * or flu) 
13 TITLE-ABS-KEY (laboratory confirmed influenza or laboratory confirmed flu or laboratory 
diagnosed influenza or laboratory diagnosed flu or polymerase chain reaction or real time 
polymerase chain reaction ) 
14 TITLE-ABS-KEY (rapid influenza diagnostic test* or fluorescent antibody test* or 
serologic* test or viral culture*) 
15 TITLE-ABS-KEY (hospitaliz* or hospitalis* or mortality or asthma exacerbation* or 
influenza like illness or ili or primary care visit* or primary care consultation* or (vaccine*  
and adverse event*) 
16 TITLE-ABS-KEY (or/12-15) 
17 TITLE-ABS-KEY (11 and 16) 
18 TITLE-ABS-KEY (animal and not (animal and human) 
19 TITLE-ABS-KEY (17 not 18) 
20 TITLE-ABS-KEY (19) , Pubyear: 1970-2015, Limit to subjarea: “ Medi”, “Immu”, 
“Phar”, “Bioc”, “Nurs” 
 







pub-date > 1969 and TITLE-ABSTR-KEY(asthma*) 
[All Sources(- All Sciences -)] 
34,301 
pub-date > 1969 and TITLE-ABSTR-KEY((influenza* or flu) and (vaccin* or 
immuni* or inocul* or efficacy or effectiveness)) 
[All Sources(- All Sciences -)] 
9,857 
pub-date > 1969 and TITLE-ABSTR-KEY((vaccin*) and (monovalent or bivalent 
or trivalent or quadrivalent or polyvalent or inactivated or live attenuated or 
recombinant or whole or subunit or split)) 
[All Sources(- All Sciences -)] 
4,993 
(pub-date > 1969 and TITLE-ABSTR-KEY((influenza* or flu) and (vaccin* or 
immuni* or inocul* or efficacy or effectiveness))) OR (pub-date > 1969 and 
TITLE-ABSTR-KEY((vaccin*) and (monovalent or bivalent or trivalent or 
quadrivalent or polyvalent or inactivated or live attenuated or recombinant or whole 
or subunit or split))) 
[All Sources(- All Sciences -)] 
13,896 
(pub-date > 1969 and TITLE-ABSTR-KEY(asthma*)) AND ((pub-date > 1969 and 
TITLE-ABSTR-KEY((influenza* or flu) and (vaccin* or immuni* or inocul* or 
efficacy or effectiveness))) OR (pub-date > 1969 and TITLE-ABSTR-
KEY((vaccin*) and (monovalent or bivalent or trivalent or quadrivalent or 
polyvalent or inactivated or live attenuated or recombinant or whole or subunit or 
split)))) 
[All Sources(- All Sciences -)] 
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Web of Science 
#14 #11 NOT #12 
Refined by: [excluding]: WEB OF SCIENCE CATEGORIES: (THERMODYNAMICS OR 
MATHEMATICAL COMPUTATIONAL BIOLOGY OR SOCIAL SCIENCES 
INTERDISCIPLINARY OR REPRODUCTIVE BIOLOGY OR RADIOLOGY NUCLEAR 
MEDICINE MEDICAL IMAGING OR ZOOLOGY OR PSYCHOLOGY 
MULTIDISCIPLINARY OR NANOSCIENCE NANOTECHNOLOGY OR NUTRITION 
DIETETICS OR ENGINEERING MECHANICAL OR DEVELOPMENTAL BIOLOGY 
OR CONSTRUCTION BUILDING TECHNOLOGY OR INTEGRATIVE 
COMPLEMENTARY MEDICINE OR CHEMISTRY ORGANIC OR CHEMISTRY 
MEDICINAL OR AGRICULTURE MULTIDISCIPLINARY OR ENVIRONMENTAL 
SCIENCES OR WOMEN S STUDIES OR BIOPHYSICS OR TRANSPORTATION OR 
SOCIAL SCIENCES MATHEMATICAL METHODS OR MEDICAL INFORMATICS OR 
PSYCHOLOGY CLINICAL OR ECONOMICS OR PHYSICS MULTIDISCIPLINARY OR 
AGRICULTURE DAIRY ANIMAL SCIENCE OR MYCOLOGY OR METEOROLOGY 
ATMOSPHERIC SCIENCES OR COMPUTER SCIENCE INTERDISCIPLINARY 
APPLICATIONS OR MATHEMATICS INTERDISCIPLINARY APPLICATIONS OR 
PLANT SCIENCES OR MANAGEMENT OR FOOD SCIENCE TECHNOLOGY OR 
EVOLUTIONARY BIOLOGY OR SUBSTANCE ABUSE OR ENVIRONMENTAL 
STUDIES OR STATISTICS PROBABILITY OR ENGINEERING ENVIRONMENTAL 
OR MATHEMATICS APPLIED OR EDUCATION SCIENTIFIC DISCIPLINES OR 
ECOLOGY OR GENETICS HEREDITY OR COMPUTER SCIENCE SOFTWARE 
ENGINEERING OR SOCIAL SCIENCES BIOMEDICAL OR SPORT SCIENCES OR 
ENGINEERING CIVIL OR ENGINEERING CHEMICAL OR 
OTORHINOLARYNGOLOGY OR ENGINEERING BIOMEDICAL OR 
ELECTROCHEMISTRY OR EDUCATION EDUCATIONAL RESEARCH OR 
AGRICULTURAL ECONOMICS POLICY)  
DocType=All document types; Language=All languages; 
#13 #11 NOT #12  
DocType=All document types; Language=All languages; 
#12 TS=(animal* NOT (human and animal))  
DocType=All document types; Language=All languages; 
#11 #10 AND #7  
DocType=All document types; Language=All languages; 
#10 #9 OR #8  
DocType=All document types; Language=All languages; 
#9 TOPIC: ((laboratory confirmed influenza or hospitali* or mortality or asthma exacerbation* or 
influenza like illness or primary care visit* or vaccin* adverse event*))  
DocType=All document types; Language=All languages; 
#8 TOPIC: ((influenza* or flu or influenza A virus or influenza B virus))  
DocType=All document types; Language=All languages; 
#7 #6 AND #3  
DocType=All document types; Language=All languages; 
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#6 #5 OR #4  
DocType=All document types; Language=All languages; 
#5 TOPIC: ((vaccin*) and (monovalent or bivalent or trivalent or quadrivalent or polyvalent or 
inactivated or live attenuated or recombinant or virosom* or whole or subunit or split))  
DocType=All document types; Language=All languages; 
#4 TOPIC: ((influenza* or flu) and (vaccin* or immuni* or inocul* or efficacy or effectiveness))  
DocType=All document types; Language=All languages; 
#3 #2 OR #1  
DocType=All document types; Language=All languages; 
#2 TOPIC: ((respiratory or pulmonary or lung) and (disease* or illness*))  
DocType=All document types; Language=All languages; 
#1 TOPIC: (asthma*)  






Publication date: 1970 – 04/11/2015 
ID                                                                                                                                                              Search Hits
#1 (chronic illness* or chronic disease* or chronic medical condition*):ti,ab,kw in 
Trials (Word variations have been searched) 
34224 
#2 (respiratory or pulmonary or lung) and (disease* or illness*):ti,ab,kw in Trials 
(Word variations have been searched) 
25340 
#3 asthma*:ti,ab,kw in Trials (Word variations have been searched) 22972 
#4 (bronchial* or respiratory or airway or lung*) and (hypersensitiv* or 
hyperreactivit* or allerg* or insufficiency):ti,ab,kw in Trials (Word variations 
have been searched) 
5636 
#5 (bronchial spasm* or bronchospasm* or bronchoconstrict*):ti,ab,kw in Trials 
(Word variations have been searched) 
3153 
#6 {or #1-#5} 72409 
#7 "influenza vaccine":ti,ab,kw in Trials (Word variations have been searched) 1709 
#8 (influenza* or flu) and (vaccin* or immuni* or inocul* or efficacy or 
effectiveness):ti,ab,kw in Trials (Word variations have been searched) 
4392 
#9 #7 and #8   1709 
#10 (vaccin*) and (monavalent or bivalent or trivalent or quadrivalent or polyvalent 
or inactivated or live attenuated or recombinant or virosom* or whole or subunit 
or split):ti,ab,kw in Trials (Word variations have been searched) 
4197 
#11 #9 or #10 4929 
#12 (influenza* or flu or influenza A virus or influenza B virus):ti,ab,kw in Trials 
(Word variations have been searched) 
5711 
#13 (laboratory confirmed or laboratory diagnosed) and (influenza* or flu):ti,ab,kw 
in Trials (Word variations have been searched) 
135 
#14 (polymerase chain reaction or rapid influenza diagnostic test* or fluorescent 
antibody test* or serologic* test* or viral culture*) 
5449 
#15 (hospitaliz* or hospitalis* or mortality or asthma exacerbation* or influenza like 
illness or flu like illness or ILI or primary care visit* or primary care 
consultation* or vaccin* adverse event* or vaccin* adverse effect*):ti,ab,kw in 
Trials (Word variations have been searched) 
52562 
#16 {or #12-#15}   61654 










ID                                                     Search                                                                           Hits                           
#1 (chronic illness* or chronic disease* or chronic medical condition*):ti,ab,kw in 
Cochrane Reviews (Reviews and Protocols) (Word variations have been 
searched) 
970 
#2 (respiratory or pulmonary or lung) and (disease* or illness*):ti,ab,kw in Cochrane 
Reviews (Reviews and Protocols) (Word variations have been searched) 
756 
#3 asthma*:ti,ab,kw in Cochrane Reviews (Reviews and Protocols) (Word variations 
have been searched) 
259 
#4 (bronchial* or respiratory or airway or lung*) and (hypersensitiv* or 
hyperreactivit* or allerg* or insufficiency):ti,ab,kw in Cochrane Reviews 
(Reviews and Protocols) (Word variations have been searched) 
90 
#5 (bronchial spasm* or bronchospasm* or bronchoconstrict*):ti,ab,kw Cochrane 
Reviews (Reviews and Protocols) (Word variations have been searched) 
27 
#6 {or #1-#5} 1537 
#7 (influenza* or flu) and (vaccin* or immuni* or inocul* or efficacy or 
effectiveness):ti,ab,kw in Cochrane Reviews (Reviews and Protocols) (Word 
variations have been searched) 
64 
#8 (vaccin*) and (monavalent or bivalent or trivalent or quadrivalent or polyvalent 
or inactivated or live attenuated or recombinant or virosom* or whole or subunit 
or split):ti,ab,kw in Cochrane Reviews (Reviews and Protocols) (Word variations 
have been searched) 
41 
#9 #7 and #8   92 





a) China Knowledge Resource Integrated Database (CNKI) 
Chinese search terms: 
检索表达式：(TI % '哮喘'OR KY % '哮喘' OR AB % '哮喘') AND ( TI % '疫苗' OR KY % '疫苗' 
OR AB % '疫苗') AND ( TI % '流感'+ '感冒' OR KY % '流感'+ '感冒' OR AB % '流感'+ '感冒') 发表
时间：从1979-01-01 到2016-01-12 
 
Search terms: (TI %  'xiaochuan'  OR KY % 'xiaochuan'  AB % 'xiaochuan') AND ( TI % 'yimiao' 
KY % 'yimiao' OR AB % 'yimiao') AND ( TI % 'liugan'+ 'ganmao' OR KY % 'liugan'+ 'ganmao' OR 
AB % 'liugan'+ 'ganmao') ;  
Publication date: 01/01/1979 - 12/01/2016 
Total: 73 
 
b) Wanfang  
Chinese search terms:                                                                                        检索表达式：(题名或
关键词:(哮喘) + 摘要:(哮喘))*( 题名或关键词:(疫苗) + 摘要:(疫苗))*( 题名或关键词:(流感) + 摘
要:(流感) +题名或关键词:(感冒) + 摘要:(感冒)) 时间：1990-2016 
 
Search terms: (TI or KY:(xiaochuan) + AB:(xiaochuan))*( TI or KY:(yimiao) + AB:(yimiao))*( TI or 
KY:(liugan) + AB:(liugan) + TI or KY:(ganmao) + AB:(ganmao)) 
Publication date: 1990- 12/01/2016 
Total: 53-1=52 (one cannot be accessed) 
 
c) ChongQing VIP  







Publication date: 1989- 12/01/2016 
Total: 1 
 
World Health Organization Library Information System (WHOLIS) 
Search terms: 
1. Influenza$ or flu 
2. Vaccine$ or immune$ 
3. 1 AND 2  
Publication date: 1970-14/01/2016 
Global Health Library (GHL) 
Search terms: 
1. Influenza, Human (MeSH term) 
2. Vaccination (MeSH term) 
3. 1 AND 2  







a) WHO  International Clinical Trials Registry Platform(http://www.who.int/ictrp/en/) 
Search terms:  
1. influenza vaccine* 
2. influenza vaccine 
3. influenza vaccine AND asthma  
Publication date: 01/01/1970 – 21/01/2016 
b) ISRCTN registry (http://www.controlled-trials.com/)  
Search terms: 
1. asthma 




c) ClinicalTrials.gov (https://clinicaltrials.gov/ ) 
Search terms: 
1. influenza vaccine AND asthma 
2. flu vaccine AND asthma  













Age  Clinical 
setting 
Selection Criteria Intervention 
 
Outcome(s) Summary 
risk of  
bias 
Inclusion Exclusion 
















































medication   
CAIV-
T  
TIV Culture-confirmed influenza illness 
caused by a subtype similar to that in the 
vaccine; 
Culture-confirmed influenza illness 
caused by any influenza subtype; 
Respiratory illness outcomes (use of any 
prescribed medication or antibiotics; 
unscheduled healthcare provider visits; 
hospitalisations;  absence from 
school/work); 
Asthma exacerbation; 
Acute wheezing illness associated with 
hospitalisation, unscheduled clinical visit 
or increased or new asthma medication 
use;  
Asthma exacerbation episode within 42 
days; 
PEFR scores pre- and post-vaccination; 
Daily asthma symptoms;  


















TIV   Place
bo 
Asthma exacerbation; 


























































Asthma exacerbation (PEF, asthma 



































Asthma-related outcomes(PEFR, asthma 
symptoms, asthma medication, time loss 

























Local & systemic adverse reactions; 
































Asthma exacerbation:  PEFR,  asthma 
















































Number, duration and severity of 
influenza-related asthma exacerbations 
virologically proven (culture, 
immunofluorescence, or RT-PCR); 
Number, duration and severity of 
influenza-related URT episodes; 
Number, duration and severity of all URT 
episodes;  
Adverse reactions of the vaccination 
(asthma & URT/LRT symptoms, number, 






































Local adverse reactions; 
Systematic adverse effects (Influenza-like 
illness symptoms, asthma symptoms); 
Medications for asthma; 
Airway symptoms; 
Medical consultations;  


































No details  Trivale










Nosocomial outbreak (influenza infection, 


















































Oral steroid medication & daily 










































































Pulmonary function (PEF);  
Cold coinciding with exacerbations;  
Medication for asthma & respiratory 
illness;  
Medical consultations;  































Split   
antigen 
trivalen
t   
Place
bo 
Clinical asthma exacerbation or airway 
hyperreactivity (PEF, PD20, asthma & 

























Early adverse pulmonary response 
(PEFR); 
Medication for asthma;  



















Spirometry and airway responsiveness 
(FEV1 & PD20 methacholine);  


































Pulmonary function (FEV1, PEFR, FVC, 
FEV1/FVC, FEF);  
Asthma exacerbation (asthma symptoms, 


































































































Adverse reactions (fever);  











































Pulmonary function (FEV, FVC, FEF) & 
Histamine bronchoprovocation tests;  
Respiratory illness (sore throat, 
rhinorrhoea);  
Influenza infection;  
Bronchodilator therapy; 





































Lung function (FEV1, VC, RAW, TGV, 
RV, TLC, PF, MEF50, V60);  

































oid,  no 
telephone 
vaccine  No 
vacci
ne 
Incidence, frequency and durations of 
asthma attacks, medication, ED visits, and  
hospitalisation for asthma attacks;  
Side effects of the flu vaccine; 



















Pulmonary function (FEV1);  
Local and systematic adverse reactions 
Unclear 




















in the last 
12 months  
Allergy to egg 
products, 
influenza 
















Upper respiratory disease;  
Asthma exacerbations;  
Hospitalisation (asthma);  
Pulmonary function (FEV1);  





































Asthma exacerbation or asthma symptoms 
(medication for asthma, pulmonary 


















Recent ARI or a 








Asthma exacerbation (asthma symptoms, 















No details  No details  Split 
virus   
Place
bo 
Symptoms & asthma medication after 
vaccination;  
Pulmonary function tests (Raw, ITGV, 
SGaw );  
Airway reactivity was measured at each 




















No details  Sensitive 
reaction to eggs, 
chicken, or 





Exacerbation of lung function (PEF);  
Respiratory symptoms;  









nose, or phlegm 
at the beginning 













No details  No details  Trivale








Influenza infection ;  
Febrile episodes;   
Asthma attacks;  
Hospitalisation 
Weak 














No details  No details  Vaccin
e    
No 
vaccine 
Hospitalisations & clinic or emergency 






















No details   COPD or 
influenza 
vaccine at other 
hospitals 
Vaccin
e   
No 
vaccine 
Asthma exacerbation accompanied by 























Acute respiratory disease (ILI, bronchitis, 































Aged <1 year  
were excluded 






infants <1 year 
old 
Vaccin
e    
No 
vaccine 





























Aged <1 year  
were excluded 












































Respiratory tract illness;  
Asthma-related events (wheezing 
episodes/asthma exacerbation, ED visits, 
hospitalizations, length of stay for 





e or oral 
monteluka

















No details  Egg allergy or 
any other 
component of the 













Respiratory infection (excluding flu & 
RSV);  
Bronchitis;  




























before the 1st 
date or after the 
last date of 
symptom onset 
among flu cases, 
Vaccinated 
within 14 days 
of illness onset 
or vaccinated 
but did not 








Vaccine effectiveness against medically-
attended ARI and laboratory confirmed 
























nt clinics  








of <7 days  




Vaccine effectiveness against medically-
attended ARI and laboratory confirmed 
influenza (RT-PCR) 
Moderate 
ACIP: Advisory committee on immunization practices; AE: Asthma exacerbation; API: Asthma predictive index; ARI: Acute respiratory infection 
or illness; CAIV-T: Cold adapted influenza vaccine – trivalent; COPD: Chronic obstructive pulmonary disease; ED: Emergency department; ILI: 
Influenza-like illness; LRT: Lower respiratory tract; PEF: Peak expiratory flow; RSV: Respiratory syncytial virus; RT-PCR: Real time – polymerase 
chain reaction; SD: Standard deviation; TIV: Trivalent inactivated vaccine; URT: Upper respiratory tract 
 





























data reported  
Expected outcomes 










No blinding  
(cross-over trial)  
 No missing 
data reported 
Expected outcomes 
were reported  
 
No details on 
baseline  














saline solution, but 
no details on 













were reported  
 
Νο report  
(unclear risk)  
















researchers blind to 
vaccination status  







were reported  
 
Fewer patients 











until the data had 
been entered onto 
the computer and 
all analytical 
programs had been 

















the study was 




all the outcomes 










administered by a 
clinician who was 
not involved in the 
assessment of 
outcomes  and the 
contents of the 
syringe were 
shielded from the 
subject’s view, 
single blind & 
No missing 
data reported  
Expected outcomes 






research nurses and 
physicians were not 












Double blind & 
placebo was 
administered 
intranasal as well, 
no description on 






were reported  
 
Small sample 
size to detect 
rare adverse 










method not described  
 
Patients were 
assigned in a 
double-blind 
fashion  
Double-blind but no 
















Single blind, but no 
report of who was 
blinded, no blind on 
outcome assessment  
No missing 
data reported  
Expected outcomes 



















out of 328 
completed 
the first three 
weeks of the 
study.  
Expected outcomes 














controls were not 
vaccinated  
No missing 
data reported  
Expected outcomes 





vaccines had HI 
titre >1:64, 
while only 8/20 
non-vaccines 
had HI titre 
>1:64 & other 
baseline details 
were not 
reported      








Patients were given 





dropped out  
Expected outcomes 





except age & 
serology  






generated list  
 





pack & gave 






















generated list  
 








No report of 
missing data  
Expected outcomes 









pack & gave 









Double-blind but no 
description of the 
external appearance 
of vaccine & 
placebo injections  
 




dropped out  
Expected outcomes 





were reported & 
sponsored by 
sanofi Pasteur 









Double-blind but no 
description of the 
external appearance 
of vaccine & 
placebo injections  
No missing 
data reported  
Expected outcomes 
were reported  
 
High type II 
error due to 
small sample 
size and effect 




method not described  
No description 
 
No description of 
the external 
appearance of 
vaccine & placebo 
injections  
No missing 
data reported  
Expected outcomes 









No description No description No missing 
data reported  
Expected outcomes 














































the vaccine in 








No description No missing 























Unclear risk Unclear risk Unclear risk Unclear 
risk 
Unclear risk Low risk Unclear risk 
Bell 1978 
(118) 
High risk Unclear risk High risk High risk Unclear risk Low risk High risk 
Castro 2001 
(127) 
Low risk Low risk Low risk Unclear 
risk 
Low risk Low risk Unclear risk 
Govaert 
1993 (130) 
Low risk Unclear risk Unclear risk Low risk Low risk Low risk Unclear risk 
Nicholson 
1998 (125) 
Low risk Low risk Low risk Low risk Low risk Low risk Low risk 
Pedroza 
2009 (137) 
Unclear risk Unclear risk unclear risk Low risk Unclear risk Low risk Unclear risk 
Redding 
2002 (138) 
Low risk Unclear risk Low  risk Unclear 
risk 
Low risk Low risk Unclear risk 
Reid 1998 
(139) 
Unclear risk Low risk Unclear risk Unclear 
risk 
Low risk Low risk Unclear risk 
Sener 1999 
(140) 
Unclear risk Unclear risk Unclear risk High risk Unclear risk Low risk High risk 
Stenius 1986 
(141) 
Unclear risk Unclear risk Low risk Unclear 
risk 
Low risk Low risk Unclear risk 
Miyazaki 
1993 (134) 
Unclear risk Unclear risk High risk High risk Unclear risk Low risk High risk 













Unclear risk Unclear risk Unclear risk Unclear 
risk 
High risk Low risk High risk 
Bueving 
2004 (113) 
Low risk Low risk Low risk Low risk Low risk Low risk Low risk 
Bueving 
2004 (126) 
Low risk Low risk Low risk Low risk Unclear risk Low risk Unclear risk 
Kmiecik 
2007 (132) 
Unclear risk Unclear risk Unclear risk Unclear 
risk 
Low risk Low risk Unclear risk 
Miller 2003 
(133) 
Unclear risk Unclear risk Unclear risk Unclear 
risk 
Unclear risk Low risk Unclear risk 
Hahn 1980 
(131) 
Unclear risk Unclear risk Unclear risk Unclear 
risk 
Unclear risk Low risk Unclear risk 
Gharagozlou 
2007 (129) 
Low risk Unclear risk Unclear risk Unclear 
risk 
Unclear risk Low risk Unclear risk 
Fleming 
2006 (128) 
Unclear risk Low risk High risk High risk Low risk Low risk High risk 
Ortwein 
1987 (136) 
Low risk Unclear risk Unclear risk Unclear 
risk 

























 Q1  Q2  Q1 Q2 Q1 Q2 Q1 Q2  Q1 Q2 Q1 Q2 Q3 Q1 Q2 Q3 Q4 
Christy 
2004 (149) 
2 5 Cohort 
analytic 
3 4 3 3 3 3 3 4 4 3 6 Individual Individual 1 3 
Jaiwong 
2015 (150) 
2 5 Cohort 
analytic 
3 4 3 3 3 3 3 4 4 3 6 Individual Individual 1 3 
Smits 2002 
(156) 
2 1 Cohort 
analytic  
1 2 2 3 3 3 1 1 4 3 6 Individual Individual 1 3 
Watanabe 
2005 (157) 
2 5 Cohort 
analytic 
3 4 3 3 2 3 2 4 4 3 6 Individual Individual 2 3 
Kramarz 
2000 (152) 
2 5 Cohort 
analytic 
1 2 3 3 3 3 3 4 4 3 6 Individual Individual 1 3 
Kramarz  
2001 (151) 
2  5 Cohort 
analytic 

















1 3 3 3 3 3 3 4 4 3 6 Individual Individual 1 3 







































3 4 3 3 3 3 1 1 1 3 6 Individual Individual 1 3 
Otero 2009 
(155) 
2 5 Cohort 
Analytic 
1 2 3 3 3 3 3 4 4 3 6 Individual Individual 1 3 
276 
 



































Christy 2004 (149) 2 2 3 3 3 3 Weak 
Jaiwong 2015 (150) 2 2 1 2 3 3 Weak 
Smits 2002 (156) 2 2 2 2 3 1 Moderate 
Watanabe 2005 
(157) 
2 2 3 2 3 3 Weak 
Kramarz 2000 (152) 2 2 2 2 3 3 Weak 
Kramarz 2001 (151) 2 2 2 2 3 3 Weak 
McLean 2014 (153) 2 2 3 2 2 2 Moderate 
Ohmit 2014 (154) 2 2 3 2 2 2 Moderate 
Abadoglu 2004 
(143) 
2 1 3 2 3 3 Weak 
Chiu 2003 (145) 2 1 3 2 3 3 Weak 
Campbell 1984 
(144) 
2 1 3 2 3 3 Weak 
Sugaya 1994 (148) 2 1 3 2 3 3 Weak 
Kava 1987 (146) 2 1 3 2 3 3 Weak 
Kim 2003 (147) 2 1 3 2 3 1 Weak 




A7. Grading the quality of evidence  
Outcome 
(No. of studies) 
Quality assessment 
 

























Serious 3 Serious 5 Some 
imprecision 7 
Likely 9 OR  0.55 (95% CI 0.44 
to 0.69); 
RR  0.19  (95% CI 0.06 
to 0.67);   























Serious 3 Serious 5 Not estimated 8 Likely 9 Not estimated 8 Very low Important 
Respiratory 
tract  







Serious 3 Serious 5 Some 
imprecision 7 
Likely 9 RR 0.28  (95% CI 0.10 
to 0.80); 








Serious 3 Serious 5 Not estimated 8 Likely 9 Not estimated 8 Very low Critical 
Medication  





















Only one study 
4 
Only one study 
4 
Only one study 
4 






Only one study 
4 
Only one study 
4 
Only one study 
4 
Likely 9 Not estimated 4 Very low Important 
1Studies with unclear or high risk of bias 
2No studies with unclear or high risk of bias 
3Various study designs, interventions and outcome definitions 
4Only one study assessed this outcome, hence consistency, directness and precision of the pooled overall estimated could not be assessed 
5Comparisons included different type of vaccines, vaccines versus placebo or vaccines versus no vaccines 
6Both studies compared the safety of inactivated vaccine versus placebo injection 
7Pooled estimates were precise in only two studies and imprecise estimates were reported in the rest studies 
8There was heterogeneity (clinical, methodological & statistical) among the studies, hence pooled estimates could not be calculated 












Absolute estimates (%) Relative or VE estimates  
 (95% CI) 
Significance 







(RCT)  (128) 
LAIV IV 46/1109 (4.1%) vs. 70/1102 (6.4%) VE: 35 (4 to 56) (antigenic match)  Significant difference 
Miyazaki 
(RCT) (134) 
LAIV No 0/19 (0%) vs. 5/20 (25%)  RR: 0.10 (0.01 to 1.62)  p-value: 0.1  
Tanaka 
(RCT) (142) 
LAIV No/placebo  2/14 (14.3%) vs. 5/8 (62.5%);  
2/14 (14.3%) vs. 8/17 (47.1%) 
RR: 0.23 (0.06 to 0.92); 
RR: 0.30 (0.08 to 1.21)   
p-value: 0.04;  
p-value: 0.1  
Sugaya    
(Non-RCT) 
(148) 
IV No 35/85 (42%) vs. 37/52 (71%)  VE: 42.1 % (21 to 57)  
Age > 7 years old: 
VE: 68%  - A(H3N2) 
VE: 44%  - B virus  




Vaccine No 0/178 (0%) vs. 8/160 (4.4%) RR: 0.05 (0.003 to 0.91)  p-value: 1.0  




Vaccine  No 184/387 (48%) vs. 548/872 (63%)  OR: 0.54 (0.42 to 0.68)  p-value <0.0001 




Vaccine No 30/65 (46%) vs. 290/501 (58%)  OR: 0.62 (0.37 to 1.05) p-value: 0.08 
Bueving 
(RCT) (113) 
TIV Placebo  24/347 (7%) vs. 18/349 (5.2%)  RR: 1.31 (0.66 to 2.61) p-value: 0.44 













IV  No  15/86 (17.4%) vs. 8/842 (19%)   RR: 0.92 (0.42 to 1.99)  p-value: 0.82 
Sugaya    
(Non-RCT)  
(148) 
IV No One asthmatic attack in the 
vaccinated group and 18 asthmatic 
attacks in total during the 1992/93 
season. No further details or raw 
numbers were reported.  











IV No  Mean (SD): 1.6 (1.6) vs. 6.2 (3.9)  
(no raw numbers were reported) 



















Vaccine No  2001/02 season: 
2/24 (8.3%) vs. 12/43 (28%)  
2002/03 season: 
8/57 (14%) vs. 20/58 (35%)  
2001/02 season: 
RR: 0.33 (0.08 to 1.33) 
2002/03 season: 








IV No No raw numbers were reported  Not reported  p-value < 0.05 
Fleming 
(RCT) (128) 
LAIV IV 0 (0.0%) vs. 2 (0.2%)  
“The small number of subjects 
required hospitalization precludes 
an assessment of efficacy”. 






















IV No Mean (SD): 0.2(0.6) vs. 1.3(1.5) 
(no raw numbers were reported)   
Not reported  p-value <0.001 
Primary 
care 
















TIV Placebo 20/347 (6%) vs. 18/349 (5%)  RR: 0.95 (0.49 to 1.82) p-value: 0.87 
Miyazaki 
(RCT) (134) 
LAIV No 0/19 (0%) vs. 6/20 (30%)  RR: 0.08 (0.00 to 1.34)  p-value: 0.08 
Tanaka 
(RCT) (142) 
LAIV No/placebo  3/14 (21%) vs. 5/8 (63%); 
3/14 (21%) vs. 9/17 (53%)  
RR: 0.34 (0.11 to 1.07); 
RR: 0.41 (0.14 to 1.21)  
p-value: 0.07; 




IV No 44/86 (51%) vs. 18/42 (43%)  RR: 1.2 (0.8 to 1.8) “No significance” 
Sugaya      
(Non-RCT) 
(148) 




IV No Mean (SD): 2.2 (2.1) vs. 6.9 (3.9) 
(no raw numbers were reported) 








Vaccine No 1/178 (0.6%) vs. 4/160 (2.5%);  
96/178 (54%) vs. 105/160 (66%); 
22/178 (12%) vs. 38/160 (24%)  
RR: 0.23 (0.03 to 2);  
RR: 0.61(0.29 to 0.95); 
RR: 0.47 (0.26 to 0.84) 
p-value: 0.18;  
p-value < 0.05;  





















IV No Mean (SD): 0.4 (0.9) vs. 2.2 (2.6)          
(no raw numbers were reported)  
Not reported  p-value < 0.001 
Medication 




Vaccine No 35/79 (44%) vs. 77/122 (63%); 
19/79 (24%) vs. 35/122 (29%);  
(Times per week): 0.87 vs. 1.61 
RR: 0.5 (0.36 to 0.66); 
RR: 0.84 (0.52 to 1.36)   






IV No Mean (SD): 0.1 (0.3) vs. 1.1 (1.2); 
                    1.6 (1.6) vs. 6.2 (3.9) 
(no raw numbers were reported) 
Not reported  p-value < 0.001 
Pulmonary 




IV No Mean (SEM):  
86.52±2.75 vs. 85.00±4.81 







LAIV IV 1178 (1.4%) vs. 1075 (1.3%) (no. 
of days)   










Absolute estimates (%) Relative estimates  
(95% CI) 
Significance 







TIV Placebo 11/255 (4.3%) (2·2 to 7·6) vs.  
  3/260 (1.2%) (0·2 to 3·3)  
RR: 3.7 (1.1 to 13.2)               p-value: 0.06 
Castro 
(RCT) (127) 
IV Placebo Absolute difference:  
-1.1 (-3.0 to 0.9)    (3 days)  
  1.1 (-1.4 to 3.6) (14 days)  




LAIV Placebo 2/24 (8%) vs. 0/24 (0%)   RR: 5.0 (0.25 to 99.1) p-value: 0.49 
Miller 
(RCT) (133) 




LAIV IV 31.2%  vs. 29.6% (95% CI: -2.2 to 
5.4)  
Not reported  No significant 
difference  
Kmiecik 
(RCT) (132)       
IV  Placebo Difference: 
2.8% (95% CI: 1.9% to 4.2%) 
Not reported  No significant 
difference  
Kim         
(Non-RCT) 
(147) 





Vaccine No Not reported  Incidence rate ratio:  
0.58 (0.36 to 0.95); 
0.74 (0.47 to 1.17); 














TIV Placebo  Local adverse reactions:  
28 vs. 9; 69 vs. 23(1999/00) 
33 vs. 8; 62 vs. 26 (2000/01) 
ILI symptoms (signif. only):  
14 vs. 6; 37 vs. 27; 24 vs. 6 
(1999/00) 
3 vs. 8  (2000/01) 
Asthma symptoms (signif. only): 
44 vs. 32 
Not reported  p-values: 
<0.01 (local 
adverse reactions) 









LAIV IV 904 (84.2%) vs. 828 (78.9%) (sys. 
events);  
283 (25.4%) vs. 222 (19.9%) 
(adverse events) 
Not reported  p-values:  










IV Placebo Mean (SD): 
10.4(4.7) vs. 10.4(4.7) (asthma 
symptom);  
25.1% vs. 20.8% (myalgia)  




<0.001 (myalgia)  
Nicholson 
(RCT) (135) 
IV Placebo Mean (SD):  
19.2(21.6) vs. 16.5(18.9) (all 
symptoms)  
















IV Placebo Local & systematic symptoms:  
16/25 (64%) vs. 9/16 (56%);  
12/25 (48%) vs. 9/16 (56%)  
RR: 1.14 (0.68 to 1.92); 
RR: 0.85 (0.47 to 1.5)  
The incidence of 
local and/or 
systemic symptoms 
was similar  
Ortwein 
(RCT) (136) 
IV IV Local side effect: 
12 (9 out of the 12 received 
subunit vaccine) 
Systemic reaction: 
5 (mainly after split vaccine); 
4(after subunit vaccine)  
Not reported  p-value:  
0.02 (local side 
effect)  
0.04; 0.02 




LAIV Placebo 7/24 (29%) vs. 8/24 (35%) (asthma 
symptoms);  
22/24 (92%) vs. 21/23 (91%)  
(local/sys. symptoms)  
RR: 0.88 (0.38 to 2.03); 









IV Placebo Mean (SD): 
4.92 (7.56) vs. 4.66 (7.3) 
Not reported  No significant 
difference   
Miyazaki 
(RCT) (134) 
LAIV No 4/19 (21%) vs. 3/20 (15%)   RR: 1.4 (0.4 to 5.5) p-value: 0.62  
Tanaka 
(RCT) (142) 
LAIV Placeco/No    2/20 (10%) vs. 3/25 (12%) 
(fever);  
16/20 (80%) vs. 13/25(52%) 
(rhinorrhea)  
RR: 0.83 (0.15 to 4.5); 
RR: 1.54 (1.00 to 2.38) 
p-value : 
No significant 
difference (fever);   
0.05 (rhinorrhea)  
Pedroza 
(RCT) (137) 
IV Placebo Local adverse reactions: 
55/132 (41.7%) vs. 12/31 (38.7%) 
(1st dose) 
46/132 (34.8%) vs. 9/31 (29%) (2nd 
dose) 
Systemic adverse reactions: 
RR: 1.1 (0.7 to 1.8); 
RR: 1.2 (0.7 to 2.2); 
RR: 0.55 (0.3 to 1.1); 









21/132 (15.9%) vs. 9/31 (29%) (1st 
dose) 
25/132 (18.9%) vs. 8/31 (25.8%) 




IV Placebo 9/17 (53%) vs. 0/5 (0%) (transient 
symptoms) 
(no asthma symptoms)  
Not reported  Not reported  
Govaert 
(RCT) (130) 
IV Placebo 0/14 (0%) vs. 0/11 (0%) (asthma 
symptoms)  




IV Placebo 193/286 (67.5%) vs. 55/286 
(19.2%)  
(any local reaction)  
162/286 (56.6%) (50.7% to 62.5%) 
vs.  
128/286 (44.8%) (38.9% to 50.7%)  
(any systemic reaction)  
RR: 3.5 (2.7 to 4.5); 




reactions in the 
vaccine group than 
placebo  
Chiu        
(Non-RCT) 
(145) 
IV Placebo Mean:  
-1.18 vs. -0.50 
Not reported  p-values:  
 0.783; 1.000 
Kim         
(Non-RCT) 
(147) 
IV Placebo Mean (SD): 
1.00 (1.93) vs. 0.94 (2.05) (day 
time symptom)  
0.85 (1.58) vs. 1.13 (1.96) 
(noctural symptom)  
Not reported  p-values >0.05 
Kava        
(Non-RCT) 
(146) 




IV Placebo No raw numbers were reported  Not reported  p-value > 0.05 









LAIV IV No raw numbers were reported Not reported  No significant 
differences were 





IV Placebo Absolute difference: 
-0.8 (-2.3 to 0.8)    (3 days); 
  0.1 (-1.8 to 2.0) (14 days) 





LAIV No 1/11 (9%) vs. 2/6 (33%) (FEV1);  
1/11 (9%) vs. 1/6 (17%)  (FVC)  
RR: 0.3 (0.03 to 2.4); 









IV Placebo PEF - change around injection:  
-2.6 (-6.3 to 1.1) vs. 1.7 (-1.2 to 
4.7)  
 Not reported  p-value:  
0.50 vs. 0.73 
Ortwein 
(RCT) (136) 




LAIV Placebo 2/24 (8%) vs. 1/24 (4%) 
(15% or > FEV1 reduction)  
RR: 2.0 (0.2 to 21) p-value: 1.0  
Sener (RCT) 
(140) 
IV Placebo Mean (SD): 
6.55 (4.97) vs. 6.88 (4.77) (PEF 
variability) 
Not reported  p-value > 0.05 
Pedroza 
(RCT) (137) 
IV Placebo Mean: 
99.1 vs. 94.2 (FEV1 - visit1);  
104.5 vs. 96.2 (FEV1 - visit2) 








IV Placebo Mean: 
2.83 vs. 3.41 (FEV1 - 48h) 




2.90 vs. 3.44 (FEV1 - 96h) 
Hahn (RCT) 
(131) 
IV Placebo No raw numbers were reported  Not reported  No significant 
difference  
Kim          
(Non-RCT) 
(147) 
IV Placebo 3 vs. 1 (exacerbation of PFT);  
Mean (SD): 
334 (137) vs. 337 (131) (am PEF);  
338 (137) vs. 331 (134)  (pm PEF)  
Not reported  p-values  > 0.05 
Kava        
(Non-RCT) 
(146) 
IV Placebo Median: 
0.42 vs. 1.09 (PD40)  
Not reported  p-value > 0.05  
Chiu        
(Non-RCT) 
(145) 
IV Placebo Mean:  
4.99 vs. -3.92 (PEF variability);  
-98.95 vs. -99.8 (FEV1)  
Not reported  p-value:  







IV Placebo Mean difference: 
-45.3   (morning peak flow)  
-168.2 (evening peak flow)  








LAIV No No increased use of 
bronchodilators:  
0/11 (0%) vs. 0/6 (0%) 





TIV Placebo 67/148 (45%) vs. 69/148 (47%) 
(1999/00)  
68/199 (34%) vs. 62/201 (31%) 
(2000/01)  
RR: 0.97 (0.8 to 1.2); 
RR: 1.1 (0.8 to 1.5)  




IV Placebo 7% vs. 5.7%  
(new or increased use of asthma 
medication) 
Not reported  p-value: 0.075 
Nicholson 
(RCT) (135) 
IV Placebo Mean(SD):  RR: 1.4 (0.5 to 4.4) (oral 
steroids)  
p-value: 




13.9(11.4) vs. 13.5(10.9) (inh. b2-
agonist); 7.4(7.6) vs. 7.2(7.2) (neb. 
b2-agonist);  
7/257 (2.7%) (1.1 to 5.5) vs. 5/258 
(1.9%)  
(0.6 to 4.5) (oral steroids)  
0.2 vs. 0.97 (neb. 
b2-agonist);  




IV Placebo No patient reported any increase in 
medication use: 0/17 (0%) vs. 0/5 
(0%)  




IV No No raw numbers were reported Not reported  p-value  < 0.01 
Sener (RCT) 
(140) 




IV Placebo No raw numbers were reported  Not reported  The need for 
medication was 





IV Placebo Bronchodilator dose: 
7 (V > P); 10 (V < P); 9 (V = P)   
Not reported  p-value > 0.05 
Kava        
(Non-RCT) 
(146) 
IV Placebo 0/16 (0%) vs. 0/11 (0%)  Not reported  No significant 
difference  
Kim         
(Non-RCT) 
(147) 
IV Placebo Mean (SD): 
1.69 (2.41) vs. 1.88 (3.20) 







LAIV Placebo 0/11 (0%) vs. 1/6 (17%)  RR: 0.2 (0.01 to 4.2) p-value: 0.3  
Bueving 
(RCT) (126) 
TIV Placebo 0/148 (0%) vs. 1/148 (0.7%) 
(1999/00) 
RR: 0.33 (0.01 to 8.1); 
RR: 2.0 (0.2 to 22.1)  













IV Placebo Absolute difference: 
-0.5 (-1.3 to 0.3) (3 days)  
  0.4(-1.0 to 1.8)  (14 days) 




IV Placebo 1/256 (0.4%) (0 to 2.2) vs. 1/256 
(0.4%)  (0 to 2.2) 
(hospital admission); 
10/244 (4.1%) (2.0 to 7.4) vs. 
7/248 (2.8%) (1.1 to 5.7) (medical 
consultation)  
RR: 1.0 (0.06 to 16); 






Kim          
(Non-RCT) 
(147) 
IV Placebo 0% for hospital admission or 
consultation 
(no raw numbers were reported)  













LAIV Placebo 4/11 (36%) vs. 4/6 (67%)  RR: 0.7 (0.2 to 2.1)  p-value: 0.5 
School/work 




IV Placebo 12 vs. 14 (both influenza seasons)  Not reported  p-values > 0.05 
Castro RCT 
(127) 







A9. Additional pooled estimates  
 
 
Figure 1: Vaccine effectiveness against influenza infection 
*Estimates are from two intervention arms from the same study (Tanaka et al, 1993).  
 1st comparison is between live vaccine vs. no vaccine and 2nd comparison between live vaccine vs. 
placebo.  






Figure 2: Vaccine effectiveness against asthma exacerbation 
*Estimates are from three influenza seasons (1993-96) from the same study (Kramarz et al, 2001). 









Figure 3: Vaccine effectiveness against hospital admission 




Figure 4: Vaccine effectiveness against respiratory illness 
*Estimates are from two intervention arms from the same study (Tanaka et al, 1993).  
 1st comparison is between live vaccine vs. no vaccine and 2nd comparison between live vaccine vs. 
placebo.  
**Three different respiratory illnesses (RSV infection, other respiratory infections & bronchiolitis) 
were assessed by the same study (Otero et al, 2009).  






Figure 5: Vaccine effectiveness against emergency visits 






























(2/3 on long-term 
corticosteroids) 
Allergy to egg N/A  N/A  Primary outcomes:   
-Number of days of hospitalisation per 
100 days at risk & the number of 
patients with influenza-like illness, 
asthma, influenza-like illness & asthma 
among hospitalised in each group; 
Secondary outcomes:  
-Early adverse pulmonary response to 
vaccine measured by PEFR 24 hours 
following vaccination; 
-Change in daily count of aerosol 
treatments with bronchodilator drug 







(145 study sites 
in Europe) 
Clinical diagnosis 
of asthma with 1 or 
more prescriptions 






disease of the immune 
system or current 
receipt of 
immunosuppresive 
therapy ( including 
N/A  N/A  Primary outcomes: 
-Incidence of culture-confirmed 
influenza illness (>=38o C  oral 
temperature, pulmonary congestion, 
pneumonia or ear infection, 2 or more 
of the following symptoms; shortness 
of breath, runny nose or nasal 
congestion (rhinorrhea), sore throat 
(pharyngitis), cough, muscle aches, 









chills, headache, irritability, decreased 
activity, vomiting, increase in 
wheezing or increased use of 
medication to treat wheezing) & HA 
inhibition assay and PCR were used to 
determine antigenic similarity between 
flu isolates and the vaccine; 
-Incidence of culture-confirmed 
influenza illness caused by any 
influenza subtype; 
Secondary outcomes: 
-Incidence of hospitalisations or 
prolongation of existing 
hospitalisation; --Unscheduled 
healthcare provider visit or 
consultation within 28 days of 
vaccination; 
-Number of days missed from school 
or work; 
-Incidence of asthma exacerbation, 
defined as acute wheezing illness 
associated with hospitalisation, any 
unscheduled clinical visit, or any new 
prescription (including rescue 
medication); 
-PEFR scores during the screening 
period and for 15 days postvaccination 
(it was measured 3 times each morning, 
before any asthma medication was 
received);  
-Daily asthma symptoms were assessed 
in the evening before the subject went 
296 
 
to sleep and were based on a 4-point 
scale (0=no symptoms;  1=occasional 
symptoms;  2=frequent symptoms;  and 
3=continuous symptoms);  
-Nighttime awakening scores were 
assessed each morning using 4-point 
scale (0=fine; 1=slept well;  slight 
wheeze or cough;  2=awake 2 to 3 
times, wheeze or cough;  3=bad night, 









history of asthma 
with perennial 








atopic asthma  
Allergy to any 
vaccine components, 
immunocompromised, 
acute febrile illness in 




against influenza for 
the 2004-2005 season 
& receive of influenza 
vaccine 2 weeks 
before inclusion or 6 
weeks after 
recruitment. 
N/A  N/A Secondary outcomes:  
-Asthma exacerbations described as 
either mild or severe according to 
criteria listed in table 1in the study & 
daytime and nighttime symptoms of 
any asthma exacerbations occurring 14 
days after each injections were 
recorded and assigned scores from 0 to 
4 according to various criteria listed in 
table 2 in the study; 
-Any Local adverse reactions (pain, 
redness, induration, pruritis, oedema, 
ecchymosis) & severe local adverse 
reactions 8 days following injection; 
Any systemic reactions (asthenia, 
malaise, headache, sweating, myalgia, 
arthralgia, shivering, fever) & severe 










Allergic to egg 
products or 
thimerosal, unable to 
N/A N/A Secondary outcomes: 
-Asthma exacerbation within 14 days 





mild to moderate 
asthma  
use the peak 
flowmeter, did not 
have a telephone, 
history of the 
Guillain-Barre 
syndrome, influenza 
vaccination the last 6 
months, febrile illness 
within 24h prior 
occurrence of one or more of the 
following: a decrease of at least 30% in 
the peak expiratory flow rate the 
second-highest morning peak  
expiratory flow rate measured during 
the study; an increase in the daily use 
of bronchodilator rescue medication 
above the average use reported in the 2 
weeks before randomisation; an 
increase in the use of systemic 
corticosteroids for asthma or the 
addition of  systemic corticosteroids to 
the treatment regime, or the 
unscheduled use of health care for the 
treatment of asthma , including a visit 
to the emergency department, 
hospitalisation, or a visit or a telephone 
call to a health care provider; 
-A decrease of at least 20% in the peak 
expiratory flow rate from the personal-
best rate during the 14 days after each 
injection;  
-Symptoms thought to be associated 
with the vaccine or placebo injection 
(rhinitis, sore throat, cough, headache, 
body aches, fever, chills, and fatigue); 
the number of days without symptoms 
of asthma; 
-The amount of time lost from work or 
school because of illness; 
-Increase in the dose of a current 
medication used for long-term control 
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of asthma or the addition of such a 
medication to the treatment regime. 
Pedroza 






based on: daily 
asthma symptoms, 





persistent asthma  
History of allergy to 
egg protein or 
thimerosal 
N/A N/A Secondary outcomes:  
-Local adverse events at the inoculation 
site (pain, erythema, induration) and 
systemic adverse events (malaise, 
fever, headache); 
-Pulmonary function tests FEV1, FEV2, 
FEV3 at 1, 2, and 3 seconds 














the preceding year;  
mild to moderate 
asthma 
Allergy to egg or 
thimerosal, a history 
of Guillain-Barre 
syndrome, influenza 
vaccine the last 6 
months or febrile 
illness within 24h of 
recruitment. 
N/A N/A Secondary outcomes:  
-Asthma exacerbation within 14 days 
after an injection defined as the 
occurrence of one or more of the 
following: a decrease of at least 30% in 
the peak expiratory flow rate the 
second-highest morning peak  
expiratory flow rate measured during 
the study; an increase in the daily use 
of bronchodilator rescue medication 
above the average use reported in the 2 
weeks before randomisation; an 
increase in the use of systemic 
corticosteroids for asthma or the 
addition of  systemic corticosteroids to 
the treatment regime, or the 
unscheduled use of health care for the 
treatment of asthma , including a visit 
to the emergency department, 
hospitalisation, or a visit or a telephone 











therapy for asthma 
or more than 52 
doses of relief 
medication during 
the previous 12 
months 
 
Other chronic disease, 





N/A N/A Primary outcomes: 
-The number of influenza-related 
asthma exacerbations virologically 
proven (culture, immunofluorescence, 
or RT-PCR)  
Secondary outcomes: 
-The number, duration, and the severity 
of influenza-related URT episodes & 









therapy for asthma 
or more than 52 
doses of relief 
medication during 




diseases, allergy to 
chicken protein and 
insufficient 
understanding of the 
Dutch language. 
N/A N/A Secondary outcomes:  
-Local adverse reactions 1-7 days after 
vaccination (erythema at vaccination 
site, stiff or painful arm);  
-Influenza-like symptoms 1-7 days 
after vaccination 
(sickness/vomiting/diarrhoea, 
tiredness/sweating, sneezing, runny or 
stuffed-up nose, burning or watery 
eyes, sore throat, hoarseness, fever or 
shivers, headache, myalgia);  
-Asthma symptoms 1-7 days after 
vaccination (cough at day/night, 
wheezing at day/night, dyspnoea);  
-Medication for airway symptoms or 
use in total 1-7 days after vaccination; 
-Consultation of doctor 1-7 days after 
vaccination; 











Not specified  N/A N/A Primary outcomes: 
-Influenza infection defined by a 4-fold 





asthma ward)  
and/or virus isolation; Virus isolation 
was performed in Madin-Darby canine 
kidney cell cultures using pharyngeal 
swabs collected days 3 and 6 after 
vaccination from both vaccines and 
placebo controls; 
Secondary outcomes: 
-Febrile illness defined by a 4-fold 
increase or greater HI antibody rise 
and/or virus isolation; 
-Adverse reactions related to flu 
vaccine were observed daily for 1 week 
after inoculation (temperature, asthma 
attacks and the  presence or  absence  
of any subjective symptoms such as 
rhinorrhea, sore throat, cough, 
headache, arthralgia or general fatigue 







Moderate to severe 
asthma with daily 
need of medication 




the criteria for 
bronchial asthma 
set by the 
American College 
of Chest 
Physicians and the 
Smokers, history of 










emphysema, cancer or 
chronic collagen 
diseases). 
N/A N/A Secondary outcomes:  
-Adverse reactions (breathlessness, 
cough, sputum production were 
assessed daily on a scale of 0 to 3 & 
fever >37.5oC, sore throat, symptoms 
of rhinitis);   
-PEF values measurements 3 times a 
day for the first 2 weeks after 
vaccination and then 2 times a day until 
the end of April 1982; 












centres and two 
asthma clinics 
in the UK) 
Diagnosis by a 
clinical specialist 
of recurrent 






hospital or during 
follow-up; stable 
asthma (requiring 
no active revision 
of medication) 
Hypersensitivity to 
eggs, chicken, or 
influenza proteins, 
pregnancy, a febrile 
illness at the 
beginning of the study 
and treatment with an 
investigational drug 
during the 30 days 
before enrolment. 
N/A N/A Secondary outcomes: 
-Asthma exacerbation occurring 72h of 
injection, defined by a decline in early-
morning PEF of more than 20% 
compared with the lowest of the best 
three early-morning PEF values during 
the 3 days before the injection 
-PEF mean changes around vaccine 
and placebo; 
-Inhaled β2-agonist use 72h before and 
after injection; 
-Antibiotic and oral steroid therapy 7 
days after each injections; 
-Unscheduled medical consultations; 
-Hospital admissions for an 









Patients with mild 
stable asthma 
Acute respiratory 
illness, allergy to 
eggs, pregnancy 
N/A N/A Secondary outcomes: 
Asthma symptoms  (night cough, 
daytime cough, chest tightness, 
wheeze, shortness of breath, and sleep 
disturbance as a result of chest 
symptoms were recorded to the 
following scores: 0=absent to 3 
=severe);  
-Daily symptoms  (0=did not occue, 
1=occurred, but not often or severely 
enough to cause inconvenience, 2 
=interfered slightly with daily 
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activities, 3=interfered a lot with daily 
activities);  
-Peak expiratory flow (PEF) recording 
every morning and every evening, 
complete daily symptom score chart, 
and record the use of bronchodilator 
drugs for 1 week;  
-The lung function measurements and 
methacoline challenge tests (PD20) 
were repeated 2 weeks after vaccine 
and placebo at the same day.   
Reid (1998) 
RCT (139) 
Not specified Patients with stable 




all tool inhaled β2 
agonists and 20 
were on inhaled 
corticosteroids) 
Not specified  N/A N/A Secondary outcomes:  
Spirometry and airway responsiveness 
(FEV1 & PD20 methacholine) were 
measured twice a 2 week interval 
before vaccination and at 48 and 96 
hours postvaccination; 










FEV1 <80% after 
withholding 
albuterol for 8h, 
reversibility 
(>12% increase in 
morning FEV1); 
Stable diagnosed 





medications within 2 
weeks of enrolment, 
history of 
hypersensitivity to 
egg or egg protein, 
acute febrile illness 
within 1week of 
enrollment, other 
pulmonary diseases in 
addition to asthma.   
N/A N/A Secondary outcomes: 
-The difference in values FEV1(% 
predicted), FVC(% predicted), 
FEV1/FVC, FEF 25-75% VC (% predicted) 
in baseline and 2 and 5 days 
postvaccination 
Number of subjects with PEFR >30% 
or >2 SD below baseline  & PEFR 
>15% or >2 SD below baseline; 
Number of days  per subject with 
PEFR >15% or >2 SD below baseline; 
-Asthma exacerbation was defined as 
asthma symptoms uncontrolled by >6 
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puffs of albuterol  metered dose inhaler 
(MDI) during 8h or the need for oral 
steroids or nebulized bronchodilator 
treatments; 
-Daily clinical asthma symptom scores 
were ranked as 0 to 3 (0=no symptoms; 
1=occasional asthma symptoms; 
2=frequent asthma symptoms; 
3=continuous asthma symptoms); 
-Nighttime awakening  scores were 
ranked 0 to 3 (0=normal sleep; 1=slept 
well but with slight wheeze or cough; 
2=awoke 2 or 3 times with wheeze or 
cough; 3=awake most of the time with 
wheeze) 
-Post-vaccination symptoms 10 days 
after vaccination were fever (>100.0oF, 
oral), cough, sore throat, runny nose, 
headache, chills, muscle aches and 
fatigue. Serious adverse events were 







Not specified <60 years old, 
High-risk group, 
living in an old 
people’s or nursing 
home. 
N/A N/A Secondary outcomes:  
-Local and systemic reactions 48 hours 
after vaccination were asked through 
the completion of a questionnaire by 










asthmatic children  
Allergy to eggs or 
chicken feathers 
N/A N/A Primary outcomes:  
-Influenza infection detected through 
virus isolation performed in MDCK 
cell cultures using pharyngeal swabs 
collected from vaccines who developed 
body temperature >37.5oC within 1 
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week of inoculation and  pharyngeal 
swabs were also collected until March 
1989 from all the participants who 
developed influenza-like illness; 
(no secondary transmission to non-
vaccinees within the same wards was 
documented, and this was serologically 
confirmed)  
Secondary outcomes:  
-Adverse reactions such as fever, upper 
respiratory tract symptoms, and 
bronchial asthma attack were recorded 









Stable asthma (all 








illness, allergy to eggs 
or pregnancy 
N/A N/A Secondary outcomes:  
-Influenza infection was defined as 
virus isolation and/or > 4-fold rise in 
serum NtAb titre between pre and 
postinoculation serum samples; 
-Pulmonary function tests, including 
FEV1, FVC,  FEV1/FVC and FEF 
performed 0, 3-4 and 7 postinoculation. 
A > 13% decrease in FEV1 or >11% 
decrease in FVC compared to baseline 
was considered significant in asthmatic 
volunteers. All tests were performed at 
the same time on each test day, usually 
in the morning;  Histamine 
bronchoprovication tests were 
performed on healthy volunteers; 
-Clinical evaluation was performed on 
0, 2, 3-4 and 7 days after inoculation. A 
temperature of >37.8oC was considered 
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fever. Signs and symptoms were 
categorised as mild, moderate or severe 
by doctors.  
-Illness was defined as signs and 
symptoms of an upper and/or lower 
respiratory illness occurring the first 7 
days postinoculation, plus volunteer’s 
perception that he/she had a respiratory 









obstruction, 9 used 
systemic steroids 
Not specified  N/A N/A Secondary outcomes:  
-Local and systematic adverse 
reactions  were measured;  
-Lung function was determined in the 
clinical laboratory every 14 days and 
patients themselves took measurements 
every day & measurements in the 
laboratory included: FEV1, VC, RAW, 





























anomalies,  Constant 
use of systemic 
corticosteroids,  Lack 
of telephone 
N/A N/A Primary outcomes:  
-Frequency, incidence and duration of 
asthma attacks; An acute asthma attack 
was defined as having one or more of 
the following at one time: increase in 
β2 agonist use, hospitalisation, use of 
corticosteroid, visiting medical doctor 
and emergency room because of 
asthma; 
Secondary outcomes:  
-Side effects of the flu vaccine (body 
pain, cough, rhinorrhea, fever, sore 
throat and malaise, over two weeks 
following the vaccination); 
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(1987) RCT  
(136) 
Unclear Reversible airways 
obstruction 
stratified by % in 
FEV1 
Not specified  N/A N/A Secondary outcomes:  
-Local and systematic adverse 
reactions; 
















asthma within the 
preceding 12 
months and had 
stable asthma ;less 
than 10% had 
severe persistent 
asthma 
Allergy to egg 
products, influenza 
vaccination the last 6 
months, febrile illness 
within 24hr before 
recruitment. 
N/A N/A Primary outcomes: 
-Exacerbation of asthma was defined as 
the occurrence of one or more of the 
following: a decrease of at least 30% in 
1-sec forced expired volume (FEV1) 
from the value measured at the begging 
of the study, an increase in the daily 
use of bronchodilator rescue 
medications (4 or more puffs of a 
bronchodilator from a metered-dose 
inhaler or 2 or more uses of nebulized 
salbutamol for the relief of symptoms), 
an increase in the use of systemic 
corticosteroids for asthma or the 
addition of systemic corticosteroids to 
the regimen, or the unscheduled visit to 
the emergency department for the 
treatment of asthma; 
Secondary outcomes:  
-Frequency of upper respiratory tract 
infections based on symptoms such as 
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fever >37.5oC, sore throat, cough, body 
aches, chills and fatigue with no 
documented underlying disease. The 
presence and durations of these 
symptoms was recorded 4 months after 
the vaccination; 
-Hospitalisation due to worsening in 
asthma; 
- FEV1 measurements before and at the 


















students had mild 
to moderately 
severe asthma, and 
outpatients had had 
moderate to severe 
asthma 
Not specified  N/A N/A Secondary outcomes:  
-Asthma exacerbation or asthma 
symptoms was measured through 
subjective data such as patients’ 
perception of their symptoms related to 
asthma including: night wheeze, cough, 
day wheeze, sputum, activity level 
during the day and the total number of 
puffs of bronchodilator dose used in 
last 24 hours and objective data such as 
measurements of peak expiratory flow 









The diagnosis and 
severity of asthma 
was made 
according to the 
Guidelines of 
Global Initiative 
on Asthma (GINA) 
Recent acute 
respiratory illness or a 
history of egg allergy 
N/A N/A Secondary outcomes:  
-Asthma symptoms, including night 
cough, daytime cough, chest tightness, 
wheeze, shortness of breath, and sleep 
disturbance were recorded according to 
the following scores: 0=absent to 
3=severe; 
-Daily symptoms were 0=did not 
occur, 1=occurred, but not often or 
severely enough to cause 
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inconvenience, 2=interfered slightly 
with daily activities, and 3=interfered a 
lot with daily activities; 
-Daily PEF variability was calculated 
according to a formula (it is provided 
in the paper);  
-FEV1 and methacholine challenge test 
(PC20) were performed on day 1 pre-
vaccination and repeated on day 14 
post-vaccination in both groups;  
Patients in both groups were requested 
to record their PEF every morning and 
every evening and to complete a daily 










diphosphate test;  
20 had mild and 7 
moderately severe 
asthma 
Not specified  N/A N/A Secondary outcomes:  
-Symptoms records such rhinorrhoea, 
cough, sore throat, increased dyspnoea, 
fever, headache, muscle or joint pain, 
and general discomfort at 2, 3 and 21 
days after vaccination and between 
visits were recorded as well as 
consumption of bronchodilator drugs; 
-Pulmonary function tests such as 
airway resistance (Raw) and 
intrathoracic gas volume (ITGV), of 
which SGaw  before and 2, 3 and 21 
days after vaccination;  
Airway reactivity was measured at 
each visit by administering aerosols of 
















increase by more 
than 15% of FEV1 
after Ventolin or 
when PC20 was less 
than 25mg/ml from 
the methacholine 
challenge test; 
Severity of asthma 
based on GINA, 3 
had severe 
persistent asthma 
Sensitive reaction to 
eggs, chicken, or 
meat, due to 
pregnancy, new 
symptoms of upper 
respiratory tract 
infection like fever, 
runny nose, or phlegm 
at the beginning og 
the research 
N/A N/A Secondary outcomes:  
-Daytime symptoms were measured as 
follows: 0=no asthmatic symptom, 
1=asthmatic symptom but did not 
affect the daily activities, 2=daily 
activities were affected a small amount 
by asthmatic symptoms, 3=daily 
activities were affected most of the 
time by asthmatic symptoms; 
-Evening symptoms were defined as 
the number of times the patient woke 
up during their sleep due to asthmatic 
symptoms and were recorded by 
patients; 
-Patients’ daily diary card on their 
clinic visits and recorded any extra 
outpatient clinic and ER visits, or 
increased use of additional medication 
due to the worsening of the asthmatic 
symptoms were checked by 
researchers; 
-Effect of influenza vaccine on 
pulmonary function 72h after 
vaccination in stable asthma was 
measured comparing the result of 
amPEF 3 days before the shot. A 
decrease of more than 20% first and 
secondly pmPEF in decrease, was 
considered that the flu shot would be 




-The number of times that fast-acting 
bronchodilator Ventolin, Bricanyl was 









moderate to severe 
asthma  
Not specified  N/A N/A 
 
Primary outcomes:  
-Influenza infection was established 
when a virus was isolated and/or the 
individual showed a 4-fold or greater 
increase in HI antibody titer to the 
epidemic influenza type A or B; 
Blood sample were drawn from the 
vaccines 3 to 4 weeks after the 2nd 
vaccination and HI tests were 
performed;  
Virus isolation was performed when 
the subjects came to the hospital with 
complaints of fever or respiratory 
symptoms, such as cough, rhinorrhea, 
and sore throat, specimes for isolation 
were collected by throat swabs and 
placed in balanced salt solution 
supplemented with 100μg/mL of 
gentamicin.  
Secondary outcomes: 
-Febrile episodes with antibody rise or 
virus isolation; 
The diagnosis of febrile illness was 
based on fever 38.0oC or higher for 2 
days or fever 39.0oC or higher for 1 
day during the period Dec. 15, 1992 ro 





(enrolled in two 
large paediatric 
Asthma severity 
was based on 
medical records 
Not specified  Data were 
obtained from 
computerised 
Not specified  Secondary outcomes:  
-Mean annual number of 

















and categorised as 
“mild, moderate, 
or severe”, When 
severity was not 
specified, asthma 
medication was 





possible by chart 
review 
or emergency department (ED) for the 























of asthma based on 
daily medication 
according to GINA 
Patients with chronic 
obstructive pulmonary 
disease (COPD) or 
being vaccinated 




medical records  
Not reported  Primary outcomes:  
-Asthma exacerbation was defined as 
asthma attacks accompanied by 
wheezing or a decrease of more than 
20% in PEF; The number of asthma 
exacerbation accompanied by ILI were 
calculated per person; 
-Influenza-like illness symptoms 
associated with influenza infection 
according to patients’ symptoms using 
a scoring methos. Each symptom, such 
as sore throat or rhinorrhea, fever, 
general fatigue, cough, and sudden 
onset, was assigned 1 point, and a total 




Outpatient Asthma criteria 
defined in the 
Not specified  Data were 
extracted 








guidelines of the 






and classified by 
a physician 
-One or more episodes of acute lower 
respiratory tract disease defined as 
physician-diagnosed influenza-like 
illness, pneumonia, bronchitis, 
bronchiolitis, asthma exacerbation or 













Asthma case had 
to meet 1 of the 
criteria: at least 1 
ICD-9 code 493 
and at least 1 
prescription for 
any asthma 
medication, or at 
least 1 prescription 
for a β-agonist 
drug and at least 1 
for cromolyn, or 
>5 prescriptions 
for any asthma 
medication; 
severity based on 
β-agonists 
prescriptions and 
the no. of 
hospitalisations 
and ED visits for 
asthma 6 months 
before the flu 
season 
Children younger than 
1 years old were 
excluded because of 
the difficulty in 
differentiating 
between asthma and 
bronchiolitis in 





Not reported Secondary outcomes:  
-Asthma exacerbation was defined as a 
hospitalisation or ED visit for asthma 
indentified from the computerized 
HMO databases (with 2-day and 2-








Asthma case had 
to meet 1 of the 
criteria: at least 1 
ICD-9 code 493 
Children younger than 
1 years old were 
excluded because of 





Not reported Primary outcomes:  
-Asthma exacerbation was defined as a 
hospitalisation or ED visit for asthma 






and at least 1 
prescription for 
any asthma 
medication, or at 
least 1 prescription 
for a β-agonist 
drug and at least 1 
for cromolyn, or 
>5 prescriptions 
for any asthma 
medication; 
severity based on 
β-agonists 
prescriptions and 
the no. of 
hospitalisations 
and ED visits for 
asthma 6 months 
before the flu 
season 
differentiating 
between asthma and 
bronchiolitis in 
infants <1 year old. 
HMO databases (no 2-week interval 







At least 4 episodes 
of wheezing in the 














at 1 month 
interval 
Primary outcomes:  
-Asthma exacerbations defined as 
wheezing episodes. 
Secondary outcomes:  
-The rate of acute respiratory tract 
illness;  
-Emergency room visits; 
-Hospitalizations, length of stay for 
hospitalization;  
-Bronchodilator usage and systemic 
steroid and both groups were followed 





with asthma at the 
Egg allergy, to 
any other component of 





centres;  Severity of 
asthma based on 
criteria of the 
Spanish Guide for 








the vaccine or those 
with serious underlying 
disease that could alter 
the effect of vaccination 








-Respiratory infections were recorded and 
episodes of bronchitis that presented the 
patients during the flu and clinical criteria 
were used (cough, fever) associated with 






acute illness for 
<7 days were 
enrolled and 
had swab 




was based on the 
ICD-9 diagnosis 
codes from the 
electronic medical 
record, they were 
at high-risk if they 
had a healthcare 
encounter leading 
to an ICD-9 code 
corresponding to a 
high-risk condition 
the year before 
enrolment  
Controls with 
symptom onset before 
the 1st date or after the 
last date of symptom 
onset among flu 
cases, Vaccinated 
within 14 days of 
illness onset or 
vaccinated but did not 














receipt of at 
least 1 dose of 
current-season 




aged 6 months 






Primary outcomes:  
-Cases were defined as persons with a 
medically attended ARI confirmed as 
influenza by RT-PCR. Controls were 
persons with a medically attended ARI 






doses by ACIP, 









acute illness for 
<7 days were 
enrolled and 
had swab 
samples taken at 
outpatient 
clinics) 
The current health 
status based on 
interview and 
subjects were 
defined as high 
risk if they had 
medical record 
documentation the 
past year prior 
enrolment  
Not reported Vaccination 











receipt at least 
1 dose of 
vaccine for the 
current season 
at least 14 days 
before illness 
onset 
Primary outcomes:  
-Cases were defined as persons with a 
medically attended ARI confirmed as 
influenza by RT-PCR. Controls were 
persons with a medically attended ARI 









Income Support and Income-based Employment Support Allowance claimants 
 (16-59)  
Job Seekers Allowance and Guaranteed Pension Credit Claimants (All ages) 
Universal Credit claimants with no employment marker 
Number of children in JSA, IS or ESA households 
Number of Adults and children dependent on adults in receipt of tax credits 
Employment 
Unemployment Claimant Count averaged over 12 months  
Working age Incapacity Benefit or Employment Support Allowance recipients  
Working age Severe Disablement Allowance recipients 
Health 
Standardised Mortality Ratio 
Hospital stays related to alcohol misuse 
Hospital stays related to drug misuse  
Comparative Illness Factor 
Emergency stays in hospital 
Proportion of population being prescribed drugs for anxiety, depression or 
psychosis  




School pupil attendance  
School pupil performance 
Working age people with no qualifications  
17-21 year olds enrolling into full time higher education 
School leavers aged 16-19 not in education, employment or training 
Housing 
Persons in households which are over-crowded  




Drive time sub-domain (weight = 2/3) 
Drive time to GP, to retail centre, to petrol station, to primary and secondary 
schools, to post office 
Public transport sub-domain (weight = 1/3) 
Public transport time to GP, to retail centre, to post office 
Crime 
Domestic house breaking 
Drug offences 
Common assault 









A12. STROBE Checklist  
 
 
Item No Recommendation 
Title and abstract 1 (a) Indicate the study’s design with a commonly used term in the title or the abstract 
(b) Provide in the abstract an informative and balanced summary of what was done and what was found 
Introduction 
Background/rationale 2 Explain the scientific background and rationale for the investigation being reported 
Objectives 3 State specific objectives, including any prespecified hypotheses 
Methods 
Study design 4 Present key elements of study design early in the paper 
Setting 5 Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, 
and data collection 
Participants 6 (a) Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. 
Give the rationale for the choice of cases and controls 
(b) For matched studies, give matching criteria and the number of controls per case 
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give 
diagnostic criteria, if applicable 
Data sources/ 
measurement 
8*  For each variable of interest, give sources of data and details of methods of assessment (measurement). 
Describe comparability of assessment methods if there is more than one group 
Bias 9 Describe any efforts to address potential sources of bias 
Study size 10 Explain how the study size was arrived at 
Quantitative 
variables 
11 Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings 
were chosen and why 
Statistical methods 12 (a) Describe all statistical methods, including those used to control for confounding 
(b) Describe any methods used to examine subgroups and interactions 
(c) Explain how missing data were addressed 
(d) If applicable, explain how matching of cases and controls was addressed 
(e) Describe any sensitivity analyses 
Results 
Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for 
eligibility, confirmed eligible, included in the study, completing follow-up, and analysed 
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(b) Give reasons for non-participation at each stage 
(c) Consider use of a flow diagram 
Descriptive data 14* (a) Give characteristics of study participants (eg demographic, clinical, social) and information on 
exposures and potential confounders 
(b) Indicate number of participants with missing data for each variable of interest 
Outcome data 15* Report numbers in each exposure category, or summary measures of exposure 
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 
95% confidence interval). Make clear which confounders were adjusted for and why they were included 
(b) Report category boundaries when continuous variables were categorized 
(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time 
period 
Other analyses 17 Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses 
 
Other analyses 17 Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses 
Discussion 
Key results 18 Summarise key results with reference to study objectives 
Limitations 19 Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss 
both direction and magnitude of any potential bias 
Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of 
analyses, results from similar studies, and other relevant evidence 
Generalisability 21 Discuss the generalisability (external validity) of the study results 
Other information 
Funding 22 Give the source of funding and the role of the funders for the present study and, if applicable, for the 




           
 












Title and abstract  
 1 (a) Indicate the 
study’s design with a 
commonly used term 
in the title or the 
abstract (b) Provide 
in the abstract an 
informative and 
balanced summary of 
what was done and 
what was found 
 RECORD 1.1: The type of data used should be 
specified in the title or abstract. When possible, 
the name of the databases used should be 
included. 
 
RECORD 1.2: If applicable, the geographic 
region and timeframe within which the study 
took place should be reported in the title or 
abstract. 
 
RECORD 1.3: If linkage between databases was 
conducted for the study, this should be clearly 





2 Explain the scientific 
background and 
rationale for the 
investigation being 
reported 
  p. 106-108 








Study Design 4 Present key elements 
of study design early 
in the paper 
  P    p. 108-110 
Setting 5 Describe the setting, 
locations, and 
relevant dates, 
including periods of 
recruitment, 
exposure, follow-up, 
and data collection 
  p. 108-110 
Participants 6 (a) Cohort study - 
Give the eligibility 
criteria, and the 
sources and methods 
of selection of 
participants. Describe 
methods of follow-up 
Case-control study - 
Give the eligibility 
criteria, and the 
sources and methods 
of case ascertainment 
and control selection. 
Give the rationale for 
the choice of cases 
and controls 
Cross-sectional study 
- Give the eligibility 
criteria, and the 
sources and methods 
of selection of 
participants 
 
(b) Cohort study - For 
matched studies, give 
matching criteria and 
 RECORD 6.1: The methods of study population 
selection (such as codes or algorithms used to 
identify subjects) should be listed in detail. If 
this is not possible, an explanation should be 
provided.  
 
RECORD 6.2: Any validation studies of the 
codes or algorithms used to select the 
population should be referenced. If validation 
was conducted for this study and not published 
elsewhere, detailed methods and results should 
be provided. 
 
RECORD 6.3: If the study involved linkage of 
databases, consider use of a flow diagram or 
other graphical display to demonstrate the data 
linkage process, including the number of 




number of exposed 
and unexposed 
Case-control study - 
For matched studies, 
give matching criteria 
and the number of 
controls per case 




effect modifiers. Give 
diagnostic criteria, if 
applicable. 
 RECORD 7.1: A complete list of codes and 
algorithms used to classify exposures, 
outcomes, confounders, and effect modifiers 
should be provided. If these cannot be reported, 




8 For each variable of 
interest, give sources 







if there is more than 
one group 
  p. 115-117 
Bias 9 Describe any efforts 
to address potential 
sources of bias 
  p. 120 
Study size 10 Explain how the 
study size was 
arrived at 
  p. 121 
Quantitative 
variables 
11 Explain how 
quantitative variables 
were handled in the 
analyses. If 
applicable, describe 








12 (a) Describe all 
statistical methods, 
including those used 
to control for 
confounding 
(b) Describe any 
methods used to 
examine subgroups 
and interactions 
(c) Explain how 
missing data were 
addressed 
(d) Cohort study - If 
applicable, explain 
how loss to follow-up 
was addressed 
Case-control study - 
If applicable, explain 
how matching of 
cases and controls 
was addressed 
Cross-sectional study 
- If applicable, 
describe analytical 
methods taking 
account of sampling 
strategy 
(e) Describe any 
sensitivity analyses 




 ..  RECORD 12.1: Authors should describe the 
extent to which the investigators had access to 






RECORD 12.2: Authors should provide 
information on the data cleaning methods used 
in the study. 
Linkage  ..  RECORD 12.3: State whether the study 
included person-level, institutional-level, or 
other data linkage across two or more databases. 
The methods of linkage and methods of linkage 
quality evaluation should be provided. 
p. 110 
Results 
Participants 13 (a) Report the 
numbers of 
individuals at each 





eligible, included in 
the study, completing 
follow-up, and 
analysed) 
(b) Give reasons for 
non-participation at 
each stage. 
(c) Consider use of a 
flow diagram 
 RECORD 13.1: Describe in detail the selection 
of the persons included in the study (i.e., study 
population selection) including filtering based 
on data quality, data availability and linkage. 
The selection of included persons can be 
described in the text and/or by means of the 












  p. 123-126 
324 
 
(b) Indicate the 
number of 
participants with 
missing data for each 
variable of interest 
(c) Cohort study - 
summarise follow-up 
time (e.g., average 
and total amount) 
Outcome data 15 Cohort study - Report 
numbers of outcome 
events or summary 
measures over time 
Case-control study - 
Report numbers in 
each exposure 
category, or summary 
measures of exposure 
Cross-sectional study 
- Report numbers of 
outcome events or 
summary measures 
  p. 127-131 
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Main results 16 (a) Give unadjusted 
estimates and, if 
applicable, 
confounder-adjusted 
estimates and their 
precision (e.g., 95% 
confidence interval). 
Make clear which 
confounders were 
adjusted for and why 
they were included 




(c) If relevant, 
consider translating 
estimates of relative 
risk into absolute risk 
for a meaningful time 
period 
  p. 127-131 
Other analyses 17 Report other analyses 
done—e.g., analyses 
of subgroups and 
interactions, and 
sensitivity analyses 
  p. 132-154  
Discussion 
Key results 18 Summarise key 
results with reference 
to study objectives 
  p. 155 
Limitations 19 Discuss limitations of 
the study, taking into 
account sources of 
potential bias or 
imprecision. Discuss 
both direction and 
 RECORD 19.1: Discuss the implications of 
using data that were not created or collected to 
answer the specific research question(s). Include 
discussion of misclassification bias, unmeasured 




magnitude of any 
potential bias 
eligibility over time, as they pertain to the study 
being reported. 
Interpretation 20 Give a cautious 
overall interpretation 




analyses, results from 
similar studies, and 
other relevant 
evidence 
  p. 155-157 
Generalisabilit
y 
21 Discuss the 
generalisability 
(external validity) of 
the study results 
  N/A 
Other Information 
Funding 22 Give the source of 
funding and the role 
of the funders for the 
present study and, if 
applicable, for the 
original study on 
which the present 
article is based 
  p. 17 
Accessibility 
of protocol, 
raw data, and 
programming 
code 
 ..  RECORD 22.1: Authors should provide 
information on how to access any supplemental 
information such as the study protocol, raw 





































Influenza A & B 1/15 6.67 24/108 22.22 12.20 54.39 
(-304.59 to 94.86) 
34.85 
(-599.09 to 93.93) 
Influenza A 1/15 6.67 24/108 22.22 12.20 54.39  
(-304.59 to 94.86) 
34.85  
(-599.09 to 93.93) 
A(H3) 0/0 0.00 25/123 20.33 0.00 0.00  
(-Inf to 100) 
0.00  
(-Inf to 100) 
A(H1N1) 0/0 0.00 25/123 20.33 0.00 0.00  
(-Inf to 100) 
0.00  
(-Inf to 100) 
Influenza B 0/0 0.00 25/123 20.33 0.00 0.00  
(-Inf to 100) 
0.00  








Influenza A & B 4/16 25.00 24/83 28.92 16.16 36.23 
(-145.58 to 83.44) 
27.43 
(-201.04 to 82.50) 
Influenza A 4/13 30.77 24/86 27.91 13.13 5.77  
(-288.05 to 77.12) 
0.75  
(-353.41 to 78.27) 
A(H3) 0/0 0.00 28/99 28.28 0.00 0.00  
(-Inf to 100) 
0.00  
(-Inf to 100) 
A(H1N1) 0/0 0.00 28/99 28.28 0.00 0.00  
(-Inf to 100) 
0.00  
(-Inf to 100) 
Influenza B 0/3 0.00 28/96 29.17 3.03 100  
(-Inf to 100) 
100  






Influenza A & B 2/11 18.18 28/79 35.44 12.22 73.96 




Influenza A 0/1 0.00 30/89 33.71 1.11 100  
(-Inf to 100) 
100  
(-Inf to 100) 
A(H3) 0/1 0.00 30/89 33.71 1.11 100  
(-Inf to 100) 
100  
(-Inf to 100) 
A(H1N1) 0/0 0.00 30/90 33.33 0.00 0.00  
(-Inf to 100) 
0.00  
(-Inf to 100) 





2/10 20.00 28/80 35.00 11.11 70.21  










Influenza A & B 2/7 28.57 15/68 22.06 9.33 16.67 
(-513.54 to 88.68) 
0.00 
(-Inf to 100) 
Influenza A 2/7 28.57 15/68 22.06 9.33 16.67  
(-513.54 to 88.68) 
0.00  
(-Inf to 100) 
A(H3) 2/7 28.57 15/68 22.06 9.33 16.67  
(-513.54 to 88.68) 
0.00  
(-Inf to 10) 
A(H1N1) 0/0 0.00 17/75 22.67 0.00 0.00  
(-Inf to 100) 
0.00  
(-Inf to 100) 
Influenza B 0/0 0.00 17/75 22.67 0.00 0.00  
(-Inf to 100) 
0.00  







Influenza A & B 1/9 11.11 19/78 24.36 10.34 77.14 
(-118.07 to 97.60) 
76.29 
(-170.48 to 97.92) 
Influenza A 0/4 0.00 20/83 24.10 4.60 100  
(-Inf to 100) 
100  
(-Inf to 100) 
A(H3) 0/1 0.00 20/86 23.26 1.15 100  
(-Inf to 100) 
0.00  
(-Inf to 100) 
A(H1N1) 0/0 0.00 20/87 22.99 0.00 0.00  
(-Inf to 100) 
0.00  
(-Inf to 100) 
Influenza B 1/5 20.00 19/82 23.17 5.75 75.09  
(-333.05 to 98.57) 
76.66  






Influenza A & B 18/50 36.00 81/274 29.56 15.43 -57.04 




Influenza A 18/50 36.00 81/274 29.56 15.43 -57.04  




A(H3) 1/11 9.10 98/313 31.31 3.40 46.21  
(-519.68 to 95.33) 
0.00  
(-Inf to 100) 
A(H1N1) 17/36 47.22 82/288 28.47 11.11 -101.77  





























(-Inf to 100) (-Inf to 100) 
Abbreviations: CI: confidence interval; NA: not applicable  
a  Adjusted for time (i.e. days) only 
b Adjusted for time (i.e. days), age, number of risk groups, swab location (i.e. GP or hospital) 
-No subgroup analyses are provided for the seasons 2000/01 to 2002/03 as there were not enough numbers even for overall VE estimates  
-From 2003/04 to 2008/09 only VE adjusted for time and age as too few number to adjust for more variables  
-There are cases with unknown influenza A subtype for all the seasons (2003-2015) which explains the total influenza A(H3) and A(H1N1) samples do 




A15. Number of medications prescribed for asthma patients during 15 



















A16. Number of asthma-related prescriptions in asthma patients  
(total: 4,571,904 prescriptions) 
  
Type of asthma-related 
medications  
Number of prescriptions  
Bronchodilators  2,653,427 
Inhaled corticosteroids  1,676,274 
Oral corticosteroids     242,203 
 
A17. Number of prescriptions in each of the four BTS steps  
(total: 8,006,171 prescriptions) 
 
 















2016/2017  652,585 
BTS steps  Number of prescriptions (% total)  
Step 0 1,936,231  (24.18)  
Step 1 2,822,827  (35.26)  
Step 2 1,158,293  (14.47) 
Step 3 2,088,820  (26.09)  
Step 0: no other step;  
Step 1: no medium or high dose of ICS;  
Step 2: medium or high dose of ICS;  
Step 3: step 2 & OCS or OCS only or OCS & step 0 or OCS & step 1 
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A18. Odds Ratio and 95% Confidence intervals of a person being 
swabbed for ILI in the asthma population compared to a person of the 
same age and sex in the general population (n=20,746,367 patient-seasons 
in 2010/11 in Scotland) 
 
Predictor  Odds Ratio  95% Confidence Intervals 
Asthma 1.76* 1.60 to 1.94 
Age  
0-10 NA NA 
11-20 0.22* 0.18 to 0.26 
21-30 0.20* 0.17 to 0.23 
31-40 0.17* 0.14 to 0.20 
41-50 0.19* 0.16 to 0.22 
51-60 0.19* 0.16 to 0.23 
61-70 0.27* 0.23 to 0.32 
>71 0.27* 0.23 to 0.31 
Sex  
Female NA NA 
Male 1.20* 1.08 to 1.33 
Age*Sex  
0-10*Male NA NA 
11-20*Male 0.63* 0.49 to 0.81 
21-30*Male 0.41* 0.31 to 0.54 
31-40*Male 0.71* 0.55 to 0.91 
41-50*Male 0.73* 0.58 to 0.92 
51-60*Male 0.93 0.73 to 1.18 
61-70*Male 0.90 0.71 to 1.12 









A19. Odds Ratio and 95% Confidence intervals of a person being infected 
with RT-PCR laboratory-confirmed influenza in the asthma population 
compared to a person of the same age, sex and socioeconomic status in the 
general population (n=44,482 swab samples from unvaccinated 
individuals from 2000/01 to 2015/16 in Scotland)  
 
Predictor  Odds Ratio  95% Confidence Intervals 
Asthma 1.28* 1.17 to 1.41 
Age  
0-10 NA NA 
11-20 1.43* 1.23 to 1.66 
21-30 1.98* 1.73 to 1.27 
31-40 1.63* 1.41 to 1.87 
41-50 1.43* 1.23 to 1.65 
51-60 1.31 * 1.12 to 1.52 
61-70 1.14 0.96 to 1.36 
>71 1.22* 1.04 to 1.42 
Sex  
Female NA NA 
Male 1.03 0.93 to 1.14 
Socioeconomic Status (SIMD)  
SIMD1 (most deprived) 1.08 0.98 to 1.19 
SIMD2 1.17* 1.06 to 1.28 
SIMD3 1.13* 1.02 to 1.24 
SIMD4 1.16* 1.05 to 1.28 
SIMD5 (least deprived) NA NA 
Age*Sex  
0-10*Male NA NA 
11-20*Male 1.31* 1.06 to 1.62 
21-30*Male 0.90 0.73 to 1.11 
31-40*Male 1.14 0.92 to 1.40 
41-50*Male 1.24* 1.01 to 1.52 
51-60*Male 1.25* 1.01 to 1.54 
61-70*Male 0.87 0.67 to 1.13 
>71*Male 0.91 0.72 to 1.15  
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